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ABSTRACT 
Biochemical and pharmacological studies of morphine-6-
glucuronide and related compounds 
Jason L. Martin 
Keywords morphine. morphine-6-glucuronide. morphine-3-
glucuronide. synthetic opiates. brain. spinal cord. ligand-binding assays. 
isolated tissue bioassays. analgesia. metabolism and distribution. 
Morphine-6-glucuronide is a minor metabolite. representing 5% of an 
administered dose of morphine. The metabolite has analgesic activity 
exceeding that of morphine and may contribute to analgesia following 
morphine administration. 
The aims of the study were to attempt to identify the reasons behind the 
improved activity of morphine-6-glucuronide over the parent compound 
and to examine a series of 6-substituted compounds. based on 6-substituted 
benzoate esters. as potential mimics of morphine-6-glucuronide. 
Morphine-6-glucuronide was seen to have similar affinity to morphine at 
l1-opioid receptors as assessed by ligand-binding assays in mouse brain 
homogenates. However a three-fold improved affinity at S-opioid receptor 
binding sites was observed and a ten-fold reduction in affinity at K-opioid 
sites. Using in vitro bioassay systems. the glucuronide showed a two-fold 
improved potency over morphine. in both the guinea-pig ileum and the 
mouse vas deferens preparations. Following in vivo (s.c.) administration in 
the mouse the glucuronide was seen to be equipotent with morphine in the 
tail-flick test. but was of much longer duration. lasting up to 9 hours. Ex-
vivo binding assays confirmed that morphine-like material was still 
present in the central nervous system six hours after administration of the 
glucuronide. but was not observed at a similar time after morphine 
administration. Activity was retained if the hydroxyl groups of the sugar 
moiety of the glucuronide were protected as esters. In contrast the more 
prevalent morphine metabolite. morphine-3-glucuronide. was inactive in 
all in vitro and in vivo tests used. and did not antagonise morphine in 
vitro or in vivo. A group of 3-substituted derivatives containing saturated 
and unsaturated substituents. did show affinity for opioid receptors. but no 
agonist activity of the compounds could be demonstrated in vitro. 
A series of synthetic 6-substituted compounds showed a variety of affinities 
for, and agonist potencies at, opioid receptors, though low affinity at K-
opioid receptors was a general finding. For example, morphine-6-
nitrobenzoate was l1-opioid receptor preferring, while morphine-6-
phthalate had improved O-opioid receptor affinity and acted via Il-opioid 
receptors in the mouse vas deferens and in vivo. However the compounds 
were weaker than morphine and the duration of action in vivo was shorter 
than morphine-6-glucuronide. 
The conclusions from these studies are that morphine-6-glucuronide and 
morphine have similar in vitro affinities at the l1-receptor, although 
morphine-6-glucuronide has somewhat improved binding affinity for Il 
receptor sites, it has less affinity for K receptor sites. Pharmacokinetic 
reasons are probably responsible for the improved activity and duration of 
action of morphine-6-glucuronide over morphine. None of the synthetic 
compounds examined are potentially useful as direct mimics of the 
glucuronide because morphine-6-glucuronide is more potent and has a 
longer duration of action than the synthetic derivatives, though alteration 
at the 6-position of the morphine nucleus can lead to dramatic changes in 
selectivity and potency of ligands for the differing opioid receptors. 
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CHAPTER 1 
INTRODUCTION 
1.1 Historical 
Pain is a subjective experience encountered by every individual during 
some stage of their life. though some people have higher thresholds to pain 
than others. Most people will experience acute pain. some will be unlucky 
enough to experience chronic pain. The cause of the pain cannot always 
be removed. so relief is the next best option and thus drugs accomplishing 
this task are extremely useful and constantly sought. 
Pain is usually a reflex and conscious reaction. which suggests an injurious 
(nociceptive) stimulus is present. Pain saves many lives because it compels 
those who can to avoid harm and to seek treatment when harm has been 
done. Some individuals however are congenitally insensitive to pain. and 
often sustain severe injury. sometimes leading to death. The relief of pain 
is always desirable. but the use of drugs for this purpose is dangerous if it 
makes diagnosis more difficult. or if it is allowed to take the place of more 
fundamental treatment. 
Opium (from the Greek word for juice) is the dried exudate from unripe 
seed capsules of the oriental opium poppy. Papaver Somniferum. It 
relieves pain and induces 'euphoria'. Opium and its derivatives have been 
the established treatment of pain for many thousands of years. Opium's 
psychological effects were known to the ancient Babylonians (4000 BC). 
and it was used to pacify children in ancient Egypt before 2000 BC. Arabian 
traders introduced the drug to the Orient mainly for the treatment of 
diarrhoea. Paracelsus. in the sixteenth century gave the name 'laudanum' 
(Latin. laudare = to praise) to preparations containing opium. Thomas 
Sydenham in 1680 introduced opium into Britain. 
In the eighteenth century opium smoking became popular in the Orient 
following the prohibition of tobacco smoking. The invention of the 
hypodermic syringe increased the problem of dependence because opiates 
administered intravenously give rise to more severe dependence. The 
recognition of this serious dependence liability stimulated a search for 
potent analgesics. which whilst retaining analgesic activity did not induce 
dependence. 
I 
In 1803. a German pharmacist. Serturner. isolated and described an opium 
alkaloid that he named morphine after the Greek god of dreams. The 
discovery of other alkaloids in opium quickly followed morphine. 
Noscapine. by Robiguet. in 1817. codeine in 1832. thebaine by Pelletier in 
1835 and papaverine by Merck in 1848. By the middle of the nineteenth 
century pure alkaloids were taking the place of preparations of opium in 
medicinal use. 
Opium contains about twenty-five different alkaloids. the most prevalent of 
which are morphine (Figure 1.1). codeine (Figure 1.2). thebaine (Figure 
1.3) and narcotine (Figure 1.4). 
Figure I. I Morphine Figure 1.2 Codeine 
o 
<0 
OMe 
Figure 1. 3 Thebaine Figure 1.4 Narcotine 
Morphine has become the most exploited analgesic known to man. In 
addition to analgesia morphine possesses a range of pharmacological 
actions (Bowman and Rand. 1980 i) both centrally and peripherally 
mediated. These are summarised in Table 1.1. 
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Table 1.1 Pharmacological actions of morphine 
I. Analgesia 
2. Euphoria or dysphoria 
3. Sedation 
4. Tolerance and dependence 
5. Depression of coughing centre 
6. Depression of the vasomotor centre with hypotension 
7. Vomiting 
8. Miosis 
9. Release of antidiuretic hormone 
10. Increase in tone and reduction in motility of the gastrointestinal tract 
11. Constriction of the bronchi 
12. Dilation of blood vessels 
13. Itching 
14. Muscle rigidity 
15. Respiratory depression 
1.2 Opioid Receptors and endogenous opioid peptides 
'Opioid' is a general term for agents with morphine-like properties. 
Analgesia associated with opioids results from interaction with specific 
opioid receptors distributed heterogeneously within the eNS. Thus the 
definition of an opioid effect, caused via action at an opioid receptor is that 
it must be antagonised by an opioid antagonist ego naloxone (Figure 1.5). 
Figure 1.5 Naloxone 
Martin (1976) suggested the existence of three different opioid receptors, 
namely, the mu (11) receptor, kappa (K) receptor and the sigma (0) receptor 
based on observations using the chronic spinal dog preparation. 
Prototype agonists for these receptors are morphine (11), ketocyclazocine 
(K) (Figure 1.6) and N-allylnormetazocine (SKF 10047)(0)(Figure 1.7) 
respectively. 
3 
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Figure 1.6 Ketocylazocine Figure 1.7 N-allylnormetazocine 
Further in vitro work using isolated tissue preparations, ego the guinea pig 
ileum, confirmed the presence of the .~ receptor site characterised by 
morphine and the 1( site characterised by ketocyclazocine. The er receptor, 
however is no longer considered of the opioid type because it is not blocked 
by the opioid antagonist naloxone. Hallucinogenic drugs ego phencyclidine 
(angel dust) act at the er receptor. 
Following the discovery of the endogenous opioid peptides, the 
enkephalins, a third receptor was confirmed to account for the actions of 
these peptides. This was named the li receptor and was first identified by 
electrically stimulating the mouse vas deferens (MVD) preparation (Lord 
et ai, 1977). The presence of these three receptors has recently been 
confirmed by cloning methods. The ~ receptor (Chen et ai, 1993) was 
cloned from rat brain and the li (Yasuda et ai, 1993) and 1( (Yasuda et ai, 
1993) from mouse brain, making use of complementary DNA techniques. 
1.2,1 Endogenous opioids 
Kosterlitz and Hughes (Kosterlitz & Hughes, 1975) isolated substances 
possessing opioid-Iike activity from porcine brain, termed 'enkephalins'. 
The enkephalins are two pentapeptides, namely methionine enkephalin 
([Met5] enkephalin) and [Leu 5] enkephalin (Figure 1.8) present in the 
ratio 3: 1 and differing only in the carboxy-terminal amino acid residue. 
Extended compounds were soon discovered. ~endorphin was one of the 
earliest extended [Met5] enkephalin to be isolated, and found to be 30 times 
more potent than [Met5] enkephalin (Holiday & Loh, 1981). Goldstein et al 
(1981) later discovered another group of endogenous opioid peptides named 
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the dynorphins. which were extended ILeu5] enkephalins; showing high 
potency in isolated tissue preparations. The opioid peptides are derived 
from three large precursor molecules. Thus pre-proenkephalin. pre-
proopiomelanocotin and pre-prodynorphin respectively are cleaved to 
yield the pro-peptides initially and then the opioid peptides (Akil et al. 
1984). 
A problem with peptides like the enkephalins and other small opioid 
peptides is that they are readily degraded and therefore care has to be 
taken when studying these molecules. Two possible solutions are available 
to overcome this problem. namely. substitution of stable amino acids or the 
use of specific enzyme inhibitors to reduce proteolysis (Corbett et al. 1982). 
In the enkephalin series substitution of glycine residue in position 2 by D-
alanine and leucine or methionine at position 5 by the corresponding D-
isomer produces an increase in potency. whilst not changing the receptor 
selectivity (Pert. 1976; Kosterlitz et al. 1980). Unfortunately this method 
cannot be employed for dynorphins because the glycine residue at position 
2 is essential for receptor selectivity. As an alternative enzyme inhibitors 
are used to increase dynorphin stability (Corbel! et al. 1982). 
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Figure 1.8 The enkephalins 
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I 2.2 Distribution of opioid receptor types in the CNS 
Using in vitro binding and competition experiments (Simon et al, 1973), the 
distribution of Jl, 0, and K - opiate binding sites has been studied in several 
species. 
Opioid receptors are widely, but heterogeneously, distributed throughout 
the CNS. The regions of the brain rich in opioid receptors are areas closely 
associated with analgesia (eg. the periaqueductal grey). 
In rat brain a population of virtually pure l1-sites is found in the thalamus, 
whereas o-sites are found in the frontal cortex. In cow brain 11 sites are 
found predominately in the substantia nigra and the thalamus. The 
highest proportion of S sites exists in the frontal cortex and the 
hippocampus. In human brain distribution is similar to that in rat and 
cow. Most regions of the human brain have a high proportion of K sites. 
The highest level is found in the hypothalamus. In guinea-pigs the 
highest density of K-sites is found to occur in layers V and VI of the 
cerebral cortex and in the pyriform cortex (Mansour et al, 1987; Shariff & 
Hughes, 1989). 
Receptors concerned with the processing of sensory information are found 
on neurones in the cortex and in the dorsal horn of the spinal cord, which 
pass messages to the brain stem, thalamus and cortical centres. 11 
Receptors are especially found in areas receiving visual, olfactory and 
nociceptive information. The presence of 11 receptors in the thalamus, 
brain stem and colliculi may correlate with a role for l1-agonists in sedation 
and respiratory depression in addition to analgesia. whereas the sedative 
actions of K-agonists may relate to the presence of K receptors in deep 
layers of the cortex. In the striatum and substantia nigra 11 receptors show 
a diffuse distribution, which may be related to modulating dopamine 
transmission in nigrostriatal pathways, with large doses of opiates 
inducing muscle rigidity and cataleptic behaviour. Dense distribution of 
opioid receptors in the limbic system may relate to the behavioural effects 
of o-opioids ego convulsions. Hypothalmic nuclei and the posterior 
pituitary gland are rich in K-sites and K-opioids have a role in 
neuroendocrine regulation ego K-agonists cause diuresis caused by an 
inhibition of vasopressin release (Mansour et ai, 1987; Shariff & Hughes, 
1989). The possible major pharmacological effects mediated by opioid 
action at 11,0 and K receptors are shown in Table 1.2. 
7 
Table 1.2 Possible major oharmacological effects mediated by opioid 
receptor types 
Opioid receptor 
lC 
Typical ligand 
morphine 
ILeul enkephal in 
[Met] enkephalin 
ethylketocyc1azone 
dynorphin 
Possible effects 
Analgesia 
Respiratory depression 
Addictive liability 
Miosis 
Muscle rigidity 
Analgesia 
Behavioural effects 
Analgesia 
Sedation/dy sphoria 
Miosis 
Diuresis 
The different receptor subtypes are located at different levels of the 
neuraxis. Intrathecal (i.t.) administration of IJ., Ii. and lC-receptor selective 
opioid compounds produces strong analgesia. whereas with 
intracerebroventricular (i.c.v.) administration. J.l selective drugs are the 
most active (Porreca et al. 1984). J.l-Receptors therefore are important in 
both spinal and supraspinal analgesia (Pasternak. 1983). 
All clinically used opiates are J.l-agonists. J.l-Receptors have been divided 
into 2 distinct sUbtypes: J.lrreceptors which bind both opiates and most 
enkephalins with similar high affinities and J.l2-receptors which bind 
morphine (Goodman & Pasternak. 1985). Experiments performed using 
selective and long-lasting J.l1- receptor antagonists. such as naloxazine and 
naloxonazine (Pasternak & Hahn. 1980). have implicated J.ll-receptors in a 
number of opiate actions. including supraspinal analgesia. but not others. 
such as respiratory depression and gastrointestinal transit (Paul & 
Pasternak. 1988). Respiratory depression and decreased gastrointestinal 
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transit are considered to be 112 actions. For example Bodnar et al (1988) 
showed that I1I-receplOrs mediate analgesia produced by microinjection of 
receptor-selective opiate peptides into the periaquaductal grey (PAG) of rat 
brain. A role for I1I-receptors was inferred since the analgesic effect of 
the l1-agonist, morphine was attenuated by naloxonazine pre-treatment. 
The peptide derivative ID-Ser2, Leu5) enkephalin-Thr6 (DSLET) binds to 111 
and 5 receptors and produces naloxonazine reversible analgesia, further 
supporting a role for 111 receptors. 
Also Heyman et al (1988) demonstrated that naloxonazine attenuated the 
analgesic effect of i.c.v. administered l1-receptor agonists morphine and 
DAMGO, but did not affect the analgesia produced by the 5-selective agonist, 
DPDPE. When the opiates were given i.t. naloxonazine did not affect 
analgesia suggesting 111 receptors are more important for supraspinal, 
than for spinal analgesia. 
1,2,3 Intracellular mechanism of olliojd action 
Opioid receptors belong to a superfamily of receptors, characterised by 
seven particularly hydrophobic stretches, consensus sites for N-linked 
glycosylation near the amino terminus, three short extracellular loops, two 
short, cationic cytoplasmic loops, and a longer cytoplasmic loop that 
connects spans five and six. They are also all of similar size (40-50kD plus 
carbohydrate) (Ross, 1989). These receptors are linked to second 
messenger systems via G-proteins. Adenylate cyclase (AC) , the enzyme 
that converts ATP to cyclic adenosine monophosphate (cAMP), constitutes 
part of a regulatory system that controls the actions of hormones and 
neurotransmitters at their sites of action. A family of GTP-binding 
regulatory (G) proteins exist that conveys information between the ligand 
activated receptors and AC. They include Gi' Go and Gs ' which lead to 
inhibition (G i or Go) or stimulation (G s)' respectively of AC. It is now 
known that Go protein is very concentrated in neural growth cones and "is 
involved in changing the electrical activity of neurones (Hepler & Gilman, 
1992). Many different Cl, ~ and y sub-units exist, making it possible for 
over 1,000 theoretical G-proteins to exist and this number is increasing. 
Gilman(l984} showed that Gs ' Gi and Go proteins were all Cl~y heterotrimers. 
The Cl subunit contains a single GTP binding site, GTPase activity and sites 
for modification by either cholera toxin for a subunit of Gs (as) or pertussis 
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toxin for ai and ao' The a subunits differ among the various G-proteins. as 
do 13(35 or 36kd) and y (6-10kd) sub units. In contrast to receptors. G-
proteins do not seem to include strongly hydrophobic regions that would 
explain how the proteins attach to the plasma membrane. but it has been 
reported that a lipophilic portion is present. One end of the gamma protein 
is bound to an isoprenoid. This lipid probably anchors the G-protein to the 
cell membrane or it helps the G-protein to attach to other proteins in the 
membrane. The a-subunits of some G-proteins are also bound to the 
membrane with the assistance from a second lipid. myristic acid (Linder & 
Gilman. 1992). 
The G-proteins interact with the receptor-ligand complex. bind GTP. and 
become activated. They then interact with AC to alter the rate of cAMP 
synthesis along with other second messengers and finally. they terminate 
their effect on AC by hydrolysing GTP to GDP. The mechanism of action of 
G-proteins was proposed by Cas se I and Selinger (1977) in the form of a G-
protein regulatory cycle (Figure \.9). Ross & Gilman (1980) modified this 
slightly. The hormone-receptor complex dissociates GDP and promotes GTP 
binding and activation of all G-proteins (Gs ' Gi and Go)' Activated a-GTP 
dissociates from py. and both a-GTP and py can then activate downstream 
processes. including AC. Hydrolysis of GTP to GDP by a. and reassociation of 
a with PY. returns systems to resting state. Hydrolysis resistant analogues 
of GTP; namely. guanylimidodiphoshate (Gpp(NH)p) and guanosine-5' -0-(3-
thiodiphosphate) (GTPyS) are often used for experimental purposes as 
stable GTP analogues to convert the receptor to a low affinity state. 
Opioids decrease cAMP levels. as shown in mouse neuroblastoma x rat 
glioma cells (NGI08-15) by inhibiting the activity of AC in these cells (Klee 
& Nirenberg. 1974). Other mechanisms for intracellular activity as well as 
AC do exist and are via ions. namely Ca2+ and K+. 11 and 1\ Agonists increase 
K+ conductance and decrease Ca2+ levels. whereas K-agonists close the Ca2+ 
channel and thus lower Ca2+ levels (Dickenson. 1991). 
Carter and Medzihradsky (1993) reported that the l1-opioid receptor couples 
to AC via Go protein in SH-SY5Y human neuroblastoma cells. whereas 
Laugwitz et al (1993) suggested an action via the Gi sUbtype Gi3 protein for 
the 11 receptor. using photoaffinity labelling experiments with the GTP 
analogue [a32p] GTP azidoanilide. McKenzie and Milligan (1990) reported 
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that the &-opioid receptor mediated inhibition of AC is transduced by G i2 
protein in mouse neuroblastoma x rat glioma hybrid cells (NGI08-15). In 
SHSY-5Y cells the Il response is via q I protein. according to Laugwitz et al 
(1993). using photoaffinity experiments. 
Abbreviations: 
R = ligand free recept.or 
RH = ligand bound recept.or 
C = inactive catalyst 
C'" = activated catalyst 
"'. P. "1= G-pro\ein subunits 
CT = cholera toxin - inhibitor 
PT = pertussis toxin - inhibitor 
Figure 1.9 G protein regulatory cycle 
The presence of GTP is essential for the coupling of opioid receptors to 
effectors (Schwartz. 1979). In turn GTP can control opioid binding as can 
ions. Pert and Synder (1974) showed that the presence of sodium ions 
reduced the affinity of opiate agonists. whilst having nO effect On the 
binding of opiate antagonists. Ions and nucleotides are thought to induce a 
conformational change in the 11 receptor (Simon et al. 1975) converting 
between a 'high agonist affinity' conformation in the absence of sodium 
and GTP to a 'low agonist affinity' conformation in the presence of sodium 
and GTP. 
The majority of early data (Creese & Synder. 1975) based on comparisons 
with estimates of pharmacological potency. implicated that the 'low agonist 
affinity' conformation. as defined by binding in the presence of sodium 
ions. as the physiologically relevant conformation. Carroll and Goodfriend 
(1984) compared data from binding in the presence and absence of sodi urn 
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ions and Gpp(NH)p with data from isolated tissue preparations. Affinities 
for a range of J.1-agonists were calculated from binding experiments run in 
Krebs/HEPES buffer and correlated extremely well with antagonist 
equilibrium constants (Ke) determined by antagonism of [D-
Ala2 ,MePhe 4Gly-ol5 j enkephalin (DAMGO) in the rat vas deferens 
preparation. These results suggest that it is the 'low agonist affinity' 
conformation that represents the relevant state of the J.1-receptor. 
The purpose of the high agonist affinity conformation is unclear. It is 
likely to represent a short-lived coupled conformation of the receptor, but 
it may represent an uncoupled form of the receptor present in non-
physiological conditions (Kent et ai, 1979). 
1.3 Morohine analogues and related drugs 
The pharmacological properties of morphine have already been discussed. 
Morphine is the recommended choice of treatment for moderate to severe 
pain by the World Health Organisation. However many attempts to 
improve on morphine have been carried out. Heroin (Figure 1.10) 
(diacetyl morphine) has been used for pain relief. It is however a more 
highly addictive drug and is often abused. 
H3CCO 
Figure 1.10 Heroin 
Oripavines ego etorphine (Figure 1.11) are very potent analgesics, but the 
World Health Organisation (W.H.O.) condemned Etorphine in 1966 because 
of the risk of dependence and the ease of illicit trafficking. Synthetic 
morphine-like analgesics, include pethidine (Figure 1.12) and methadone 
(Figure 1.13). Pethidine is used in labour and post-operative pain. 
Methadone is used to treat addicts because of its longer duration of action, 
which means the withdrawal syndrome is relatively slow in onset, longer 
in duration, and much less intense. 
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Figure 1. 11 Etorphine Figure 1. 12 Pethidine 
Figure 1.13 Methadone 
Substitution of an allyl group on the nitrogen atom in many cases produces 
compounds which are antagonists ego naloxone which antagonise the 
analgesic. euphoric and respiratory depressant effects of opiates and may 
precipitate withdrawal symptoms in addicts. 
Nalorphine (Figure 1.14) and pentazocine (Figure 1.15) are narcotic 
analgesic-antagonists. Whilst maintaining analgesic activity. such 
compounds cause much less tolerance. respiratory depression. constipation 
or vomiting than morphine. Thus the potential for abuse by addicts is less. 
They do however have psychotomimetic effects. 
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Figure 1.14 Nalorphine 
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Me 
Figure 1.15 Pentazocine 
A synthetic programme of the N-substituted analgesic-antagonist group of 
compounds led to the introduction of buprenorphine (Figure 1.16) into 
clinical use. Buprenorphine is a partial agonist, being potent and long 
lasting with low physical dependence and low abuse potential. It is non-
psychotomimetic, but does cause vomiting. 
H3CO = 
HO-C""CH3 
& 
C(CH3la 
Figure 1.16 Buprenorphine 
1.4 Pharmacokinetics and metabolism of morphine 
Morphine is readily absorbed from all routes of administration, except 
transdermal. Peak plasma levels are achieved within 15-20 mins of 
intramuscular and subcutaneous administration, and within 30-90 mins 
after oral administration. Peak levels after administration are much lower 
than after parenteral routes, since oral morphine undergoes extensive 
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first-pass metabolism in the liver (Glare & Walsh. 1991). With repeated 
administration. the oral-parenteral relative potency ratio is 1:3. After 
absorption. morphine is rapidly and widely distributed and crosses the 
blood -brain barrier. With therapeutic doses. plasma protein binding is 
only 20-35%. and the volume of distribution is 1.6 1. The primary site of 
morphine metabolism is the liver. Morphine can also be administered 
spinally. Epidural morphine enters the subarachnoid space. but is also 
absorbed into the systemic circulation. Only 5% of a dose crosses the dura. 
When morphine is administered in the lumbar region it is quickly 
redistibuted in the cerebrospinal fluid in a rostral direction. explaining the 
high incidence of systemic side effects following spinal administration. 
Drug metabolism can be divided into two parts. namely. Phase 1 reactions. 
ego oxidation. reduction and hydrolysis. and Phase 11 reactions. which 
increase the water solubility of the compounds. and allow for easier 
excretion ego acetylation. sulphation. methylation. amino acid conjugation 
and glucuronidation. Drugs can be eliminated from the body by a variety 
of routes. urinary. biliary and in the form of faeces. Elimination of drugs 
is increased by four factors. namely by metabolites which have reduced 
lipid solubility. Iow volume of distribution. do not bind to plasma proteins 
and are not actively transported. 
Morphine is metabolised in man by the cytochrome P-450 system in liver 
to give a variety of metabolites. including morphine-6-glucuronide (M6G) 
(Figure 1.17). morphine-3-g1 ucuronide (M3G), morphine-3.6-glucuronide 
(M3.6.G) (Figure 1.18). normorphine (Figure 1.19). normorphine-6-
glucuronide (Figure 1.20). and morphine-3-ethereal sulphate (M-3-ES) 
(Figure 1.21). 
HO 
~CO~O OH o 
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Figure 1.17 M6G 
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Figure 1.18 M3,6G 
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Figure 1.19 normorphine 
Figure 1.21 M-3-ES 
G1ucuronidation is the major metabolic process present and M3G (Figure 
1.22) is the major metabolite accounting for over 50% of administered 
morphine. Woods (1954) isolated and identified M3G from canine urine, 
and later M3G was isolated from human addicts urine by Fujimoto and Way 
(1957, 1958). M6G is a minor metabolite, accounting for about 5% of an 
administered dose of morphine (Peterson et ai, 1990; Sawe et ai, 1983 ii) 
UDP-glucuronyl transferase, the enzyme responsible for performing 
glucuronidation, exists in multiple forms A to D. Morphine is 
glucuronidated by the B form of glucuronyl transferase enzyme (Burchell, 
1981), mainly in the liver, to a limited extent in the intestine and kidney, 
and to a lesser extent in the placenta (Miettinen, 1963). Dutton and Storey 
(1954) demonstrated the presence of UDP-glucuronic acid (Figure 1.23) and 
glucuronyltransferase in liver tissue. Strominger (I957) characterised 
UDP-glucuronic acid dehydrogenase and the reduced 
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diphosphopyridine nucleotide system as essential contributors to 
glucuronide synthesis. The formation of morphine glucuronides is shown 
in Figure 1.24. 
Figure 1.22 Morphine-3-glucuronide 
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Figure 1.23 UDP-GA 
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Figure 1.24 Formation of morphine glucuronide 
Morphine glucuronide is excreted into the bile and hence the intestine. 
However the intestine contains significant amounts of J3-glucuronidase. 
resulting in the formation of free drug. which is then reabsorbed. 
transported to the liver and then undergoes re-conjugation and re-
excretion. This enterohepatic recirculation may make a significant 
contribution. prolonging the half-life in the body. resulting in the 
potentiation of the pharmacological action of morphine. In addition 
Fishman and Green (1957) reported in vitro the transferase activity of J3-
glucuronidase. Thus a second possible pathway of M6G formation may 
occur through J3-glucuronidase catalysis of morphine. 
Sulphation to form 3-ethyl sulphate of morphine requires an active donor. 
3' -phosphoadenosine-5' -phosphosulphate (PAPS). produced from ATP and 
sulphate. Many drugs that can be glucuronidated can also be sulphated. 
thus leading to the possibility of competition for substrate between 2 
pathways. Generally sulphate conjugation predominates at low substrate 
concentration and glucuronide conjugation at high concentration. due to 
the kinetics of the reactions. and the limited supply of PAPS in the cell 
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compared with UDP-glucuronic acid. 
Morphine and its metabolites are excreted by the kidney. Urinary free 
morphine accounts for <10% of an administered dose. The elimination half-
life of morphine is approximately 2 h and is independent of route of 
administration. Total body clearance is 21 ml/min/kg. the same as hepatic 
blood flow (Table 1.3). The relationship between plasma morphine 
concentrations and pharmacological effects is not clearly defined 
currently. but is influenced by pharmacodynamic factors. such as 
development of tolerance and individual pain thresholds (Glare & Walsh. 
1991). 
Table 1.3 Pharmacokinetic parameters of morphine. M3G & M6G after Lv. 
and oral (p.o) injection 
to.5(elim)(h) 
tmax(h) 
Vd(l) 
C(ml/min/kg) 
MORPHINE 
iv 
1.7-3.5 
3.2-5.2 
11-33 
to.5(elim) - elimination half life 
po 
1.3-3.5 
0.5-1.5 
tmax - time to reach maximum concentration 
Vd - volume of distribution 
C - clearance 
(Taken from Glare & Walsh. 1991) 
M3G 
iv po 
3.5 8 
0.25 1.25 
1,4 I Species differences in morphine metabolism 
M6G 
iv po 
2.7 10.7 
0.75 1.5 
Substantial interspecies differences in drug metabolism frequently occur 
and this can be a good indication of the nature and duration of 
pharmacological and toxicological activities. 
Yeh isolated and detected morphine metabolites from the urine of several 
mammalian species (Yeh et al. 1979). M3G and M6G are found in humans. 
guinea-pigs. rats. rabbits (Kuo et al. 1991). monkeys (Rane et al. 1984). dogs 
(Misra. 1970). In cats. M3G is a minor metabolite and M6G is not observed 
(Yeh et al. 1979). Morphine ethereal sulphate was observed in humans and 
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cats. Oguri et al (1970) also showed that in rabbits and guinea-pigs 
morphine was excreted as conjugates. whereas in rats morphine was 
excreted as the free base. Dihydromorphinone is observed in guinea-pigs. 
rats. rabbits and monkeys. a- and ~ dihydromorphines were observed in 
guinea-pigs. Hydroxylated morphine is observed in guinea-pigs. rats. 
rabbits. and cats. More recent work performed in the guinea-pig (Kumagai 
et al. 1990) shows the presence of other metabolites namely. morphinone. a 
morphinone-glutathione adduct. morphine-glutathione adduct and 
morphinone-cysteine adduct as shown in Figure 1.25. 
Dechelotte et al (1993) investigated the glucuronidation of morphine at the 
3- and the 6-position in cells from the stomach. intestine. colon and liver of 
the guinea-pig. Morphine was taken up by all cell types in a time-
dependent manner. There was evidence for a carrier-mediated 
accumulation in liver cells. but not in other cell types. The epithelium of 
the small and large intestine along with the liver contribute to the 
formation of the 'active' M6G, whereas gastric and intestinal epithelia are 
involved in the inactivation of morphine to M3G. The M3G/M6G ratio 
averaged 3.5, 4.7 and 5.4 for colonic, intestinal and liver cells respectively. 
Kuo et al (I 991) also detected M6G and M3G in the urine of guinea-pigs and 
rabbits in the metabolism of codeine using HPLC. Yue et al (1990) showed 
that glucuronidation of morphine and codeine proceeded similarly in both 
human liver and kidney microsomes. 
Excretion ratios of the M3G to M6G are approximately 4: 1 and 50: 1 in 
guinea-pigs and rabbits respectively. The urinary excretion of M6G in 
mice and rats was too small to be determined (Kuo et ai, 1991). The ratios of 
UDPGT activities toward 3- and 6- hydroxyl groups of morphine in liver 
microsomes of mice, rats, guinea-pigs. rabbits and rhesus monkeys were 
approximately 300:1, 90:1,4:1,40:1 and 50:1 respectively (Rane et ai, 1984). 
In rats natural (-) morphine is only glucuronidated at position 3. forming 
(-) M3G. whereas the unnatural (+) morphine is glucuronidated 
preferentially at position 6, forming (+) M6G (Rane et ai, 1985). 
Morphine glucuronidation is deficient in premature human neotates and 
M3G is detected. but M6G is not (Hartley et ai, 1993). 
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Figure 1.25 Morphine metabolism in the guinea-pig 
1.5 Pharmacological properties of morphine metabolites 
1.5.1 M6G 
The metabolite morphine-6-glucuronide (M6G) is reputed to possess a more 
potent analgesic activity than morphine (Paul et ai, 1989 i). It is possible 
that M6G accounts for a major component of the analgesia when morphine 
is administered. M6G avoids first-pass metabolism, and as a result of this 
gives more predictable kinetics, whilst retaining its analgesic activity. 
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Morphine appears to produce an exaggerated clinical response in patients 
with renal disease (Chan & Matzke. 1987). The presence of renal 
impairment significantly reduces the patients' dosage requirements of 
morphine. possibly because of the accumulation of M6G. rather than 
morphine. Osborne et al (1986) described that patients with renal failure 
experienced respiratory depression. following morphine treatment. 
Svensson et al (1982) showed by HPLC that M6G and M3G. but not morphine 
were the only compounds detectable. Hence the classic signs of morphine 
intoxication were attributed to accumulation of M6G. which is usually 
renally excreted. Previous workers have linked the respiratory depression 
observed with morphine administration to M6G (Christens en & Jorgensen. 
1987). supported by M6G causing a dose-dependant ventilatory depression 
in conscious dogs (Ronald. 1989). Gong et al (1991) observed respiratory 
depression in rats and postulated that the potent ventilatory depression 
induced by M6G is related to its antinociceptive effect. Hasselstrom et al 
(1989) reported on a 7 year old girl with renal failure who experienced 
long lasting respiratory depression after morphine was administered 
intravenously. The plasma concentrations of the active metabolite M6G 
were more than 10 times those normally seen. 
Hanks (1991) investigated the oral to parenteral relative potency ratios for 
morphine. He reports that a ratio of 1:6 applies to single oral 
administration of morphine. and a ratio of 1:3 to repeated administration. 
The difference may be attributed to the presence of the active metabolite 
M6G and the enterohephatic circulation of morphine. In contrast Osborne 
reports after oral administration. the mean M6G/morphine area under the 
curve of a graph plotted of concentration versus time (AUC) ratio in 
normal patients was 9.7:1. greater than 3:1 previously reported by McQuay 
et al (1987). whereas the mean M3G/morphine A UC ratio was 56: I (Osborne 
et al. 1990). greater than 20:1 reported by Sawe et al (1983 i). 
Hanna et al (1990) reported that in patients with chronic cancer. 
intrathecal M6G has analgesic activity exceeding that of intrathecal 
morphine and of longer duration. The mean potency ratio for M6G 
morphine calculated from cumulative pethidine requirements was 2 : 1. 
Osborne et al (1992) suggests that M6G given intravenously offers 
significant advantages over morphine because M6G does not induce nausea 
and vomiting like morphine does. Another advantage of M6G over 
morphine is that the safety margin of M6G was about 3 times that of 
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morphine using the EDSO/LDSO ratio (Shimomura et ai, 1971). 
Hand et al (1987) measured CSF levels of morphine, M6G and M3G after Lm. 
and oral routes and suggested M6G to account for 8S% of the analgesic 
effect of morphine. Peters on et al (1990) reported a mean M6G/morphine 
plasma concentration ratio of 7: I in cancer patients receiving chronic 
therapy with oral morphine. It was established that accumulation of M6G 
with chronic morphine therapy is related to the renal function of the 
patient. M6G contributes to the clinical response to morphine treatment 
because of extensive first-pass glucuronidation of morphine and therefore, 
higher ratios of M6G/morphine in plasma. 
The activity observed with M6G is surprising because of the presence of the 
polar hydrophilic sugar group would be expected to reduce the 
Iiphophilicity of the drug. This would suggest that M6G does not penetrate 
the blood-brain barrier and predicts an increased elimination from the 
body via biliary and urinary routes. This is obviously not the case. 
Yoshimura et al (1973) investigated the penetration of M6G and morphine 
into the brain of rats using [14C]-M6G and [14Cl-morphine. Results from 
these experiments indicated that even though M6G was a very polar 
compound, it did penetrate the blood-brain barrier and interact with the 
'analgesic receptor' without hydrolysis of the glucuronide. This was 
shown by the presence of only M6G in the brain confirmed by TLC. 
Highest levels achieved were lIS of morphine. Levels of [14C]-M6G and 
[14Cl-morphine were also found in the liver, kidneys and blood (Table 1.4). 
Table I 4 Distribution of morphine and M6G in the body of rats 
Radioactivity 
(%/g tissue or ml blood) 
Compound Brain Liver Kidney Blood 
Morphine 0.028 0.44 2.36 0.028 
M6G 0.0057 0.68 0.91 0.043 
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M3G was shown to penetrate the blood-brain barrier (BBB) as well as M6G 
because significant amounts of M3G were found in the brain and plasma of 
rats at 45 mins after i.p. injection of [14Clmorphine. The radioactivity 
determined to be M3G accounted for 10% and 30% of the total radioactivity 
in the brain and plasma respectively. M3G did not show any analgesic 
effect after s.c. or i.c.v. injection, suggesting M3G reaches but does not 
interact with the 'analgesic receptor' in the brain (Shimomura et aI, 
1971). 
The lack of analgesic activity of M3G has been confirmed (Yoshimura et al 
1973; Pasternak et aI1987). Pasternak et al (1987) also showed that M3G had 
no affinity for ).1, oor le opioid receptors. However Smith et al (1990) showed 
that M3G is a potent antagonist of morphine and M6G induced analgesia 
when administered i.c. v. Gong et al (1992) also showed M3G to antagonize 
M6G's actions, namely its analgesic and ventilatory depression effects, 
when administered i.c.v or i.t. It was also found that M3G stimulated 
ventilation implying M3G is an antagonist of morphine and M6G (Smith et 
aI, 1990). In fact M3G produces hyperalgesia in rats when administered by 
the intrathecal and i.c.v. routes (Yaksh & Harty, 1988). 
The question still remains as to how M3G and M6G enter the CNS. Partridge 
(1988) quotes four ways in which drugs could be transported into the brain. 
These are :-
1. Carrier-mediated transport ego glucose carrier 
2. Receptor-mediated transport ego receptors for peptides 
3. Plasma protein-mediated transport ego steroids are transported 
through the BBB by binding to circulating plasma proteins, such as 
albumin or specific globulins. 
4.Drug delivery ego invasive, pharmacologic (lipid soluble pro-
drugs), or physiologic (chimeric peptides). 
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1.6 Aims of the project 
The aim of the project was firstly to attempt to explain the reasons behind 
the increased analgesic activity of M6G and its longer duration of action 
over morphine. M6G avoids first pass metabolism. thereby having more 
predictable kinetics and this is obviously a major advantage over morphine 
in terms of drug administration. Unfortunately M6G may retain the 
unwanted side effects of morphine. such as dependance and respiratory 
depression. 
Secondly the project was to evaluate synthetic analogues of M6G designed 
in the hope that they would give a more predictable level of pain relief. 
similar to M6G. and would retain potency over a long duration. It would be 
hoped that these compounds would also show a reduced incidence of side-
effects. 
The approach was to determine the affinity of M6G and 6-derivatives for 
opiate receptors and the efficacy of M6G and related compounds in various 
isolated tissue models. Also to study the in vivo activity of compounds in 
antinociceptive tests and correlate this with distribution studies within the 
CNS. 
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CHAPTER 2 
MATERIALS AND METHODS 
2,1 Materials 
Equipment 
Brandell cell harvester M-4SR (Brandell, U,S,A,); 
Minaxi Tricarb 4000 Series Liquid Scintillation Counter (United 
Technologies, Packard USA); 
LKB Bromma 2330 Beckman uitraspin SS centrifuge, USA (Scientific and 
Research Instruments (SRI); 
Square wave stimulators; Grass SSS; Square Wave Stimulator (Grass medical 
instuments, Quincy, Mass" U,S,A,); 
Washington 400 MD2R chart recorder; Isotonic transducers (Harvard 
bioscience); 
Kinematica Polytron PTA lOTS homogeniser (Kinematica of Switzerland); 
Gilson HPLC system with Gilson Holochrome UV variable wavelength 
detector, Altex ODS Cs reverse phase column and C IS reverse phase column 
(Anachem, Herts), 
Animals 
Male mice (CS I strain) (30-S0g), male Wistar rats (200-2S0g) and male 
syrian hamsters (\40-200g) were from Nottingham University Medical 
School. Male Dunkin-Hartley guinea-pigs (400-S00g) were from Arnold 
Hall, Burton-on-Trent. 
All animals were fed on a standard laboratory diet and kept on a 12 hr 
light/dark cycle at a temperature of 20°C, 
Chemicals 
Peptides 
Tyr-[D-Ala2GlyNMePhe4Gly-oISjenkephalin (DAMGO) and 
Tyr-[D-Pen-Gly-Phe-D-Penjenkephalin (DPDPE) (Sigma), 
Drugs 
Morphine hydrochloride (a gift from Macfarlan Smith); morphine-6-
glucuronide (Ultrafine chemicals); morphine-3-glucuronide, naloxone 
(Sigma chemical company); normorphine (a gift from Prof. H,W, 
Kosterlitz); J3-funaitrexamine (a gift from Glaxo Pharmaceuticals); (-)-N-
m ethy 1- N - (7 -( I -pyrrolid i ny 1)-1-0 x aspi ro( 4,S )dec -S-y I) benzene acetam ide 
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(U69593, a gift from the Upjohn company). 
Novel opiate compounds were synthesised at Loughborough University 
(Anna DiPretoro), or at Bristol University (John Lewis). 
All drugs and peptides were made up as 10mM stock solutions in water, 
except for the compounds synthesised at Loughborough University, which 
were made up in dimethyl sulphoxide (DMSO) and diluted with water or 
buffer as appropriate, and stored at -20·C. For in vivo studies drugs were 
made up in sterile saline or if less soluble, in saline containing 0.25% 
carboxymethyl cellulose. 
Buffers arui Biochemicals 
Tris[hydroxymethyllaminomethane hydrochloride (Tris), N-
ethy Ima lei mi de (NEM); N -2-hydroxy ethy Ipiperazine-N' ethanesul phonic 
acid (HEPES); 5'-guanylimidodiphosphate (Gpp(NH)p); Isocitrate 
(trisodium salt); isocitrate dehydrogenase; ~-nicotinamide adenine 
dinucleotide (~NADP); uridine 5'-diphosphoglucuronic acid; nicotinamide; 
magnesium chloride. All chemicals were of analytical grade and obtained 
from Sigma chemical company. 
Other chemicals 
Ecoscint scintilation fluid (National Diagnostics); acetonitrile and 
trichloroacetic acid (both HPLC grade) (Fisons plc.). 
Radiochemicals 
[3H1DAMGO (60Ci/mmole)/(Figure 2.1), [3H1DPDPE (40Ci/mmole) (Figure 
2.2), [3H1U69593(60Ci/mmole)(Figure 2.3), and [3H1Naloxone (52Ci/mmole) 
were from Amersham International plc., [3H1 CTOP (64.4Ci/mmole)(Figure 
2.4) (New England Nuclear) and [3H1CI977 (21.1Ci/mmole) (Figure 2.5) 
(Amersham International plc). 
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Tritiated lieands used:-
[3H ]3 .5 Tyr-D-AlaGiyNMePheGiy-ol 
Figure 2.1 [3H]DAMGO 
I I [3 H13 •5 Tyr-D-Pen-Giy-Phe-D-Pen 
Figure 2.2 [3H]DPDPE 
Figure 2.3 [3H]U69593 
I I 
[3H1 D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 
Figure 2.4 [3H]CTOP 
Figure 2.5 [3H1CI977 
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Solutions 
Tris buffer was prepared as 50mM in distilled water and the pH adjusted to 
7.4 with HCI(4N). Tris-NaCI buffer contained 100mM NaCI. 
Krebs buffer solution for the myenteric plexus longitudinal muscle 
(MPLM) and the rat vas deferens (RVD) preparations comprised the 
following :-
NaC! (6.92g/I). KCI (O.35g/I). KH2P04 (O.16g/l). CaC12.2H20 (O.375g/1 for 
MPLM and 0.188g/l for RVD). NaHC03 (2.lg/I). MgS04.7H20(O.29g/l) and 
glucose (2g/I). The buffer was gassed with 95% °2.5% CO2, 
Krebs solution for the mouse vas deferens (M VD) preparation was as above. 
but with the omission of MgS04 .7H20 (Ward et al. 1986). Krebs/HEPES 
buffer was made up as Krebs buffer (above) with HEPES at a concentration 
of 25mM adjusted to pH 7.4 with 0.88M ammonia solution. 
2.2 Methods 
2.2.1 Ligand binding assays 
(j) Brain hQmogenates 
Brains were removed from male CSI mice (discarding the cerebellum) and 
homogenised in Tris buffer (50mM. pH 7.4) at 10% tissue w/v. The 
homogenate was centrifuged at 25.500g for 20 mins. The supernatant was 
discarded and the pellet resuspended in buffer. The suspension was 
incubated at 37°C for 30 mins. then recentrifuged. The pellet obtained was 
resuspended in buffer to obtain a 1 :60 tissue w/v ratio. This dilution 
corresponds to a protein concentration of approximately I mg/ml as 
determined by Lowry's method (Lowry et al. 1951). 
For saturation binding assays tubes were set up containing 20111 of tritiated 
ligand and 960111 of brain homogenate in a total volume of Iml. 20111 of 
naloxone (lOI1M)was added to each tube to determine the non-specific 
binding. For competition assays tubes contained labelled ligand (usually 
1.0nM final concentration) plus increasing concentrations of competing 
cold ligand. or 20111 of water or 20111 of naloxone (lOI1M). which represented 
the total bound ligand and non-specifically bound ligand values 
respectively. Assay tubes were incubated at 25°C for 40 mins. unless stated 
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otherwise. At the end of the incubation period the tube contents were 
filtered through glass filter papers (Whatman GFB) which were presoaked 
in either Tris buffer pH 7.4 or Tris-buffer pH 7.4 containing 
polyethyleneimine (0.1 %) to reduce non-specific binding to filters. The 
tubes were washed three times with 3ml of ice cold Tris buffer and the 
washings were also filtered. The filters were placed in scintillation vials. 
ecoscint scintillant fluid added. and the filters soaked for 8 h. The 
radioactivity remaining on the filters was counted in a Minaxi Tricarb 4000 
Series Liquid Scintillation Counter al an efficiency of 58%. 
Binding parameters KO and Bmax were obtained using the LIGAND 
programme. following Scatchard analysis using the EBDA programme 
(McPherson. 1985). ICSO values for competing ligands were determined 
using a logistic curve fitting programme developed by Barlow (1991). 
(iD Guinea-pig myenteric plexus longitudinal muscle homogenate 
Guinea-pigs were killed by cervical dislocation and the ileum rapidly 
removed and placed in ice-cold Krebs solution. The myenteric plexus-
longitudinal muscle was carefully detached from the ileum. washed. 
chopped and homogenised in ice-cold Tris buffer (SOmM. pH 7.4). The 
homogenate was prepared as above but the final resuspension 
corresponded to approximately 2mg/ml of protein. Binding assays were 
performed as above. 
2.2.2 Alkylation by B-funaltrexamine (B-FNAl 
Homogenates of mouse brain were prepared in Tris buffer and Tris/NaCI 
buffer as described in 2.2.I(i) and incubated for 60 mins at 37°C with ~FNA 
(lOOnM). Ligand binding assays were performed after four washes in Tris 
buffer. including an incubation at 37°C for 60 mins to remove non-
irreversibly bound ~FNA. 
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23 Isolated tissue studies 
2 3 I Tissue preparation 
a) Guinea-pig myenteric plexus-longitudinal muscle (MPLM) bioassay 
Male Dunkin-Hartley guinea-pigs (400-500g) were killed by cervical 
dislocation. The ileum was removed and immediately placed in aerated 
Krebs solution at room temperature (Ward et al. 1986). After flushing out 
the contents. strips of myenteric plexus longitudinal muscle (MPLM) were 
removed and mounted. under a tension of Ig. in 3ml organ baths previously 
coated with silicon to reduce adsorption of peptides onto the glass surface. 
Tissues were bathed in Krebs solution at 37°C. aerated with 5% C02 in 95% 
C2. After allowing a recovery period of I h. each tissue was stimulated 
through platinum ring electrodes using square wave pulses at 
supramaximal voltage at a frequency of 0.16Hz and a pulse width of 400IJ.S. 
b) Mouse. hamster and rat vas deferens preparation 
Male CSI mice 930-50g). male Syrian hamsters (140-200g) or male Wistar 
rats (200-250g) were killed by cervical dislocation. The vasa deferentia 
were removed immediately. and mounted under a tension of 0.5g in 1.8ml 
organ baths. previously coated with silicon to reduce adsorption losses of 
peptides. Tissues were bathed in Krebs with MgS04 (rat) or without MgS04 
(mouse and hamster) at 37°C. aerated with 5% C02 in 95% 02. After allowing 
a recovery period of I h. each vas deferens was stimulated through 
platinum ring electrodes using square wave pulses at supramaximal voltage 
at a frequency of O.IHz and a pulse width of 2501J.S (rat) or using a train of 3 
square wave pulses of I ms duration and 250ms delay at supramaximal 
voltage at a frequency of O.IHz (mouse and hamster). 
2.3.2 Experimental 
For all in vitro preparations the same procedure was performed as follows:-
a) Agonist potencies 
Agonists were added to the organ baths in a cumulative way such that 
when the response to anyone dose reached a maximum the next dose was 
administered. until approximately 80% inhibition of twitch height was 
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attained after about four cumulative doses. The tissues were washed by 
overflow with Krebs solution until the original twitch height was restored. 
The potency of agonists was assessed by measurement of lC50 's, the 
concentration of agonist causing 50% inhibition of the electrically evoked 
twitch. 
b) Antagonist affinities 
Antagonists were preincubated with the appropriate tissue for 15 mins, 
prior to the addition of an agonist. Dose-response curves for agonists were 
obtained before the addition of an antagonist and then repeated in the 
presence of varying concentrations of the antagonist (normally 10, 30, 
100nM). Dose-ratios were calculated at 50% inhibition and Schild plots 
constructed. Antagonists were removed from the tissue by continuous 
washing until the response to the added agonist was fully recovered. In 
some experiments antagonist Ke values were calculated using a single-dose 
method. The antagonist equilibrium dissociation constant (Ke) is a measure 
of affinity and was determined for a partial agonist in the rat vas deferens 
by pre-incubating the test compound for 15 mins and observing the effect 
on the dose-response curve for the full j.l agonist DAMGO. Antagonist 
equilibrium dissociation constants (Ke) were obtained by analysing the 
results according to Kosterlitz and Watt (1968) (see Chapter 3). 
c) Alkylation by !-UNA and NEM in the MPLM 
The agonist potency of Iigands were first determined, then tissues washed 
and ~FNA(100nM) added for a contact time of 60 mins. The ~FNA was then 
removed by continuous washing for about 60 mins. The agonist potency of 
Iigands was then remeasured. The effect of ~FNA on agonist potency was 
expressed as a dose-ratio shift. This was also used to determine the affinity 
of compounds by the method of Furchgott (1966) (see Chapter 3). In some 
experiments NEM was used as an alkylating agent. Tissues were treated 
with 10j.lM NEM as for ~FNA. 
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2.4 Metabolism studies 
24.1 Preparation of liyer mjcrosomes 
Livers taken from various male animals (CSI mice. (30-S0g). Wistar rats 
(200-2S0g). Dunkin-Hartley guinea-pigs (400-S00g) and New Zealand white 
rabbits (lS00-17S0g) were washed in 0.2SM sucrose. and blotted dry on 
filter paper. The livers were chopped using scissors. diluted four-fold with 
0.2SM sucrose. homogenised with a glass pestle and centrifuged at 12.S00g 
for 10 mins. The supernatent was taken and recentrifuged for 60mins at 
100.000g to afford a microsomal fraction. The pellet was resuspended in 
Tris (2.SX w/v) (SOmM. pH7.4). The microsomes were either used 
immediately or stored in liquid nitrogen. For some experiments mice were 
treated with phenobarbital (80mg/kg i.p.) for 4 days. before the livers were 
removed (Puig & Tephly. 1974). 
2 4 2 Morphine metabolism 
The method of Sanchez and Tephly (1974) was used with some 
modifications :-
The assay conditions were UDPGA (S.OmM). MgCI2 (S.OmM). Tris HCI (SOmM). 
pH 7.4 at 37°C. and microsomal protein (4.0mg). morphine (l.SmM) in a 
total volume of 1.0ml. In some experiments Triton X-lOO (2.5%) was also 
used. Control reactions had no UDPGA or contained boiled protein. 
Reactions took place on a shaking water bath (37°C) and were stopped after 
30 mins by the addition of 100111 of 10% trichloroacetic acid to a SOIlI aliquot 
of the assay mixture. and centrifuged briefly on an ultracentrifuge to 
precipitate protein. Supernatants( 10111) used for HPLC were injected onto 
the HPLC column. after addition of a spike (1011g of morphine). to enable 
the assay to be quantitative. 
2.5 Separation of morphine and its metabolites 
2.5.1 Methods available for studying morphine metabolites 
Several sensitive methods exist for the determination of low levels of 
morphine and its metabolites. in biological fluids. Radioimmunoassays can 
detect levels down to picogram amounts. but until relatively recently 
lacked specificity and could not differentiate between morphine and 
structurally related morphine metabolites (Berkowitz et al. 1974). Thus the 
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need for specific antisera. However Hand et al (1987) reported the analysis 
of morphine, M3G and M6G by differential radioimmunoassay, using 
iodinated labels and three different antisera in man. Lee et al (1991) 
described a sensitive and specific RIA for morphine. The limit of detection 
was 0.3ng/ml in plasma for morphine, but with cross-reactivity occuring 
at 0.7% with hydromorphone-3-glucuronide. 
Spectrofluorometric and radiochemical morphine assays also have low 
specificity unless morphine is purified before analysis (Garrelt & Gurkan, 
1978), although Colbert et al (1988) described a simple polarisation 
f1uoroimmunoassay to detect the opiate group of drugs in urine. Gas 
chromatography (GC) with electron-capture detection (ECD) required 
extraction and the formation of a volatile morphine derivative before 
measurements can be taken (Wall ace et ai, 1980). Tasker & Nakatsu (1986) 
described a GC-MS method, but the equipment was expensive. Wall ace 
(1980) also repored the use of HPLC with electrochemical detection with 
ng/ml sensitivity, greater than GC-ECD. Todd et al (1982) used HPLC-ECD to 
detect down to 20pg of morphine. Svensson et al (1982) reported the use of 
ion-pair HPLC to determine morphine, M6G, and normorphine. This 
procedure was sensitive to interference and only allowed the tentative 
identification of M6G. More recently Svensson (1986) detected morphine, 
M6G, and normorphine, but the quantitative detection of these compounds 
using ECD was not possible due to the differing redox potentials of the 
compounds. Venn et al (1989) reported on HPLC with native fluorescence 
detection. The limit of detection quoted was 0.5ng. It was a successful 
method of separating morphine, M3G, M6G and codeine, being very fast and 
specific. A variation of this method, with UV detection was used: -
5,5,2 Separation analysed using HPLC 
Metabolites were actually separated using an Altex Ultrasphere RP C8 
column, with a precolumn of the same material, using a flow rate of 
Iml/min. HPLC was used with UV detection. The Emax for morphine and 
normorphine is reported to be 285nm in aqueous acid (Clarke, 1986), but 
225nm was found to be the most sensitive wavelength. The solvent system 
consisted of a gradient containing different proportions of CH 3 CN 
(0.1 %TFA) and H20 (O.I%TFA), over a time period of 30 mins. 
The initial objective was to find a suitable method for separating morphine 
and its metabolites. For quantitative purposes a spike was used in samples 
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before injection (morphine, 10Ilg), after the use of phenytoin and 
phenobarbital as an internal standard (Lear et ai, 1991) proved to be 
inappropriate due to extremely long retention times. 
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Figure 2.5 Effect of acetonitrile concentration on retention time for 
normorphine (open circles), M3G (closed circles), M6G (closed circles) & 
morphine (open squares) under isocratic elution 
From Figure 2.5 it can be seen that 2% CH3CN gave the greatest peak 
separation of morphine and its metabolites, but the retention times were 
long. At concentrations above this the retention times were shorter, but 
inadequate separation occured. A gradient system was thus devised (Figure 
2.6) to give maximum separation of the compounds, and varied from 2 to 
10% and back to 2% acetonitrile over 25 mins. Retention times obtained 
using this gradient system were 8.2±0.2~ 9.8±0.1, 12.0±0.2 and 14.0±0.2 mins 
for M3G, normorphine, M6G and morphine respectively. 
35 
12 
10 
8 
(5 
§ 6 
tI< 
4 
2 
0 
0 5 10 15 20 25 30 
Time(mins) 
Figure 2.6 Gradienl system used (sample injected at 0 mins) 
Calibration curves were obtained for morphine (Figure 2.7), M6G (Figure 
2.8), M3G(Figure 2.9) and normorphine (Figure 2.10), and these four 
compounds were successfully separated using this gradient system (Figure 
2.6). A less sensitive setting was used for morphine because of the 
quantities of morphine to be detected. 
36 
200 
180 y ~ - 2.6521 + 1.4707x R"2 - 0.997 
160 
E 140 E 
~ 120 ~ 
.. 
.I:: 100 
... 80 .. 
.. Q. 60 
40 
20 
0 
0 20 40 60 80 100 
Concentratlon/ug 
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Figure 2.8 Calibration curve for M6G 
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Figure 2.10 Calibration curve for normorphine 
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2 6 Lipophilicities of morphine and related compounds 
Drugs were made up in phosphate buffer pH 7.4 (1mg/ml) and Iml of 
octanol was added, the flask stoppered, and shaken for 24 h at room 
temperature, centrifuged and the UV absorbance of the resulting two 
layers was read at 285nM. log P is a measure of a compounds lipophilicity 
and was calculated as the logarithm of the ratio of the absorbance in 
octanol to that of phosphate buffer. 
In order to determine lipophilicities of a variety of compounds the 
retention times of test compounds were determined using a Gilson HPLC 
system with a C I 8 RP column at 280nm. An isocratic solvent system was 
used of 16% CH3CN in H20 at a flow rate of Iml/min. A graph was 
constructed of log P against log k' (log k' is the capacity factor for the 
column and is defined as the difference between the retention time for test 
and reference compounds, divided by the retention time for the reference 
compound) for morphine, codeine, heroin and methadone and from this log 
P values were interpolated from log k' values for the test compounds. The 
shortest retention time is used as the reference compound, and in this case 
is morphine-6-fluorobenzoate. 
2.7 Stability of momhine and related compounds 
The stability of several synthetic compounds was qualitatively determined 
by TLC using silica gel 60 F254 as the stationary phase and a mobile phase of 
75% CHCI31 25% MeOH/3 drops NH 3. Compounds to be examined from 
aqueous solution were extracted by the method of Shimomura et al (1971) 
as follows :- 100111 of 10mM stock solution of compound was mixed with 900111 
of homogenate (1 :60 w/v tissue concentration) or Tris buffer pH 7.4 in a 
glass stoppered test tube. After 30 mins at 25°C, 3 dmps of ammonia were 
added, then Iml chloroform:isopropanol (3: I) and the tube vortexed. The 
organic (bottom) layer was taken and the extraction step was repeated on 
the aqueous layer. The organic extracts were combined and dried over 
magnesium sulphate. An aliquot (500111) was taken, the solvent was blown 
off with nitrogen and the residue resuspended in 100111 of methanol and 
spotted on a TLC plate. 
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28 In vivo experiments 
2 8 I ADlinociceptjye properties of morphjne and related compounds 
Morphine sulphate and related compounds were administered s.c. to CS) 
mice. Six control mice (injected with vehicle) and 6 test mice were used 
for each study. Analgesic activity was assessed using the tail-flick test with 
tail immersion in water at 50°C. The cut off time was lOs. The time to reach 
maximal analgesia was deduced and ED50 values were obtained for each 
drug as a measure of potency. The saline points were subtracted from the 
test points and the dose required to give 50% of the maximal tail-flick 
latency (ED50) was deduced. 
2.8.2 Distribution of morphine and M6G into the CNS 
The distribution of morphine and morphine-6-glucuronide into the brain 
and spinal cord was determined using an ex-vivo binding assay as follows :-
Mice were killed by cervical dislocation 60 mins after s.c. injection of 
morphine (5mg/kg) or M6G (5mg/kg). The brains and spinal cords were 
rapidly removed and placed in liquid nitrogen. Control brains from saline 
injected animals were pooled. homogenised and used to construct a 
morphine calibration curve. This calibration curve was used to determine 
the amount of morphine present in the test brain. by interpolating the 
specific binding value obtained from the test brain to give a morphine 
concentration. Control cords were treated in a similar manner. but a full 
dose-response curve was not obtained because the mouse spinal cords did 
not weigh very much. Analgesia was assessed using the tail flick test at 
50°C as above. Tail flick tests were performed before dosing and before the 
mice were killed. Six mice were used for controls (saline) and six for 
treatments. The penetration of compounds into the CNS was assessed in 
terms of 'morphine equivalents' present in nM. which was interpolated 
from a calibration curve of % specific [3H1DAMGO bound versus morphine 
concentration performed in mouse brain or spinal cord homogenate. 
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CHAPTER 3 
ANALYSIS OF BINDING AND ISOLATED TISSUE 
DATA 
3 I Radjoreceptor assays 
Binding assays are based on the principle of the Law of Mass Action where' 
a simple bimolecular interaction between a drug and its receptor are 
considered. Assuming the binding of the ligand (L) to its receptor (R) 
follows this law then at equilibrium for a reversible Iigand-receptor 
interaction, where [LR] = concentration of ligand-receptor complex and 
k+1 
.. 
alL] + b[R] .. c[LR] [I] 
k_ I 
a, b, and c represent the stoichiometry of the reaction. At steady state or 
equilibrium, the rate of the forward reaction equals the rate of the reverse 
reaction 
[2] 
Therefore the association binding constant, K A , and the dissociation 
binding constant, KD are as below 
KO = k_ I =[L]a[R]b 
[L]a[R]b [LR]c [3] & [4] 
so KA and KO can also be determined under steady-state conditions. KO is 
the equilibrium dissociation constant and is an indication of the affinity of 
the radioligand for its binding site. 
There is a maximum number of specific receptor sites per unit of tissue, 
Bmax such that :-
[LR] +[R] = Bmax [5] 
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[LR) = Bmax[L) (6) 
[L) + KD 
Now if [RL) is bound ligand = Band. [L) is free ligand = F 
B/F=Bmax -B 
(7) 
we get the Scatchard plot (Figure 3.1) 
B/F 
Gradient = -1 I KD 
B 
Figure 3.1 Scatchard analysis 
The assumption is made that :-
i) [L) = mass I volume. 
ii) one molecule of L combines with one molecule of R. 
iii) the response is proportional to [LR], and. 
iv) both Land R sites are homogeneous species. 
There are 2 stages in the determination of the equilibrium constant (KO> 
and apparent maximum number of binding sites (Bmax) for a given tissue 
receptor and radio ligand: 
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i) incubate the radioligand at various concentrations with a 
fixed concentration of tissue, 
ii) determine the amount of bound and free ligand by employing 
a suitable separation technique - usually filtration as used in this study or 
centrifugation. 
Unfortunately radiolabelled ligands often bind non-specifically to both 
biological and non-biological matter, e.g. non-receptor tissue, filters and 
test tubes. A measure of the specific binding is given by the difference 
between total binding and the binding that occurs in the presence of a 
large excess of unlabelled ligand. The unlabelled competitive ligand is 
better if it is chemically very different to' the radioligand so that it does not 
interact at the same non-specific receptor site. In current studies all non-
specific binding is defined using the opioid antagonist naloxone at a 
concentration of 1011M. 
As mentioned previously KDis a ratio of the binding reaction's reverse and 
forward rate constants (K D = k_1 I k+ I ). It is possible to determine these 
rate constants and thus K D can be verified. 
3,1.1 Determination of inhibitor binding constants (Kil 
Dissociation constants determined as inhibition constants (Ki) are obtained 
from competition curves which are generated by incubating a fixed 
concentration of radioligand with increasing concentrations of unlabelled 
ligand and finding the concentration of unlabelled ligand required to 
displace 50% of specific radio ligand binding, the IC50 :-
1 + [L]I KD [8] 
if labelled and unlabelled ligand interact competitively at the receptor site 
(where Ki is the binding affinity of the unlabelled ligand). 
The IC50 can be obtained from a Hill plot of the data (Figure 3.2) or by 
curve-fitting (Barlow, 1991). 
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log IC50 
~ 
i 
6 = 1/26 
o 
log 6 - 6 
o 
log [unlabelled ligand] 
Figure 3.2 Hill plot 
where Bo = no unlabelled competing ligand, and 
B = with competing ligand 
The concentration of free competing ligand is difficult to determine and is 
approximated to the value of the total concentration of competing ligand. 
This can be done if the amount of bound competing ligand is low compared 
to Ki (Bowman & Rand, 1980 ii). 
32 In vitro bioassays 
3.2.1 Antagonist potencies 
3,2,1,1 Jlsjng the Schjld Plot 
The Schild Plot 
In order to define a receptor at which an agonist acts it is necessary to 
employ an antagonist, and the ability of the antagonist to compete with an 
agonist at that receptor is determined as the value described either as a Ke 
or as a pA2. These values are a measure of the affinity of the antagonist for 
the receptor. The Ke value can act as an indicator of the receptor 
selectivity for the agonist. 
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A competitive antagonist can be regarded as a drug that interacts 
reversibly with a set of receptors to form a complex. but unlike an agonist-
receptor complex. it fails to elicit a response (ie. it exhibits no intrinsic 
activity). The antagonist-receptor complex can therefore be characterised 
by a dissociation constant. and expressed as: 
loo 
Antagonist + Receptor Antagonist-Receptor Complex 
K2 
[A] [R] [AR] 
where K I and K2 are the association and dissociation rates for the complex. 
According to the law of mass action.the rates of the forward and the 
reverse reactions are the same once equilibrium is attained therefore: 
KI[A][R] = K2[AR] 
and: 
K2 [AR] [9] 
where Ke is the antagonist dissociation constant. 
When both an antagonist [A] and an agonist [L] are present. the various 
interactions with receptors can be expressed: 
[L] + [A] + [R] :,,;::loo~[AR] + [LR] 
where [L] is the concentration of agonist and [LR] is the concentration of 
the agonist-receptor complex. 
If the total number of receptors is [R t], then the number of free receptors 
[R] can be expressed as: 
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[R] = [~] - [AR] - [LR] 
Dividing through by [LR] 
[R] = [~] - [AR] - I 
[LR] [LR] [LR] [10] 
The principles applied to the antagonist are valid for an agonist therefore: 
KO = [L][R] ie [R] = KO 
[LR] [LR] [L] [ 11] 
where KO is the dissociation constant for the agonist. 
Substituting equations [11] and then [9] into [10]: 
KO = [~] - [AR] - I 
[L] [LR] [LR] 
Since [AR] = [A] [R] (from [9]) 
Ke 
KO = [~] [A] KO - I 
[L] [LR] Ke[O] 
which reduces and rearranges to: 
[LR] [12] 
The reciprocal of this equation gives the fraction of receptors occupied by 
an agonist in terms of concentrations and dissociation constants of agonist 
and antagonist. Assuming that [LR]/[Rt].ie the proportion of receptors 
occupied by the agonist is equal to E/Emax (the ratio of effect produced by a 
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given dose of agonist to the maximal possible effect) then the reciprocal of 
the equation expresses any given response to an agonist as a fraction of the 
maximum possible response. When the concentration of the antagonist is 
zero then equation [12) simplifies to: 
[LR) = [L) 
[L) + KD [ 13) 
Equation [12) also predicts that the linear portion of the agonist 
concentration response curves carried out in the presence and absence of 
a competitive antagonist will be parallel. but displaced to the right in the 
presence of antagonist. The important feature of competitive antagonism 
is that it may be overcome by increasing concentrations of agonist. ie. the 
maximum response is not affected by a competitive antagonist. The degree 
of shift to the right of the agonist logarithmic concentration response 
curve is proportional to the antagonist concentration and to the affinity of 
the antagonist for the receptor. 
The affinity of the antagonist for any given receptor type is inversely 
proportional to the antagonist-receptor dissociation constant Ke. The value 
of the Ke can be determined from the concentration of agonist producing 
equal responses in the absence [Lo). and the presence [LA) of antagonist. 
Since the response to the agonist is equal. the proportion of receptors 
occupied is assumed to be the same. 
Therefore from equations [12) and [13) 
= 
which can be rearranged and reduced to :-
The value of the Ke is independent of the agonist used provided the agonist 
competes for the receptor. When the concentration of antagonist ([A2D is 
such that: 
then 
ie the value of the dissociation constant for the antagonist is the 
concentration of antagonist with which the ratio of concentrations of 
agonist producing equal responses in its presence [LA] and absence [Lo] 
equals 2. 
The negative logarithm of the molar concentration of antagonist with 
which the ratio of equi-effective concentrations of agonist in the presence 
and absence of antagonist is 2. has been designated by Schild as the pA2 
value. thus: 
pA2 = -log[A2] = log[I/[A211 [14] 
Equation [14] can be converted to a form containing pAx where pAx is the 
negative logarithm of the molar concentration of antagonist in the 
presence of which the potency of the agonist is decreased x times. 
x-I = [Ax] 
taking logs 
log[x -1] = 10g[Ax] - 10gKe [ 15] 
Equation [15] predicts that the plot of log[x - 1] versus log[Ax] is a straight 
line. the intercept on the log [A] axis giving the value of logKe or -pA2. The 
slope of the line is 1 provided the agonist is acting at a single receptor 
class. Deviation from the unit slope is consistent with a system of more 
than one receptor class. It should be noted that the slope of the Schild plot 
ought to be unity if a selective agonist has been displaced from a single 
receptor (Bowman & Rand. 1980 ii). 
48 
Departures from linearity for the double log relationship can be due to; 
(a)Tissue uptake of agonist. 
(b)The use of insufficient incubation times for the antagonist 
resulting in a non-equilibrium situation. 
(c)The use of antagonists that are toxic. 
The first two problems result in slopes that are less than unity. whereas 
problem (c) gives a slope greater than unity. 
3.2.1.2 Antagonist potencies where partial agonism is shown in the rat vas 
deferens (Figure 3 3) 
Kosterlitz & Watt (1968) showed that all narcotic analgesic drugs have dual 
agonist and antagonist actions. whether they are used clinically as 
'agonists' or 'antagonists'. 
The equilibrium constant (Ke) as an indication of the drugs antagonist 
activity is defined 
= a(l-y) [ 16] 
y 
where a is the molar concentration of the antagonist and y is the fraction 
of receptors occupied which is determined from the dose-ratio (DR). that is. 
the ratio of the concentration of the agonist. morphine. required to depress 
the twitch in the presence or absence of a given concentration of an 
antagonist. Since:-
y = DR-I = a [17] & [18] 
DR DR-I 
The dose-ratio is determined as shown in Figure 3;3. 
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Antagonist 
~ AgO"I (M3) 
M2 
Figure 3.3 Measurement of the antagonist affinity of a partial agonist by 
the determination of its equilibrium constant. Ke' At the arrow marked 
antagonist. the partial agonist is added and produces a depression of the 
twitch equal to a depression caused by a full agonist (eg. DAMGO) in 
concen tration M I' The full agonist was added 20 mins later to give a 
concentration M3' the total depression was equal to a reduction in the 
height of the twitch caused by the full agonist in a concentration M2 in 
the absence of the antagonist. 
DR = [19] 
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32.2 Determination of agonist potency usjng Furchgo!l'S analysis 
3.221 Efficacy .i!.!!..d.spare receptors 
Assuming the Law of Mass Action is obeyed 
[LR] = [L] [20] 
where [L] is the concentration of agonist 
Ke is the equilibrium dissociation constant of drug for its receptor 
However only fractional occupancy of the total receptor population may be 
required to elicit a maximal response. Stephenson (1956) suggested the 
biological response was a function of stimulus (S) generated by interaction 
of ligand and receptor. The relationship between stimulus and response is 
50% of the maximal response achievable, thus :-
~ = f(s) = fe[LR] = fe[L] [21] 
Em [Rt] [L] +Ke 
where f(s) is a function of the stimulus and e is the efficacy. relating 
stimulus to occupancy. Efficacy may range from 0 to 1. If e=O then f(s) = 0 
and the drug will bind but cause no biological response ie. act as an 
antagonist. 
Experimental evidence has provided support for the spare receptor 
concept. Exposure of isolated tissues to irreversible receptor antagonists 
ego ~-funaltrexamine (~-FNA), and Il-chlornaltrexamine (~-CNA) causes 
parallel shifts in opioid potency with no change in maximal response until 
high dosage (Williams & North, 1984; Lajtha, 1989). 
Furchgoll (1966) argued that efficacy, as defined in equation [21], is drug 
and tissue dependent, and reflects the ability of the agonist to induce an 
active receptor-effector complex. Thus: 
e = E [~] [22] 
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Intrinsic efficacy, E, should be constant for a given drug-receptor pair 
across species and tissues, whereas e will vary with receptor density. 
The various tissue and drug-related factors associated with agonist response 
may be summarised as follows 
= (23) 
Agonist activity is apparently dependent upon the following 
factors ;-
I. Agonist dissociation constant Ke' 
2. Intrinsic activity, E, of the agonist. 
3. The function (f) relating stimulus (s) to response. 
4. The total receptor concentration [Rt ). 
322,2 furchgott's method 
Considering equation (23) it is clear that IC50 values are not a reliable 
indication of agonist affinity. The furchgott method (Chapter 2, page 32) 
involves partial inactivation of receptor numbers, using an irreversible 
antagonist, to measure Ke' The basis of this approach is that equiactive 
concentrations of agonist before ([A)) and after([A ')) inactivation produce 
an equivalent biological stimulus (furchgott, 1966). 
Thus 
Ea = Ea' (24) 
Em Em 
then 
f(s) = f(s' ) (25) 
Assuming only receptor number is changed by the irreversible ligand 
then 
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e [A] = qe [A '] [26] 
Ke + [A'] 
where q is the fraction of free receptors (ie. those not blocked). 
This simplifies to 
1 = I + 1- q [27] 
[A] q [A'] 
A plot of I/[A] versus I/[A '] will yield a straight line with a slope of 1/q and 
an intercept of 1- ql Ke 
Thus: 
Ke = slope -I [28] 
intercept 
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CHAPTER 4 
IN VIVO ANTI NOCICEPTIVE ACTIVITY OF 
MORPHINE AND ITS GLUCURONIDE 
4 I Introduction 
M6G is reputed to be much more potent than morphine when administered 
centrally, either i.c.v. or i.t., (Paul et ai, 1989 i; Frances et ai, 1992) whereas 
when given peripherally they 'are reported as being equipotent in the 
mouse tail-flick test (Paul et ai, 1989 i). The time course of M6G analgesia is 
also much longer. The potencies were compared when administered s.c. as 
was the ability of the compounds to penetrate the eNS. A preliminary 
investigation of the ability of tissues from various species, including the 
mouse, to metabolise morphine to M6G was also investigated. 
4 2 Results 
4.2.1 Antinociceptive properties as measured by the tail-flick test 
Morphine and morphine-6-glucuronide (M6Q) 
Morphine sulphate (Smg/kg) administered s.c. to mice reached the cut off 
maximum (10 s cut off) analgesia in 60 mins and this level of analgesia was 
maintained for 60 mins. This can be seen from Figure 4.1. Using a time of 
60 mins a dose-response curve to various concentrations of administered 
(s.c.) morphine was constructed (Figure 4.2). The dose required to afford 
the maxim ally allowed analgesia was S mg/kg, with a half-maximum (ED50) 
of 2.2mg/kg. EDSO values were calculated by subtracting the saline 
controls from the test curves and the curve re-drawn and is the 
concentration of drug required to produce a half-maximum tail-flick 
latency. 
In contrast a similar dose of M6G reached maximum in 30 mins, but 
significant analgesia was still observed after 9 h (Figure 4.3), and maximum 
allowed analgesia was maintained for 5.S h. However the potency of M6G 
was similar to that of morphine (Figure 4.4), affording maximal effect at 
Smg/kg and a half-maximum at 1.9mg/kg. The two compounds are 
compared in Figure 4.5. 
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Figure 4.1 Time course for morphine (closed circles, 5mg/kg s.c.) and saline 
controls (open circles) assessed using the mouse tail-flick test. Six mice 
were used for each point. * Represents p < 0.05 indicating that the 
morphine points are significantly different from the saline points, as 
determined using the Wilcoxon signed rank test. 
12 
10 
~ 8 ~ 
~ 
» 
u 6 
= 
" «i 
....l 4 
2 
0 
0 2 
• 
468 
[Morphine] mg/kg 
• 
10 12 
Figure 4.2 Dose-response curve for morphine (closed circles) and saline 
controls (open circles) assessed using the mouse tail-flick test 60 mins after 
s.c. injection. Six mice were used for each point. * Represents p < 0.05 
indicating that the morphine treatment is significantly different from the 
saline treatment, as determined using the Wilcoxon signed rank test. 
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Figure 4.3 Time course of M6G (closed circles. 5mg/kg s.c.) and saline 
controls (open circles) assessed using the mouse tail-flick test. Six mice 
were used for each point. • Represents p < 0.05 indicating that the M6G 
points are significantly different from the saline points. as determined 
using the Wilcoxon signed rank test. 
12 
• • 
• 10 
8 
~ 
~ 
~ 
» 6 u 
= B • 
'" 4 ....l
2 
0 
0 2 4 6 8 10 12 
[M6G] mg/kg 
Figure 4.4 Dose-response curve for M6G(closed circles) induced 
antinociception and saline controls (open circles) for 60 mins assessed 
using the mouse tail-flick test. Six mice were used for each point. • 
Represents p < 0.05 indicating that the M6G treatment are significantly 
different from the saline treatment. as determined using the Wilcoxon 
signed rank test. 
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Figure 4.5 Potency of morphine (closed circles). M6G (open circles) 
compared in the tail flick test 
M6G in which the glucuronide hydroxyls and acid functions were protected 
as esters. ie. morphine-6-protected glucuronide (17) (Figure 4.6) was also 
examined (Figure 4.7). 
HO 
F.~j 
otf:{ 
OAc 
, CH3 
N 
Figure 4.6 M6G (protected) 
In vivo analysis of this compound gave very similar results to that of M6G. 
The time courses were the same (Figure 4.7). as were the ED50's for the two 
compounds and shape of the dose-response curves were the same (Figure 
4.8. Table 4.1). 
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Figure 4.7 Time course for M6G (protected sugar) (closed circles, Smg/kg) 
induced antinociception and saline (0.2S% CMC) controls (open circles) 
assessed using the mouse tail-flick test. Six mice were used for each point. * 
Represents p < O.OS indicating that the M6G (protected sugar) treatment is 
significantly different from the saline (0.2S% CMC) treatment, as 
determined using the Wilcoxon signed rank test. 
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Figure 4.8 Dose-response curve for M6G (protected sugar) (closed circles, 
Smg/kg) and saline (0.2S% CMC) controls (open circles) for 60 mins 
assessed using the mouse tail-flick test. Six mice were used for each point. 
* Represents p < O.OS indicating that the M6G (protected sugar) points are 
significantly different from the saline (0.2S% CMC) points, as determined 
using the Wilcoxon signed rank test. 
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Table 4 I Anlinociceptiye actIVIty comparison of morphine. M6G and M6G 
(protected) Onset and duration are taken for peak analgesia 
Morphine 
M6G 
M6G (protected) 
onset offset , duration # active • ED50 
(mins) (mins) (mins) (h) (mg/kg) 
30 
30 
60 
270 
1050 
1050 
90 
330 
300 
4 
11 
11 
2.2±0.3 
1.9±0.3 
1.5±0.4 
*No significant difference was determined by the t-test (pO.05), , 
represented the duration of maximal (cut-off) antinociception, and # the 
length of time latency was significantly above the saline controls. n=6. 
The onset is the time taken to reach maximal tail-flick latency, whereas the 
offset is the time taken to go from maximal latency to the saline baseline. 
Morphine-3-glucuronide (M3G) 
The lack of an effect after M3G administration on the tail-flick response 
over 4 h is shown in Figure 4.9. This confirmed M3G administered on its 
own did not appear to act as an anti nociceptive agent, its profile being not 
significantly different from that of saline. The effect of M3G co-
administration with 3mg/kg morphine s.c is shown in Figure 4.10. No 
antagonism of morphine analgesia was seen under the conditions 
employed. 
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Figure 4.9 Time course for M3G 10 (open circles), 30 (closed squares) & 
100mg/kg (open squares) administered s.c. in the tail-flick test p>0.05 for 
all concentrations of M3G versus saline (closed circles) using the t-test 
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Figure 4.10 Effect of M3G (30mg/kg) on morphine (closed circles, 3mg/kg) 
induced analgesia. Saline+morphine (open circles, 3mg/kg) and saline 
(open squares) 
Codeine and codeine-6-glucuronide (C6G> 
Codeine is a frequently used analgesic and also often present in antitussive 
preparations. Because M6G had an increased potency over morphine, 
codeine-6-glucuronide (C6G) may also have an increased potency over 
codeine. Codeine and C6G were tested in the mouse tail flick test and were 
seen to have similar duration of action (Figure 4.11, Table 4.2) and 
potencies (Figure 4.12, Table 4.2), with peak analgesia maintained for 2 h. 
and an onset of action of I h. Codeine retained its analgesia for longer 
than C6G, but the compounds were equipotent, affording EDSO's of 7.8 and 
7.2mg/kg respectively (Table 4.2). 
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Table 4 2 Comparison of the antinociceptiye properties of codeine and C6G 
in the mouse tail-flick test. following s.c. administration 
Codeine 
C6G 
EDSO 
(mg/kg) 
7.8±0.6 
7.2±OA 
active 
(h) 
3-4 
2 
duration 
(h) 
2.0±O.2 
2.0±0.2 
onset 
(h) 
1.0 
1.0 
offset 
(h) 
1.0±0.2 
1.3±0.2 
The active period was the total time that the drug was antinociceptive. 
whereas the duration of action was the time that the drug gave its maximal 
permitted analgesia. 
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Figure 4.11 Time course for codeine (open squares. 30mg/kg). C6G (closed 
circles. 30mg/kg) and saline controls (open circles) assessed using the 
mouse tail-flick test. Six mice were used for each point. * Represents p < 
0.05 indicating that the codeine and C6G points are significantly different 
from the saline points. as determined using the Wilcoxon signed rank test. 
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Figure 4.12 Dose-response curve for codeine(open squares), C6G(closed 
circles) and saline controls (open circles) assessed 60 mins after s.c 
administration, using the mouse tail-flick test. Six mice were used for each 
point. * Represents p < 0.05 indicating that the codeine and C6G treatment 
are significantly different from the saline treatment, as determined using 
the Wilcoxon signed rank test. 
4,3 Distribution of morphine-like activity in the hrain and spinal cord 
after s,c. administration of morphine and M6G 
A direct measure of CNS penetration of a drug was obtained by using ex-
vivo binding techniques to assess the brain levels achieved following 
systemic administration. Investigation of morphine distribution in the 
brain and spinal cord was determined using an ex-vivo binding assay. 
Calibration curves were constructed in mouse brain and spinal cord for a 
range of morphine concentrations and are shown in Figures 4.13 & 4.14. 
Slopes for the two displacement curves in mouse brain and spinal cord 
homogenate are the same. The displacement curve in mouse spinal cord is 
incomplete because mouse cords did not weigh as much as mouse brains. 
Thus the points for the cord calibration curve were chosen in the region 
that was thought to be most relevant. 
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Figure 4.13 Calibration curve for displacement by morphine of [3H]DAMGO 
(1.0nM) in mouse brain homogenate for 40 mins at 25°C 
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Figure 4.14 Calibration curve for displacement by morphine of [3H]DAMGO 
(1.0nM) in mouse spinal cord homogenate for 40 mins at 25°C 
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From the control curves for mouse brain and spinal cord quantities of 
morphine in test tissues were determined by interpolating off the curve. A 
concentration of 6.3±1.8nM morphine was found in the brain (this 
corresponded to a total brain level of 216pmoles/whole brain) and 
2.7±0.8nM morphine was present in the spinal cord 1 h after morphine 
(Smg/kg) was administered s.c. 
Following M6G (Smg/kg s.c.) administration for 1 h 1.8±O.2nM and 
2.0±0.2nM morphine equivalents were found in the brain and spinal cord 
respectively. Thus about three times as much morphine penetrated into 
the brain compared to M6G. whereas equivalent amounts of morphine and 
M6G were found in the spinal cord. The relative CNS penetration. 
determined by dividing the brain level (in ng/mg protein) by the dose 
administered. for morphine and M6G. and gave ratios of 7.2 and 2.S in 
brain. and 3.1 and 2.8 in spinal cord (Table 4.3). Thus morphine penetrated 
the brain to a greater extent than M6G. as expected. but this was not found 
to be the case in the spinal cord. 
Table 4.3 Comparison of morphine and M6G in their ability to penetrate 
into the CNS 
(mg/kg) (nM) (ng/mg protein) 
CNS Dose Level Level Ratio 
M (s.c.) Brain S 6.3±1.8 36.0 7.2 
M6G (s.c) Brain S 1.8±0.2 12.S 2.5 
M (s.c.) Cord S 2.7 IS.4 3.1 
M6G (s.c.) Cord S 2.0 13.8 2.8 
Six mice are used for each experiment. except for the cord where n=l. 
pooled from 6 mice. 
From the time course experiments it was apparent that M6G was much more 
longer acting than morphine. whilst retaining similar potency. after 
peripheral administration. M6G was still fully active after 6 h. whereas 
morphine started to lose activity after 2 h. To determine if M6G's longer 
duration of action was due to the continued presence of M6G or an 
alternative mechanism. ex-vivo binding assays were also performed 6 h 
after administration of morphine (Smg/kg). M6G (Smg/kg) or saline. 
After 6 h 2.S±0.4nM morphine equivalents were present in brains of M6G-
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treated animals. whereas <O.lnM morphine equivalents were present in 
brains from the morphine treated animals. Thus morphine-like material 
was still present 6 h after M6G administration to produce its effects. but not 
with morphine. 
The experiment was repeated following a high dose of morphine sulphate 
(50mg/kg s.c.) to mice. The animals were killed after 30 mins. at the time 
of maximal analgesia. A latency of >IOs (n=6) was observed for morphine. 
with a saline control of 3.2±0.2s (n=6). In treated mice 72.9±7.7% (n=6) of 
[3H1DAMGO was specifically displaced from mouse brain. which 
corresponded to a morphine concentration of 52.2±6.3nM (n=6). In the 
spinal cord 70.3±1.1 % of [3H1DAMGO was specifically displaced. which 
corresponded to a morphine concentration of 58.6±2.lnM. Thus when 
morphine is administered at this higher dose of 50mg/kg to mice by the 
subcutaneous route. equivalent amounts of morphine penetrated into both 
the brain and the spinal cord. The difference observed between the two 
dose of morphine used (5 or 50mg/kg) may be due to the different times of 
determination used and different kinetics of distribution. 
4.4 Metabolism of morphine 
Morphine metabolites were separated by HPLC. using the gradient system 
developed. as described in the methods (Chapter 2). The retention times for 
M3G. normorphine. M6G and morphine are given in Table 4.4. 
Table 44 Retention times for morphjne. M6G. M3G and normorphjne 
Compound Retention time/mins (n=6) 
M3G 
normorphine 
M6G 
morphine 
8.2 ± 0.2 
9.8 ± 0.1 
12.0 ± 0.2 
14.0 ± 0.2 
4.4.1 Metabolism in liver homogenates 
Glucuronidation of morphine was investigated in livers from several 
species. namely mouse. guinea-pig. rat and rabbit. Under the conditions 
used no significant glucuronidation was observed in any of these liver 
homogenates (Figure 4.15). G1ucuronidation was also investigated in other 
tissue homogenates. namely brain. kidneys and intestines. but no 
conversion of morphine was observed here either. 
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Figure 4.15 Lack of of morphine metabolism in mouse(black). rat(grey). 
guinea-pig (black hashed lines) and rabbit (white hashed lines) liver 
homogenates. Boiled enzyme controls after 6 h afforded values of 98±3. 
96±3. 98±2 and 94±6% of the % control morphine values in mouse. rat. 
guinea-pig and rabbit liver respectively. Values were not significantly 
different from 100%. as assessed in the student t-test. 
Following this livers from phenobarbital pre-treated mice were used 
(Sanchez & Tephly. 1974; Puig & Tephly. 1974). Livers were removed from 
mice pretreated with phenobarbital (80mg/kg i.p. for 4 days). The results 
of a 6 h time course of glucuronide formation in homogenates of these 
livers are summarised in Table 4.5. Results showed a 20% conversion to 
M3G. but the 6-glucuronide was detected in only very small quantities 
(approximately 1.0%). 
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Table 4.S Glucuronidation of morphine in homogenates of livers from 
phenobarbital treated mjce 
Time (h) 
% recovery of morphine 
0 0.5 I 3 6 
Morphine lOO 92.3±2.1 90.S±3.8 82.9±7.3 72.0±9.1 
M3G 0 6.2±2.7 9.2±0.6 16.4±7.2 2S.2±8.8 
M6G 0 0.8±0.2 1.0±0.3 0.8±0.3 0.8±0.3 
Morphine lOO n.t. 101.3±8.8 100.7±0.7 97.8±4.1 
(control) 
n.t. denotes not tested 
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4.5 Discussion 
No glucuronidation of morphine was detected in studies performed here in 
mouse. guinea-pig. rat or rabbit liver or in mouse brain. kidney or ileum. 
Possibly 4mg of protein quoted by Sanchez and Tephly (1974) to give them 
optimal glucuronidation was not adequate in experiments performed here. 
Lawrence et al (\992) reports that morphine metabolism within the 
guinea-pig liver produces both M3G and M6G in a ratio 1 :4. although the 
use of the detergent Brij 58 and magnesium ions (15mM) is necessary for 
optimal production. The findings in mouse kidney are in contrast to Yue 
et al (1988). that the human kidney does glucuronidate morphine to M3G 
and M6G. whilst Wahlstroem et al (I988) reports that brain microsomes 
glucuronidate morphine. Glucuronic acid. a co-substrate for 
glucuronidation. has been identified by Shashoua et al (1986) in rat brain. 
The possibility of glucuronidation of morphine within the eNS is an 
interesting area. and thus needs to be re-examined. 
Use of livers from phenobarbital-treated mice did produce glucuronidation. 
Other authors have shown the need for phenobarbital treatment. either 
p.o. in the animals drinking water (Hanna et al. 1993) or i.p. (Sanchez & 
Tephly. 1974; Puig & Tephly. 1974; Rane et al. 1985) or a combination of both 
(Bock et al. 1980). Phenobarbital increases glucuronyl transferase-type 
2(GT2) enzyme glucuronidation by 3-10 fold depending on the method used. 
Using phenobarbital (80mg/kg i.p.for 4 days) morphine metabolism was 
observed in vitro. in mouse liver. affording the 3-glucuronide (up to 25% 
of recovered metabolites after 6 h). but only approximately I % of the 6-
glucuronide. Thus there is no evidence that M6G is important in the 
mouse. In confirmation of this Yeh et al (1979) reports the amount of M6G 
to be too small to be determined quantitatively. However in vivo data does 
show M6G in the urine of humans. rats. monkey. dog. guinea-pigs and 
rabbits (Yeh et al. 1979; Kuo et al. 1991; Rane et al. 1984; Misra et al. 1970). 
Morphine and M6G had similar potencies in the mouse tail flick test. when 
injected s.c. (EDSO's of 2.2 and t.9mg/kg respectively). but M6G did have a 
much longer duration of action than morphine. 9 h compared to 2 h. 
M6G(protected) had a similar potency to M6G (t.5mg/kg) and a similar in 
vivo profile. It is likely that the protected sugar is rapidly metabolized to 
M6G in vitro and in vivo and this could be followed up in future. The 
protected glucuronide could thus be used as a useful replacement to M6G. 
acting as a prod rug. The synthesis is much easier and more economical (Di 
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Pretoria. 1994). The results for M6G and morphine in the mouse tail-flick 
test agreed with those of Shimomura et al (1971) who reported that M6G was 
4 times as potent in mice in the hot plate test. with twice the duration 
(Shimomura et al. 1971). compared with morphine when injected s.c. The 
duration of the analgesic effect may be a consequence of a lower rate of 
metabolism of M6G than morphine (Frances et al. 1990). The potencies of 
M6G and morphine are shown in Table 4.6 for different routes of 
administration. Morphine and M6G have similar potency when 
administered s.c. or p.o. However when injected i.c.v. M6G is reported to be 
330 times as potent as morphine. In agreement. Paul quotes M6G to be 90 
times as potent i.c.v. (20 times in rats) and 650 times as potent as morphine 
i.t. (Paul et al. 1989 i). as does Gong et al (1991). who find M6G to be 200 times 
more potent when administered centrally and assayed in rats using the 
tail-flick and hot plate tests. but only 9 times in the writhing test. When 
given i.c.v. in rats. M6G is 60 times more potent than morphine when 
examined in the formalin test (Abbott & Palmour. 1988; Abbott & Franklin. 
1991). In electrophysiological experiments M6G is 13 -fold more potent 
than morphine when given i.t.. in inhibiting C-fibre-evoked activity in 
rats (Sullivan et al. 1989). In summary M6G is more more potent when 
given centrally (i.t. > i.c.v.) than morphine. whereas both compounds 
exhibit similar potencies when administered systemically. As can be seen 
wide variations are evident in the assessment of the analgesic potencies of 
M6G and morphine. from the different authors. Possible reasons for these 
differences are due to species and strain differences as well as different 
analgesic tests used. 
Table 46 Potencies fEDSO's nmoles/mouse) of morphine and M6G in the 
mouse tail flick test 
ED50 (nmoles/mouse) 
s.c. i.c.v. p.o. 
Morphine 79.8 1.65 918 
M6G 49.3 0.005 504 
M/M6G 1.62 330 1.82 
In vivo binding studies show that M6G exerts its antinociceptive effect at 
low «1%) fractional occupancy of [3Hldiprenorphine-specific binding 
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sites. by co-injecting M6G with [3Hldiprenorphine. In contrast morphine 
needs to occupy 9.5 (writhing) to 47 (tail-flick) times more opioid binding 
sites to produce the same antinociceptive activity (Frances et al. 1992). 
Frances et al (1992) suggests that the higher pharmacological potency of 
M6G (i.c. v) compared to morphine is either due to its enhanced stimulation 
of 'opioid receptor-transducer-effect or complexes' ie. second messenger 
systems or to elevated local concentrations in brain regions involved in 
antinociception. The same group has since reported that the analgesic 
potency of M6G is related to a LiCI-sensitive pathway and not to adenylate 
cyclase inhibition. thus indicating that a phosphoinositide pathway could 
be preferentially involved (Frances et al. 1993). Lambert & Hirst (1993) 
investigate binding and inhibition of cyclic AMP formation in intact SH-
SY5Y neuroblastoma cells for morphine. M6G and M3G. M6G is about 4 times 
weaker than morphine in binding. but is equipotent in inhibiting cyclic 
AMP formation. M3G is ineffective in both assays. Christensen et al (1991) 
show that morphine and M6G inhibit dopamine-stimulated cyclic AMP 
formation in rat striatal membranes. affording values of I and 511M 
respectively. These findings do not however explain M6G's higher 
anti nociceptive action. 
It is suggested by Frances that thermal analgesia at the level of the spinal 
cord. is mediated mainly through S receptors. since DPDPE is more potent 
when given i.t.. whereas DAMGO is more effective when given i.c.v .• and 
morphine is equipotent by both routes (Frances et al. 1992). The 
stimulation of S spinal sites by i.t. M6G could account for the high degree of 
antinociception elicited in thermal nociceptive tests. due to its higher 
affinity for S receptors as discussed in Chapter 5. 
The difference in activity between 6-0H and 6-glucuronide was not 
observed with the codeine equivalents. Codeine and C6G had an almost 
identical in vivo profile. their potencies were the same. as were their 
onsets and offsets of action. The only difference was that codeine was 
slightly longer acting than C6G. 
Following s.c. administration. three times as much morphine penetrated 
the brain as did M6G. whereas both compounds penetrated the cord to an 
equivalent extent. 1 h after systemic administration. M6G thus seemed to 
act much more strongly after penetration into the brain and to be removed 
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more slowly from the brain as compared with morphine. because M6G had a 
longer duration of action than morphine. Indeed 6 h after systemic 
administration. <O.lnM morphine equivalents were present after 
morphine. but 2.5nM morphine equivalents were present after M6G. These 
findings are in agreement with Frances et al (1992). who shows M6G to be 
ID-fold less effective at penetrating the brain than morphine. These 
differences might be explained by a more hydrophilic nature of M6G. due 
to the sugar moiety. 
The present results show that after s.c. administration of morphine. twice 
as much gets into the brain as the cord. whereas with M6G equivalent 
amounts get into both the brain and the cord. This contradicts findings 
after i.v. injection of morphine. Bhargava et al (\992) quotes the level of 
morphine to be highest in the spinal cord. The highest concentration in 
the brain was found in the hypothalamus and the lowest in the amygdala. 
However with larger dosing equivalent amounts were found. 
Retention times obtained using HPLC indicated that morphine and M6G had 
similar lipophilicities. Carrupt et al (1991) also suggest that the 
Iipophilicities of M6G and morphine are not that dissimilar. This is 
explained by the fact that M6G may exist in a predicted folded conformation 
(Figure 4.16a.) as opposed to the extended conformation (Figure 4.16b. both 
figures produced using the Evans and Sutherland workstation). thereby 
masking the polar hydrophilic groups. so the groups are thus unexposed 
and the compound appears more lipophilic to biological membranes. M3G 
can also exist in folded and extended conformations. explaining its ability to 
penetrate the blood-brain barrier. but to a lesser degree than M6G. 
Morphine is still a relatively hydrophilic compound. hence both M6G and 
morphine have relatively long durations of action. The drugs are disposed 
of more slowly than a more lipophilic compound such as methadone. which 
penetrates the blood-brain barrier rapidly and its duration is determined 
by its slow release from receptor sites. Because M6G is more hydrophilic 
than morphine. the onset and offset would be predicted to be longer in 
vivo. Antinociception is seen at a similar time after administration. 
suggesting they have the same onset rate. M6G (protected) in which the 
hydrophilic groups are protected as esters would be predicted to have faster 
kinetics than M6G. because it is more lipophilic. In fact M6G (protected) 
takes longer to show analgesia. but this may be because of the use of saline 
+ 0.25% carboxy methyl cellulose as the vehicle. as opposed 
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Figure 4.16 M6G in <a) the folded conformalion using the Evans & 
Sutherland <liHf ~ 32.61kcaIlmole) 
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(b) extended conformation ("'Hr =28.54kcallmole) 
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to saline for M6G, and the drug takes longer to diffuse out of the polymer. 
However it could be the need for removal of the. protecting groups. It thus 
appears likely that the morphine protected sugar was metabolised to M6G, 
and the results obtained here are due to formed M6G. However, this 
suggestion was not confirmed by stability studies performed in mouse 
brain homogenate, which suggests that the protected sugar was stable (see 
page 138). This could mean that the carboxy and hydroxy groups on the 
sugar in M6G are not essential for potency or duration of action. Before 
any definate conclusions can be deduced from these results though, M6G 
must be injected in 0.25% CMC to directly compare the results obtained from 
the M6G (protected sugar) in 0.25% CMC. 
In contrast to M6G, M3G was shown to be totally inactive up to doses of 
100mg/kg s.c. in the mouse tail-flick test in agreement with Shimomura er 
al (1971). In addition M3G was shown not to antagonise antinociception 
induced by morphine. These results differed from those of Smith er al 
(1990), who showed M3G to be hyperanalgesic, and Gong er al (1991) also 
reported that M3G stimulated ventilation. There are contradicting views as 
to whether M3G is an antagonist to morphine and/or M6G analgesia. Smith 
er al (1990) reports that this is the case when M3G is administered Lc.v. or 
Lp. to rats. Interestingly M3G causes allodynia when administered Lt. or 
i.c.v., as does morphine itself, a condition in which an ordinarily 
innocuous stimulus is perceived as being painful. M3G is about thirty times 
more potent than morphine in causing this effect when administered i.t. 
The response causes aggressive behaviour, indicative of a pain state. This 
response is however a non-opioid effect (Yaksh & Harty, 1988). 
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CHAPTER 5 
BINDING AND ISOLATED TISSUE STUDIES OF 
MORPHINE AND ITS GLUCURONIDE 
In vivo studies confirmed the antinociceptive activity of M6G and in 
particular its longer duration of action compared to morphine. To 
determine if this was due to differences in receptor activity of the two 
compounds. studies were performed in vitro. 
5 I Characterisation of the binding of u.&. and K ol1ioid ligands to 
homogenates of mouse brain 
The saturation binding of [3H1DAMGO (11). [3H1DPDPE (&) and [3H1U69593 (K) 
to mouse brain homogenate was determined at 25°C for 40 mins (Table 5.1). 
Table 5.1 Binding characteristics for [3H1DAMGO. [3!:!lDPDPE and [3!!JU69593 
in mouse brain 
KD(nM) 
Bmax (pmoles/g) 
DAMGO 
1.37±0.21 
8.49±0.93 
DPDPE 
5.7S±0.62 
11.36±1.3 
Values are means ± sem of ;;, 3 experiments 
U69593 
1.67±0.32 
9.30±1.30 
The high affinity of each ligand for respective receptors confirms the 
presence of 11. & and K sites in mouse brain. From Table 5.1 the % of sites 
was determined as 11 (29.1). & (39.0) and K (31.9). thus there are similar 
levels of 11 and K receptors. but slightly more & receptors. Analysis of 
[3H1U69593 binding in guinea-pig brain afforded similar affinity to that 
obtained in mouse brain. namely a KD of 0.95±0.24nM. but a reduced Bmax 
of 3.31±0.25pmoles/g. 
The ability of morphine. M6G. M3G and some selective opioid ligands to 
displace selective tritiated Jigands for 11 (DAMGO). & (DPDPE) and K (U69593) 
opioid binding sites in mouse or guinea-pig brain homogenates was 
determined. Results are shown in Figures 5.1 and 5.2 and Table 5.2. As 
expected morphine was selective for 11 receptor binding sites (Ki 6.2nM). 
but also had greater affinity for K than & binding sites. M6G on the other 
hand was less selective for 11 over & binding sites. but had much lower 
affinity for K-opioid binding sites (ten-fold). The selectivities of M6G. 
morphine and DAMGO are shown in Table 5.3. the lower the number. the 
more selective the drug was for the 11 site. Results from binding assays 
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showed morphine to be more IJ./o selective, whereas M6G was more IJ./le 
selective. 
The O-protected glucuronide analogue of M6G showed a very similar 
receptor profile to that of M6G. In contrast M3G had no affinity for 11,0, or 
le sites. 
Displacement of [3 H]DPDPE by both morphine (Figure 5.2) and M6G (Figure 
5.1) was biphasic with the first component representing approximately 
20% displacement of specifically bound [3H ]DPDPE. This was particularly 
clear with M6G (refer to Figure 5.2). Thus taken over the whole range of 
concentrations the slope of the displacement was 0.7. The slopes of the 
other displacement curves were all approximately unity, consistent with 
activity at single sites (Table 5.4). 
5 2 Receptor binding profile of M6G and morphine 
Table 5 2 Effectiye inhibition constants (Ki/nM) for morphjne, s.wiu<. 
metabo!ites and control opiojds in brain homogenates 
mouse 
Morphine 6.22±0.86 
M-6-G 7.90±1.48 
M6G (p) 11.2±2.6 
M-3-G >10,000· 
DAMGO 2.45±0.40 
DPDPE >10,000 
U69593 >10,000 
Ki (nM) 
o 
mouse 
218±41.2 
*75.1±15.6 
33.0±3.24 
>10,000' 
42.5±7.88 
4.76±1.44 
>10,000 
mouse 
84.7±4.01 
*850.15± 118 
820±26.3 
>10,000# 
2218±518 
600±124 
2.51±1.22 
guinea-pig 
40.83±3.23 
*766±27.3 
>10,000 
1.80±0.81 
Values are means ± sem of ~ 3 experiments. * Significantly different from 
results for morphine p< 0.005 (student's t-test). 10,OOOnM M3G displaced 
27.9% of [3H]DAMGO (1.16±0.llnM,· ); 30.3% of [3 H]DPDPE (0.74±0.02nM, ,) 
and 25.8% of [3 H ]U69593 (1.07±0.13nM, #), M6G (p) is the O-protected 
glucuronide of M6G (compound 17). 
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Table 5 3 Selectivities of M6G. morphine and DAMGO for u. l\ or K-sites. taken 
from Table 5. 2 
M6G 
M6G(p) 
Morphine 
DAMGO 
K· "'K· Ii 1'" 1 
0.105 
0.330 
0.029 
0.006 
0.010 0.088 
0.010 0.040 
0.152 2.580 
0.006 0.019 
Table 5.4 Slopes for displacement of [3HJDAMGO. [3HlDPDPE and [3HJU69593 
by morphine. M6G. M6G (p). DAMGO. DPDPE & U69593 
K 
Morphine 1.03±0.03 0.97±0.04 0.95±Q.08 
M6G 0.93±0.07 1.05±0.08# 1.05±Q.05 
M6G (p) 0.95±0.08 1.I0±0.09# 1.02±Q.06 
DAMGO 0.98±0.08 0.94±0.02 
DPDPE 0.89±0.04 
U69593 0.90±Q.06 
# represents the linear portion of the displacement curve. from 15 to 85% 
displacement. IC
50 
values were re-calculated. assuming that 85% is now 
100% control. and a new curve plotted. 
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Figure 5.1 Displacement of tritiated DAMGO (c(osed circles. 1.12±O.09nM). 
tritiated DPDPE (open circles. O.74±O.02nM) and tritiated U69593 (closed 
squares. O.50±O.OlnM) in mouse brain by M6G 
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Figure 5.2 Disp(acement of tritiated DAMGO (closed circles. 1.l9±O.20nM). 
DPDPE (open circles. O.74±O.02nM) and U69593 (closed squares. 1.07±O.26nm) 
in mouse brain homogenate by morphine 
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5.2.1 Binding of [3 HlDAMGO at low concentrations of u ligands 
Abbott & Palmour (1988) reported effects of M6G on ~-binding at low 
(subnanomolar) concentrations. Competition studies against [3H1DAMGO as 
low as 10- I IM competing ligands were carried oul. As can be seen in 
Figure 5.3 the binding of [3 H1DA MGO was unaffected at these lower 
concentrations of the ~ ligands morphine. M3G or M6G . 
.01 . 1 
[mu-ligand] nM 
Figure 5.3 Displacement of [3 H1DAMGO (O.99±O.06nM) by subnanamolar 
concentrations of morphine(closed circles). M3G(open circles) and 
M6G(open circles) 
5.2.2 Binding to opioid K receptors in guinea-pig cerebellum 
Since the K-receptor binding of morphine and M6G in mouse brain were so 
different further binding studies were perforined in guinea-pig 
cerebellum. a tissue containing predominantly K-receptors. for 
comparative purposes. Morphine again showed a higher affinity for K 
receptor binding sites than M6G. though the absolute Ki values depended 
upon the tritiated ligand used. When using the antagonist 
[3Hldiprenorphine or the agonist [3H1U69593 to label K sites. differences 
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were obtained of approximately 11 and 27 - fold respectively. However 
morphine had 4 and M6G had approximately 10 fold higher affinity for K 
receptors in brain compared to cerebellum, suggesting tissue differences. 
Table 5,5 Comparison of K binding in guinea-pig brain and cerebellum for 
morphine and M6G 
cerebellum 
Ki (nM) 
cerebellum 
[3Hldiprenorphine [3H1U69593 
M6G 6170±622.6 
Morphine 546.8±59.89 
*>10,000 
370±25.6 
Brain 
850.15±117.8 
84.67±4.0l 
* 10,OOOnM corresponded to 71.4±2.3% contrpl [3 H1U69593 binding. 
5.2.3 Binding studies in mouse spinal cord 
In mouse spinal cord homogenate morphine showed a slightly higher 
affinity for 11 receptor sites than M6G with Ki values of 5.4 and 14.8nM 
respectively (Table 5.6), but values were similar to brain. Again as in 
brain tissue, M6G had a 6-fold higher affinity for the 1) receptor than 
morphine (68.7 compared to 405.2nM). These values were of the same order 
as the Ki values determined in brain. 
Table 5.6 Effective dissociation constants for morphine & M6G at the u and 1) 
receptors in mouse spinal cord. 
Morphine 
M6G 
Ki (nM) 
*5.4±0.60 
·14.8±0.42 
402.2±42.6 
6S.7±4.2 
Values were means ± sem of ~ 3 experiments. Labelling of 11 and 1) receptor 
sites was done with [3H1DAMGO or [3H1DPDPE. * p<0.005 in the students t-test 
(significantly different from M6G), • Ki for M6G was significantly 
different in the brain (Table 5.2) compared to the cord (p<O.OOI). 
so 
5,24Binding in.~myenteric plexus longitudinal muscle (MPLM) 
The binding properties of morphine and M6G were also studied in the 
MPLM (Table 5,7), To obtain an acceptable degree of specific binding 
initial studies varying tissue concentration were performed, 
Table 57 Effect of tissue concentration on % specific binding using 
r3HlDAMGO (2,67+0.42nM) at 25°C for 40 mins 
Dilution (w/v) 
IS 
30 
60 
% Specific binding 
14,9±4,3 
41.5±3,S 
62,S±5,2 
A dilution of 60 times w/v. approximating to Img/ml of protein. was chosen 
for these studies, Affinities of Morphine and M6G in MPLM measured by 
the displacement of [3 H1D AMGO were assessed. and afforded similar Ki 
values of 3,1±0,6 and 2.4±0,SnM respectively, 
~Binding 1I1lulltli.n.brain under different buffer conditions 
Affinities of M6G. morphine and DAMGO were determined against the 
antagonist [3Hlnaloxone using Tris buffer pH 7.4 in the presence and 
absence of the stable GTP analogue. guanylimidodiphosphate (Gpp(NH)p. 
501!M) and NaCl (lOOmM), 
Results showed that M6G and morphine had similar affinity for I! receptors 
under these conditions (Table 5,S), Displacement curves are shown in 
Figures 5.4-5,6, DAMGO had a significantly higher affinity (1S9nM) than 
the alkaloids, 
Affinities determined in HEPES/Krebs for M6G. morphine and DAMGO 
against [3Hlnaloxone gave values of 101.2±20,1. 121.3±33,S and l1S.4±16,2nM 
respectively, 
SI 
Table S 8 Affinities CKilnM) of M6G, morphjne and DAMGO for u receptors. 
using r3H!naloxone CO.44+Q,Q4nMl. in the presence or absence of Gpo(NH>p 
CSQuM ) and NaCl(! QQmM) in rat brain homogenates 
M6G 
morphine 
DAMGO 
lQ,39±4,33 
2,83±Q,29 
S,97±2,19 
Na-Gpp(NH)p 
*423,97±50,82 
340,20±51,48 
l89,32±76,02 
shift 
40,8 
120,2 
31.1 
Values are means ± sem of <: 3 experiments, * p<0,05( in the students t-test) 
compared with DAMGO, The KD for naloxone was the same in the presence 
or absence of Gpp(NH)p and NaCl and was 2,00nM, 
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Figure 5.4 Displacement of [3Hjna]oxone (0.44±0,04nM) by M6G in rat brain 
in the presence (open circles) and absence (closed circles) of Gpp(NH)p 
(50~M) and NaCl (lOOmM) 
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Figure 5.5 Displacement of [3Hlnaloxone (0.44±0.04nM) by morphine in rat 
brain in the presence (open circles) and absence (closed circles) of 
Gpp(NH)p (50I1M) and NaCI (JOOmM) 
120 
100 
~ 80 
0: 
0 
0 60 
~ 
40 
20 
0 
.1 10 100 1000 10000 
(DAMGO) nM 
Figure 5.6 Displacement of [3Hlnaloxone (0.44±0.04nM) by DAMGO in rat 
brain in the presence (open circles) and absence (closed circles) of 
Gpp(NH)p (50I1M) and NaCI (JOOmM) 
The displacement curves did have slopes of 1.0, probably due to the ability 
of [3Hlnaloxone to label other sites, ie 1i and K, in addition to IJ.. However the 
83 
affinity of morphine and M6G in the presence of sodi urn and Gpp(NH)p 
were similar. and much lower than in Tris-buffer. 
Computer analysis of the lines allowed for comparison only of the 11-
component. using logistic curve fitting (Barlow. 1991). The results are 
shown in Table 5.9. with the two components (11 and non-l1) of the 
displacement curve shown. As can be seen DAMGO. morphine and M6G had 
similar affinities for the high affinity component. though the affinity for 
the non-11 component varied from 600 nM for DAMGO to 5199nM for M6G. in 
the presence of NaCl and Gpp(NH)p. The relative proportion of 11 to non-11 
sites was 78.4 : 21.6 %. The non-11 component being made up of 14.3 and 7.3 
% for 0 and 1C sites respectively. Thus it is unlikely that the non-11 
component is all subtype. 
Table 59 Affinities of M6G. morphine and DAMGO for Il receptors. using 
13Hlnaloxone in the presence and absence of Gpp(NH>p and NaCl 
~) Hig!H~r ~ffiDil~ (Il) corn pon eM 
Ki (nM) 
Tris Tris-Na-Gpp{NH)p 
M6G 2.52±0.14 63.5±3.40 
morphine 1.76±0.31 89.1±4.56 
DAMGO 0.87±0.20 51.4±4.65 
b) Lower affinit~ (DOD-Il) component 
Ki (nM) 
shi ft 
25.2 
50.6 
59.1 
Tris Tris-Na-Gpp{NH)p shift 
M6G 
morphine 
DAMGO 
358±52.6 
89.1±4.5 
198±30.1 
5199±301 
1001±54.3 
600±32.6 
14.5 
11.2 
3.0 
Because [3Hlnaloxone binds to all three receptors it was decided to use a 
more selective ligand for the 11 receptor. namely the cyclic somatostatin 
analogue. [3H1CTOP{Figure 5.7). which is reported to be a highly selective 11 
antagonist (Yamamura et al. 1989). Prior to displacement experiments. the 
binding of this ligand was studied. 
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H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 
Figure 5.7 crop 
Experiments were performed to investigate the effect of protein 
concentration on the specific binding of [3 H)CTOP. Values ranged from 49 
to 69%. A 1/100 dilution (9.6mg tissue weight) of brain was chosen to 
perform future experiments, as this gave the maximum specific binding. 
Yamamura et at (1989) reports the use of other compounds to facilitate 
[3 H)CTOP binding, namely bovine serum albumin (BSA) and phenyl methyl 
sulphonyl fluoride (PMSF). From the results shown in Table 5.10. It can be 
observed that the use of BSA and/or PMSF did not produce any 
improvement to the % specific binding. Consequently [3 H)CTOP binding 
was performed under conditions used for other opioid ligands, ie in Tris 
buffer pH 7.4. without any additions. 
Table 5.10 Effect of BSA and PMSF on specific binding of r3 mcror 
Conditions 
control 
BSA 
PMSF 
BSA+PMSF 
% Specific binding 
52.7±5.4 
58.8±4.2 
50.8±3.7 
54.7±4.1 
The time taken for [3H)CTOP binding to reach equilibrium was determined 
at both 25°C and 37°C in mouse brain homogenates. Equilibrium binding 
was reached at 120 and 60 mins respectively (Figure 5.8). It was noticable 
that binding at 25°C was greater than that at 37°C. 
Na/Gpp(NH)p, equilibration was reached after 60 mins 
binding was much reduced (8-fold). 
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In the presence of 
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Figure 5.8 Time course for specific [3 H]CTOP(O.35±O.05nM) binding in 
mouse brain homogenates at 25°C (closed circles) and 37°C (open circles). 
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Figure 5.9 Time course for [3H]CTOP (O.16±O.OlnM) specific binding in the 
presence of NaCl (lOOmM) and Gpp(NH)p (50~M) at 25°C 
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Characteristics of the binding of [3 H]CTOP in mouse and rat brain in the 
presence and absence of Na+ are reported in Table 5.11. As can be seen the 
KD for [3 H]CTOP shifts in NaCI and Gpp(NH)p to lower affinity by greater 
than 10-fold. Saturation binding results for [3 H]CTOP were different in 
mouse and rat brain homogenates (Table 5.11, Figure 5.10). Scatchard 
analysis of the data in mouse and rat brain is shown in Figure 5.11. 
Table 5 II Characteristics of binding of r3HlCTOP in mouse and rat brain 
homogenates 
NaCI/Gpp(NH)p 
Bmax/fmoles/mg Ko'nM Bmax/fmoles/mg 
Mouse 0.30±0.03 97.8±1O.9 7.62±0.83 77.5±6.32 
Rat 0.65±0.07 59.7±7.3 n.t. n. t. 
Values are means ± sem of <: 3 experiments. Binding was performed at 25°C 
for 40 mins. n.t. denotes not tested. 
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Figure 5.10 Specific binding of [3 H]CTOP to homogenates of brain (9.6mg 
tissue weight) from mouse (closed circles) and rat (closed triangles) at 25°C 
and for 40 mins (representative experiment) 
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At higher concentrations of [3 H]CTOP the specific binding seemed to 
increase for rat homogenate and resulted in a complex Scatchard Plot. Due 
to this the values for the rat are approximate, but fitted as a single site by 
LIGAND. In mouse homogenate a plateau was maintained. 
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Figure 5. I I Scatchard analysis for [3H ]CTOP in mouse (closed circles) and 
rat brain (9.6mg tissue weight)(closed triangles) at 25°C and for 40 mins 
For comparative purposes the binding of [3 H ]DAMGO binding was studied in 
rat brain homogenate (Figures 5.12 and 5.13), and afforded a KD of 
0.80±0.12nM and a Bmax of 67.9±5.6fmoles/mg. 
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Figure 5.12 Specific binding of [3H1DAMGO to rat brain homogenate (9.6mg) 
at 25°C for 40 mins 
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Figure 5.13 Scatchard analysis of [3 H1DA MGO binding in rat brain 
homogenate (9.6mg tissue weight) at 25°C for 40 mins 
As can be seen from the results in Table 5.12 the maximal binding capacity 
(Bmax ) obtained for [3H1DAMGO and [3H1CTOP was comparable in both 
mouse and rat brain homogenate. 
89 
Table 5 12 Comparison of Bmax values (fmoles/mg protein) for [3HlDAMGO 
ruu!..l3HlCTOP in mouse and rat brain homogenate 
Mouse 
Rat 
DAMGO crop 
82.6 
67.9 
97.8 
59.7 
5.2.6 Competition studies using [3HJ CTOP in mouse brain 
The binding of [3 H]CTOP was studied in the presence and absence of NaCI 
(lOOmM) and Gpp(NH)p (5011M). Competition studies with opioids were 
performed to compare displacement curves under high (Tris) and low 
(NaCl. Gpp(NH)p) agonist affinity states of the ll-receptor. The results are 
summarised in Table 5.13. The difference between displacements (sodium 
shift) for DAMGO in mouse brain against [3H]CTOP is shown in Figure 5.14. 
as a representive graph of these results. The results were somewhat 
confusing because no significant shifts was observed for the 11 agonist 
Iigands (Table 5.13). Affinities obtained in Tris with [3 H]CTOP for ll-Iigands 
were much lower than those obtained with[3 H]naloxone (Table 5.8) and as a 
result of this the shifts are much less with [3 H]CTOP. Also the fact that 
[3 H]CTOP itself shifts 10 times. probably mask any agonist shifts. In 
addition shallow slopes were obtained for the displacements. as shown for 
DAMGO in Figure 5.14. 
Table 5 13 Affinities (Ki/nM) of M6G. morphine. naloxone. fentanyl and 
DAMGO for u receptors.using [3HlCTOP (0.38+0.02nMl. in the presence or 
absence of Gop(NHlp (50uM ) and NaCIOOOmM) 
Tris Tris-Na Shift 
Morphine 17.1±5.21 18.0±3.21 1.1 
M6G 19.7±4.12 37.3±6,47 1.9 
Naloxone 3.12±0,45 1.72±0.62 0 
Fentanyl 13.1±3.82 12.9±2.91 0 
DAMGO 24.7±5.32 81.8±6.82 3 
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Figure 5.14 Sodium shift for DAMGO in mouse brain using [3 H]CI'OP 
(0.38±O.02nM) in the presence (open circles) and absence (closed circles) 
of Gpp(NH)p (50!1M) and NaCI (I00mM) 
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5 3 Isolated tissue studies 
5 3 I Myenteric plexus longitudinal muscle (MPLM) 
The potency of various agonists including morphine and M6G was assessed 
in the MPLM (Table 5.14). Graphs are shown in Figures 5.15-5.18. 
Table 5.14 Potency OC50 's) and naloxone equilibrium constants( KeL1.n. 
MPLM for a series of opiates and related compounds 
IC50/nM Slope 
M6G *58.0±4.30 3.00±0.80 0.94±0.01 
M6G(p) 40.6±4.32 3.05±0.92 0.89±0.05 
Morphine 130±7.20 3.45±0.59 1.02±0.03 
U69593 2.20±0.41 9.00±2.11 0.97±0.06 
DAMGO 11.8±1.20 1.60±0.06 0.98±0.04 
Codeine 1600±150 
M3G >10,000 
Values are means ± sem of ~ 3 experiments. * p<O.OOI (Students t-test) shows 
IC50 's for M6G and morphine are significantly different. Schild plots were 
employed to calculate Ke values. 
M6G (IC50 58nM) showed a 2-fold increase in potency over morphine (IC50 
130nM). Naloxone Ke's derived from Schild plots of antagonist data 
(Figures 5.17 & 5.19) gave values against both agonists of approximately 
3nM, ie. in the expected range for 11 receptors. Slopes of 1.0 were obtained 
confirming an action solely via a single receptor population. M6G 
(protected) (IC50 41nM) showed similar potency to that of M6G (IC50 58nM). 
DAMGO and U69593 are selective 11 and 1C agonists respectively and both 
were very potent in this preparation. M3G had no effect in the MPLM up to 
IO,OOOnM. Similarly codeine had a much reduced potency compared to 
morphine, but was considerably more potent than M3G. 
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Figure 5.15 Inhibition of electrically induced contractions of the guinea-
pig MPLM by M6G in the absence (open circles) and presence of varying 
concentrations, 10 (closed circles), 30 (closed squares) and 100nM (closed 
triangles) of naloxone 
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Figure 5.16 Representative Schild plot for naloxone antagonism of the 
response to M6G 
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Figure 5.17 Inhibition of electrically induced contractions of guinea-pig 
MPLM by morphine in the absence (open circles) and presence of varying 
concentrations, 10 (closed circles), 30 (closed squares) and 100nM (closed 
triangles) of naloxone 
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Figure 5.18 Representative Schild plot for naloxone antagonism of the 
response to morphine 
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5.3.2 The rat vas deferens preparation 
The rat vas deferens contains a reduced 11 receptor population compared to 
the guinea-pig MPLM or the mouse vas deferens (Smith & Rance, 1983) and 
therefore partial agonists act as antagonists and only highly efficaceous 11 
compounds produce a response. Consequently such a preparation can be 
used as an indication of efficacy in a series of compounds. For example, 
morphine acts as a partial agonist (Smith & Rance, 1983). This also allowed 
for the determination of affinity constants, by determining shifts observed 
against more efficaceous compounds, which acted as full agonists in this 
preparation (eg. DAMGO). 
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Figure 5.19 Inhibitory potency of l1-agonists DAMGO (closed circles), M6G 
(open circles) and morphine (closed squares) in the rat vas deferens 
preparation in Krebs with 0.188g/l Ca2+ 
Table 5.15 IC50 'sCnMl obtained for u-Iigands in the rat vas deferens 
IC50/nM 
DAMGO 306.8±45.8 
M6G >10,000 
M3G >3000 
Morphine >10,000 
Codeine >100,000 
Values are means ± sem of ~ 3 
Max % inhibition IC20 (nM) 
observed 
91±4 110±9.3 
40±2 850±45 
0 
32±3 2000±203 
0 
experiments 
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n 
6 
4 
3 
3 
3 
Figure 5.19 shows the relative potency of I! ligands. M6G and morphine do 
not reach 50% inhibition, whereas DAMGO reached >90% inhibition, but a 
large reduction in potency for DAMGO is observed compared with the MPLM 
(IC50 of 12 nM in the MPLM to 307nM in the RVD). The calcium chloride 
concentration (0.188glI) used in the RVD was half that used in the MPLM. 
M6G and morphine thus had a much reduced maximum effect observed 
compared with values in the MPLM, and were also shifted dramatically 
(58nM and 120nM in the MPLM to > IO,OOOnM in the RV D) (Table 5.15, n 
values are given in Table). Codeine showed no agonist effect at all. The 
relative efficacies of morphine and M6G were 18.0±8.0 and 7.8±3.0 times less 
potent than DAMGO, using a modification of the Furchgott analysis (Chapter 
3, page 52). 
In this preparation therefore M6G and morphine can be used as 
antagonists and thus affinity values were obtained for the compounds at I! 
receptors. Assays were done using IOOOnM morphine and M6G against 
DAMGO as an agonist and results were analysed using the technique 
developed by Kosterlitz & Watt (1968). To ensure that DAMGO acted as a full 
agonist, the tissues were bathed in Krebs solution with half the normal 
Ca2+ present (Sheehan et ai, 1988) (With a quarter Ca2+ no response was 
observed) (Figure 5.20). The shifts in DAMGO dose-response curves are 
given in Table 5.16 together with the apparent Ke values determined. 
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Figure 5.20 Effect of calcium concentration, 0.375g/1 (closed circles) and 
0.188g/l (open circles) in the RVD for DAMGO 
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Table 5.16 Dissociation constants [Ke(nMl for M6G and morphine in the rat 
vas deferens versus DAMGO 
M6G 
Morphine 
Dose-ratio 
9.7±2.6 
2.2±0.4 
194±28 
1007±188 
Values are means ± sem of ;" 3 experiments 
5 3 3 Furchgolt analysis of u-agonists in the myenteric plexus longitudinal 
muscle 
In order to obtain a measure of affinity for M6G and morphine in the 
MPLM, the method of Furchgott was used (refer to methods pages 52-3). 13-
FNA at dose of lOOnM for 1 h was employed as an alkylating agent to reduce 
11 receptor number (Figures 5.21-5.26). Furchgotl analysis were 
constructed by interpolating from the linear portions of the dose-response 
curves values for A and A'. As can be seen the effect of I3-FNA was least 
pronounced for the DAMGO dose-response curve, whereas it caused the M6G 
curve to tip over markedly. From these curves the affinity for I! receptors 
(Ke) and the percentage of 11 receptors remaining (q) were determined and 
are shown in Table 5.17. 
Table 5.17 Furchgotl analysis for u-ligands in myenteric plexus 
longitudinal muscle using B-FNA as an irreversible u-antagonist 
M6G 
Morphine 
DAMGO 
100nM 
Ke/IlM q/% 
O.90±O.1O 
1.90±0.41 
O.83±O.1 
5.33±O.95 
5.57±0.43 
6.18±O.87 
Values are means sem ± of ;" 3 experiment 
From this M6G had twice the affinity of morphine for the I! receptor; 
affinities of O.9IlM and 1.91lM respectively were determined (Table 5.17). 
97 
100 
80 
~ 
0 
:a 60 
:;: 
= 
"If. 40 
20 
0 
1 10 100 1000 10000 
(M6GI nM 
Figure 5.21 Effect of ~FNA(100nM, open circles) pre-treatment on the 
potency of M6G (closed circles) in the MPLM 
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Figure 5.22 Furchgott analysis for M6G. A is the concentration of M6G 
before inactivation, whereas A' is the concentration of M6G after 
inactivation with ~FNA. 
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Figure 5.23 Effect of J3-FNA (lOOnM. open circles) pre-treatment on the 
potency of morphine (closed circles) in the MPLM 
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Figure 5.24 Furchgotl analysis for morphine. 
morphine before inactivation. whereas A' 
morphine after inactivation with J3-FNA. 
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Figure 5.25 Effect of J3-FNA (IOOnM, open circles) pre-treatment on the 
potency of DAMGO (open circles) in the MPLM 
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Figure 5.26 Furchgott analysis for DAMGO. A is the concentration of DAMGO 
before inactivation, whereas A' is the concentration of DAMGO after 
inactivation with J3-FNA. 
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Affinity constants were similarly obtained using N-ethyl malemide (NEM) 
as an alternative alkylating agent to Jl-FNA and the results compared. It 
can be seen that affinity constants obtained following IOIlM NEM treatment 
were of a similar order to those obtained following Jl-FNA pretreatment 
(Table 5.1S). 
Table 5.1S Comparison of affjniIies obtained using either NEM or I3-FNA 
NEM Jl-FNA 
Ka (IlM) q(%) Shift Ka (IlM) 
DAMGO 0.3±0.1 6.2±0.9 7.2±2.1 O.S±O.l 
Morphine 1.6±0.3 S.2±1.I 5.9±l.9 1.9±0.4 
M6G 0.S±0.2 2.1±2.4 16.4±0.5 0.9±0.1 
U69593 0.02±0.004 25.0±2.3 17.2±5.0 
5 3 4 Mouse vas deferens preparation 
M6G and morphine were also studied using the MVD preparation (Table 
5.19, Figures 5.27-5.30). This preparation contains mainly li opioid 
receptors, but also has populations of 11 and K receptors. 
Table 5.19 Potencies fIC50 (nM)] of various compounds and naloxone Ke 
values. in the mouse vas deferens preparation 
IC50/nM Ke/ nM 
DAMGO 24.7±3.0 1.9±0.6 
M6G 104±17.1 2.6±0.9 
M6G (p) 140±11.3 2.9±0.6 
Morphine 173±62.S 3.6±0.S 
DPDPE 2.S±0.6 20.4±2.6 
Values are means ± sem of., 3 experiments. 
M6G and morphine showed a similar potency in the MVD, affording IC50's 
of 104 and 173nM respectively. Both actions were antagonised by naloxone 
affording Ke's in the range expected for 11 receptors. Morphine-6-0-
protected glucuronide M6G(protected) exhibited a similar potency to that of 
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M6G. This was inagreement with the similar receptor profile to M6G and 
similar IC50 values obtained in the MPLM and MVD (Figure 5.31). 
100 
,.. 
;; .. 
u c ~~ eo 
u OD GO ~ 
'i'E 
0 
(; u 60 
"0 
C 
GO 
U 
0 
" :;:"0 
- C 
.,- 40 
.<: 
-= 
.. 20 
0 
1 10 100 1000 10000 
IM6Gl nM 
Figure 5.27 Inhibition of electrically induced contractions of the mouse 
vas deferens by M60 in the absence (open circles) and presence of varying 
concentrations, 10 (closed circles), 30 (closed squares) and 100nM (closed 
triangles) of naloxone 
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Figure 5.28 Representative Schild plot for naloxone antagonism of the 
response to M 60 
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Figure 5.29 Inhibition of electrically induced contractions of the mouse vas 
deferens by morphine in the absence (open circles) and presence of 
varying concentrations. 10 (closed circles). 30 (closed squares) and 100nM 
(closed triangles) of naloxone 
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Figure 5.30 Representative Schild plot for naloxone antagonism of the 
response to morphine 
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Figure 5.31 Inhibition of contraction of the field stimulated MPLM (closed 
circles) and MVD (open circles) by morphine-6-0-protected glucuronide 
5.3.5 The hamster vas deferens preparation 
The hamster vas deferens contains soley opioid receptors of the 5-type. 
Since M6G had a 3 times higher affinity for the Ii receptor than morphine 
in binding the potencies of the two compounds were compared in this 
isolated tissue preparation. DPDPE was shown to be a partial agonist, 
reaching a maximum inhibition of SI % (Figure 5.32). Morphine and M6G 
also only acted as partial agonists, the maximum inhibition reached was 
40±4 and 3S±3% for M6G and morphine respectively when extrapolated 
from the dose-response curves up to 3,000nM (Barlow, 1991) (Figure 5.32). 
M6G was seen to be slightly more potent than morphine, though both were 
only weak partial agonists (Table 5.20). 
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Table 5,20 Potencies of morohine and M6G in the hamster vas deferens 
preparation 
*IC50(nM) • IC25(nM) 
DPDPE 52,8±4,30 
M6G 171±12,6 
Morphine 283±14,3 
7,52±1.25 
286±15,3 
715±36,4 
* expressed as concentration required to give 50% of the maximum effect of 
each agonist, • represents 25% of the maximal effect of DPDPE, 
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Figure 5,32 Potencies of DPDPE (closed circles) morphine (closed squares) 
and M6G (open circles) in the hamster vas deferens preparation 
5,3,6 Alkylation of u receptors 
A possible explanation for the longer duration of action of M6G over 
morphine is that it binds irreversibly or at least very tightly to Il-receptors 
(Yoshimura et ai, 1976), If this is the case it should be possible to 
demonstrate this in similar experiments to those using I3-FNA, From Figure 
5,33 it can be seen that in mouse brain homogenate, I3-FNA (lOOnM, 60 
mins) alkylated 50% of Il receptors, whereas under similar conditions 
M3G(lIlM) and M6G(lIlM) did not affect binding following washout, not 
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deviating significantly from 100%. 
Also in the presence of NaCl (lOOmM) and Gpp(NH)p (50/lM). when the 
receptor is likely to be in a more physiological state no alkylation with M6G 
was evident. Thus M6G and M3G did not appear to act as irreversible /l 
antagonists in conditions promoting high or low affinity states of the 
receptor. 
Cl) 
Cl 
'" 'E
Cl) 
~ 
Cl) 
a. 
Figure 5.33 Degree of alkylation of /l receptors by M3G. M6G and ~FNA. H20 
represents vehicle controls. 
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i.1 Discussion 
5 4 1 Binding 
Characterisation of opioid binding sites. in the brain of CS! mouse. showed 
similar proportions of J.l.B and K receptors. (ie 29. 39. and 32% respectively). 
These percentages corresponded to Bmax values of 8.49. 11.36 and 9.30 
pmoles/g respectively. Robson et al (1985) investigated the relative 
proportions of J.l: B: K receptors in two other strains of mice. namely DBA/2 
mice and C57BL/lO mice. and finds them to be 51 : 29 : 20 and 44 : 35: 21 % 
respectively. These two strains of mice having a higher proportion of J.l 
receptors than in the CSI mice. suggesting strain differences. In guinea-
pig brain the proportions of receptors is reported by Kosterlitz to be 20-24 
(J.l): 32-40 (B) : 40-44 (K) % (Kosterlitz et al. 1981). whereas in the rat brain 
it is 46: 42 : 12 % (Gillan & Kosterlitz. 1982) and in rabbit brain 43: 19: 38 
%. Thus both species differences and strain differences exist (Robson et al. 
1985). and so the majority of the investigations and evaluation of M6G and 
related compounds in biochemical experiments were carried out using CS! 
mouse brain homogenates to complement in vivo experiments in the same 
strain of mice. 
Yoshimura (1977) suggests that some morphine-6-substituted compounds 
act as irreversible alkylating agents in rat CNS. A possible explanation of 
M6G's increased analgesic activity and longer duration of action over 
morphine. could be that it irreversibly alkylates J.l-receptors as does ~FNA. 
It was shown that in mouse brain homogenate ~FNA alkylates 50% of J.l 
receptors. which agrees with many authors including Franklin and 
Traynor (1992). who find this level of alkylation in guinea-pig brain 
homogenates. However no alkylation was observed with M3G or M6G. 
either in the presence or absence of NaCl (lOOmM) and Gpp(NH)p (50).lM). 
Thus M6G and M3G did not act as irreversible J.l antagonists at high or low 
affinity states of the J.l receptor. A slight increase in [3H1DAMGO binding 
was observed in the presence of M6G in the high affinity receptor state. 
but this was not significantly different from 100%. and therefore could not 
be interpreted as any alteration of receptors. It may be that nucleophilic 
reactions carried out by Yoshimura (1977) cannot be directly comparable to 
the method employed here and indeed to the in vivo situation. 
107 
Binding studies of M6G and morphine have previously been performed in 
various species. though not using the same species to study all three opioid 
receptor types. In the present studies in mouse brain homogenate M6G had 
the same affinity (Ki = 7.90nM) for the 11 receptor as morphine (Ki = 
6.22nM). In mouse spinal cord. the determined affinity of M6G for the 11 
receptor was half that for morphine. with Ki's of 14.8 and 5.4nM 
respectively. This was not statistically different from affinities obtained in 
mouse brain. These values are similar to those obtained by Frances et al 
(1992). using the rabbit cerebellum for 11. where a Ki for M6G of 20nM is 
obtained. Previous workers (Paul et al. 1989 (i); Pasternak et al. 1987; 
Frances et al. 1992; Pasternak & Wood. 1986) show morphine has 4-fold 
higher affinity for 11 receptors than M6G. affording Ki's of 2.5-5.6 and 10.6-
20.3nM respecti vely. while Christensen & Jorgensen (l987) report that M6G 
has a three times lower affinity for the opioid receptor than morphine as 
measured by the displacement of [3H1 naloxone in bovine brain (IC50's of 
90 and 30nM respectively). 
No effects were obtained on [3H1DAMGO binding at subnanomolar 
concentrations of M6G. This disagrees with Abbott and Palmour's (1988) 
findings. that at low concentrations M6G enhances the binding of 
[3Hletorphine. [3 H1 dihydromorphine. and [3 H1 naloxone to rat brain 
membrane receptors by 30%. whilst at higher concentrations M6G 
displaced the radiolabelled compounds. giving Ki's of about 30nM. 
compared with 3nM for morphine. This implies that the effect occurs at 
concentrations that would be expected in extracellular space (15-20% brain 
volume) after i.c.v. injection of a O.Olmg dose. Abbott's findings suggest 
that either linked agonist binding sites share a common antagonist 
component. or receptor sub types are arranged in complexes such that 
binding at one site. alters the affinity of binding at the second site. and 
receptor sub types interconvert as the physiological environment alters. 
However the present findings lend no support for this. 
Although morphine showed a similar affinity for 11 receptors as M6G. this 
relative affinity in binding studies contrasts with the reputably far greater 
potency of M6G in vivo following central administration. This was possibly 
because binding studies can never truly reflect physiological conditions. 
such as the intra- and extracellular orientation of the membranes to 
different concentrations of ions. nucleotides and other factors which have 
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not yet been determined. which may have greatly influenced receptor 
function in vivo. Importantly. binding studies only indicated the affinity 
of a compound for the receptor under specified conditions. These do not 
give an indication of the efficacy of the compound in producing a 
physiological response. However even in the isolated tissue preparations 
the potencies of the two compounds were of a similar order. 
No evidence for the existence of multiple J.l subtypes was evident from 
binding studies. but has been suggested by many workers (Pasternak and 
Wood. 1986; Franklin and Traynor. 1992; Rothman et al. 1989). Hucks et al 
(1992) finds M6G (82nM) to have a 4-fold lower affinity for the 112 receptor 
than morphine (11nM). The 112 receptor is postulated to be responsible for 
mediating the respiratory depression and gastrointestinal effects after 
morphine administration (Pasternak & Wood. 1986). It is expected 
therefore from these findings. that after M6G administration in man. 
reduced respiratory depression and vomiting would be seen. Unfortunately 
though M6G has been linked as a possible component to the respiratory 
depression caused by morphine administration (Osborne et al. 1986; 
Christensen & Jorgensen. 1981; Ronald. 1989). The predicted reduced 
incidence of nausea and vomiting is confirmed by Osborne et al (\992) who 
reports that after i.v. administration no nausea or vomiting is observed. 
In contrast the affinity of morphine and M6G for Ii receptors. labelled with 
tritiated DPDPE. differed by 3-fold. M6G having the higher affinity. These 
results are comparable to those obtained by Frances et al (1992) who used 
rat brain to study the Ii receptor. thus indicating that species variation may 
not affect opiate binding of M6G. and indicates the label is binding similar 
sites. even though Frances used tritiated DTLET to label Ii sites .. Similarly. 
Oguri et al (1910) shows that M6G has more cross-reactivity with the Ii 
receptor than morphine. though using the non-selective (W Ii) ligand [3 H] 
[Leu5] enkephalin. Therefore by glucuronidating morphine at the 6-
position (M6G). the affinity for the 11 receptor is somewhat reduced. but the 
affinity for the Ii receptor is enhanced. From this data the enhanced in 
vivo potency of M6G may be related to an enhanced interaction with the Ii 
receptor. though isolated tissue studies (discussed later. 5.4.2). do not show 
great differences. 
M6G displayed a biphasic dose-displacement curve against [3H]DPDPE. The 
reasons for this were unknown. but may indicate the ability of M6G to 
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differentiate two subtypes of 0 receptor (Cotton et ai, 1985; Traynor & Elliott, 
1993). In rat spinal cord Traynor er al (1990) suggest the possibility of a 
common high affinity site for 0- and l1-opioid receptor agonists, for the 
displacement of [3 H]DPDPE by DAMGO and morphine. This could be 
extended to imply 11-0 interactions existing. In support of such a concept, 
Qi et al (1990) found that at sub-antinociceptive doses I)-agonists can 
modulate antinociceptive responses to l1-opioid receptor agonists in the 
mouse tail-flick test and Russel et al (1987) reports that after i.t. 
administration of 11 and I) agonists, cross-tolerance exists between both 
agonists. From binding studies, Rothman er al (1988) divides o.receptors 
into two subtypes, those that are associated with l1-receptors (called 
ocomplexed or I)cx) and those not associated (called I>ooncomplexed or I)ncx)' 
Based on studies with different agonists and antagonists, another 
subdivision of I) receptors has been proposed not related to 0cx or I)ncx' 
namely 01 and ~ receptors. 1)1 receptors have been nominated as those 
activated by DPDPE and blocked by [D-Ala2, Lys4,Cys5] enkephalin (DALCE), 
and ~ receptors as those activated by [D-Ala2] deltorphin II and [D-Ser2, 
Leu 5] enkephalin-Thr6 (DSLET) and blocked by the noncompetitive 
derivative of naltrindole, naltrindole S' - isothiocyanate (Jiang et ai, 1991). 
The ability of M6G to act at one particular o-opioid receptor may be 
responsible for its enhanced potency. This was also shown in mouse spinal 
cord, where M6G showed a 6-fold higher affinity for the spinal 0 receptor 
than morphine, with Ki's of 68.7±4.2 and 402.2±42.6nM respectively. This 
observation could partly contribute towards the explanation for Paul and 
co-workers (1989 i) findings, that M6G showed a 650 times increased 
potency over morphine, when both compounds were injected 
intrathecally. 
It has been suggested above that M6G's effectiveness after i.t. 
administration may be due to an enhanced I)-mediated effect. However Paul 
et al (1989 ii) suggests that the effect is due to a mechanism involving 112 
receptors. This is on the basis that the Ill-selective antagonist 
naloxonazine blocks the analgesic effect of systemic and i.c.v. M6G and. 
morphine, but not after i.t. administration, suggesting a 112 mechanism 
within the spinal cord. However the results do indicate that M6G elicits its 
analgesic actions through the same receptor mechanisms as morphine. 
Morphine and M6G differentiated 1( receptors to varying extents, as 
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demonstrated by the data obtained in mouse brain homogenates. Morphine 
had a IO-fold higher affinity than M6G. These results compared to those 
obtained by Frances et al (1992). who uses the guinea-pig cerebellum to 
study the " receptor and reports that M6G has 19 times less affinity for " 
sites than morphine. whereas M6G is 11 times more IJ./" selective than 
morphine. being comparable to DAMGO (Table 5.3) (Martin et al. 1993). 
Further binding studies in the guinea-pig cerebellum. which contains a 
largely (84%) "-population (Robson et al. 1984). confirmed this finding. 
though the actual magnitude of the difference depended on the tritiated 
ligand used. Values of 11 and 27-fold differences were obtained when 
using [3Hldiprenorphine and [3 H1U 69593 respectively. Both M6G and 
morphine had higher affinity for" receptors in brain compared to 
cerebellum. whereas there was no significant difference in affinity 
between the two compounds in guinea-pig cerebellum. using 
[3Hldiprenorphine or [3 H1U69593. Therefore the difference in affinities of 
morphine and M6G in brain and cerebellum may indicate tissue 
differences. possibly differences in receptor characteristics. The existence 
of ,,-subtypes has been suggested by several authors. Such sUbtypes have 
been classified as "I' those receptor subtypes that preferentially bind 
aryl acetamide " opioids such as U69593. or "2' those that bind 
benzomorphan "opioids such as bremazocine and EKC (Horan et al. 1993; 
Wollemann et al. 1992). Although this classification is by no means final. 
it does offer a possible explantion to some of the anomolous findings. 
However more extensive studies need to be performed to establish if real 
differences do exist between affinities measured in brain or cerebellum. 
Opioid receptors are allosterically modulated by ions. in particular sodium. 
and linked to G-proteins. Thus in the presence of Na+ (lOOmM) and 
Gpp(NH)p (50I1M) the receptor population is largely converted to a low 
agonist affinity state. which may represent the uncoupled form of the 
receptor. Richardson et al (1992) report that both receptor-coupled and 
uncoupled G-proteins exist. Naloxone as an antagonist with no efficacy 
should recognise all states of the receptor. but under conditions promoting 
low agonist affinity. the ability of agonists to compete with [3 H1 naloxone is 
greatly decreased (Carroll et al. 1988). In the present studies the affinity of 
morphine. M6G and DAMGO for 11 sites. were decreased and afforded similar 
low affinities. approximately 400nM. as measured against [3Hlnaloxone in 
rat brain homogenate in the presence of sodium ions and 
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guanylimidodiphosphate. Some workers suggest that this low affinity state 
is the physiological relevant receptor state (Carroll et al. 1988). If so. then 
both compounds have similar affinities for the 11 receptor under 
physiological conditions. However present results may indicate that the 
low affinity state is not the physiological relevant receptor state. as 
differences were observed between affinities obtained in the presence of 
sodium ions and guanylimidodiphosphate and affinities obtained in isolated 
tisssue preparations. The affinity of M6G in Tris-sodium and 
guanylimidodiphosphate (400nM) correlated reasonably with that obtained 
in the guinea-pig MPLM (900nM) and the RVD (200nM). but the affinity of 
morphine in Tris-sodium and guanylimidodiphosphate (300nM) did not 
correlate well with that obtained in the guinea-pig MPLM (I900nM) and 
the RVD (lOOOnM). Carroll et al (1988) showed a good correlation between 
affinities obtained in the guinea-pig ileum and binding assays performed 
in Krebs/HEPES for a range of J.l-agonists. Morphine though gave similar 
values to those obtained here of 1788 and 416nM in the guinea-pig ileum 
and binding assays respectively. thus not correlating particularly well. So 
it seems the correlation does not fit for every J.l-ligand. but for some J.l-
Iigands the low affinity state is the physiological relevant receptor state. 
The affinities of morphine and M6G were also investigated by binding 
assays in Tris buffer pH 7.4. in a peripheral tissue. namely the MPLM. and 
afforded Ki values of 3.1 and 2.4nM respectively. Corbett et al (1985) report 
a J.l : S : !C binding ratio of 25 : 26: 49 % respectively and an affinity for 
[3 H)DAMGO at the J.l receptor of 2.27nM. comparing well with the values 
obtained here. In the present studies M6G afforded similar affinities for J.l 
receptors in both brain. cord and plexus (7.9.14.8 & 2.4nM) as did morphine 
(6.2. 5.4 and 3.1nM). 
The displacement profiles in the assays performed. under conditions 
promoting low affinity receptor states. did not have slopes of 1.0 against 
naloxone. probably due to the ability of naloxone to label other sites. Sand 
!c. in addition to J.l receptors. The M6G displacement curve was shallower 
than morphine. and indicated a greater selectivity and thus differentiation 
between receptor types·. especially over !C. 
In order to avoid the problem caused by the lack of selectivity of 
[3 H)naloxone. studies using the more J.l-selective ligand. [3 HJCTOP were 
performed. [3 H)CTOP. like naloxone is an antagonist and would be expected 
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to label both high and low affinity states with similar affinities. 
[3 H)CTOP binding was investigated in mouse brain and an equilibration 
time of 120 mins at 25°C and 60 mins at 37°C were obtained. The kinetics for 
[3 H)CTOP were slightly at variance with Yamamura et al (1989) who reports 
a quicker equilibration time of 90 mins at 25°C and 25 mins at 37°C. It was 
interesting that higher binding was observed at 25°C than 37°C. which is 
again in agreement with Yamamura et al (1989). 
The maximal I.l binding capacity Bmax as measured using OAMGO in rat and 
mouse brain was 67.9 and 82.6 fmoles/mg respectively. Bmax's determined 
using [3 H)CTOP in rat and mouse brain were 59.7 and 97.8 fmoles/mg 
respectively. Thus the I.l antagonist CTOP and the I.l agonist OAMGO appeared 
to label a similar population of sites. The affinity (Kol of [3 H)CTOP for these 
I.l-sites in mouse brain was 0.30nM. and in rat brain 0.65nM. Yamamura et 
al (1989) quotes a Bmax of 94 fmoles/mg for [3 H)CTOP in rat brain and a KO 
of 0.16nM and Kosterlitz and Paterson (1990) report [3 H)CTOP to label a 
single class of binding site. with a KOof 0.12±0.0InM. 
Saturation analysis for [3 H)CTOP in Tris buffer for the rat gave a low 
correlation coefficient for one site. but a high coefficient for one site in 
mouse brain homogenate. However displacement studies in the mouse did 
not afford monophasic curves. From the nature of the dose-response 
curves for the I.l-ligands. it was possible that two separate sites were 
involved. As [3 H)CTOP is a highly selective I.l-antagonist (Yamamura et al. 
1989). this may indicate the ability of [3 H)CTOP to bind to high and low 
affinity I.l-opioid receptor states in mouse brain. However using the 
logistic curve-fitting programme of Barlow (1991) it was not possible to 
differentiate more than I-site. Shifts obtained in NaCl and 
guanylimidodiphophate using [3H)CTOP were inconclusive because of the 
shallow slopes obtained and the lack of shifts produced. Affinities obtained 
in Tris with [3 H)CTOP for I.l-ligands were much lower than those obtained 
with[3H)naloxone (Table 5.8) and as a result of this the shifts are much less 
with [3H)CTOP and this could explain why no shifts were observed. Also 
though [3 H)CTOP itself was seen to be sensitive to NaCl and Gpp(NH)p. thus 
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making it difficult to determine any shift with the competing agonists. 
Thus in the presence of NaCl and guanylimidodiphosphate, a decrease in 
affinity of [3 H]CTOP was observed to 7.62nM, and a reduction in 11 receptor 
density to 78 fmoles/mg. This confirms the findings of Yamamura et al 
(1989), that NaCl reduces the number of binding sites by 31% and the 
affinity by 20-fold, whereas Gpp(NH)p (30I1M) reduced the affinity three-
fold, but not the number of binding sites. 
As expected by virtue of the 3-substituent M3G had no measurable affinity 
for opioid receptors, 11, I) or K, agreeing with Paul et al (1989 i) who find it 
to have very low affinities ( >500 at 11, >1000 at I) in cow brain and >250nM at 
K in guinea-pig brain) and Christensen et al (1991), who reports an affinity 
of> 1O,000nM for 11 receptors in cow brain. All these findings disagree with 
Chen et al (1991), who quotes an affinity of 37.lnM for M3G at the 11 
receptor in rat brain homogenate. This discrepancy is difficult to explain, 
though minor methodological differences are present. 
5.4,2 Isolated tissue bioassays 
In vitro work was performed in the MPLM and MVD. There is much 
evidence to support that receptors in the these peripheral tissues are very 
similar to the brain receptors that mediate the analgesic action of the 
narcotic analgesic (Kosterlitz et ai, 1975). In support of this similar 
binding affinities were obtained for agonists in mouse brain and guinea-
pig MPLM. 
In the mouse vas deferens preparation an IC50 value was obtained for 
morphine of 174.4nM, which is lower than the 794.3nM quoted by Schulz 
(1979) and 492nM by Kosterlitz & Watt (1968), while Smith (1984) reports 
that morphine acts as a partial agonist in the MVD preparation. The 
differences are probably due to different strains of mice used. M6G shows 
a somewhat higher potency (IC SO 104nM) than morphine. Similar 
affinities for naloxone were obtained, giving Ke values of 2.6nM and 3.6nM 
against M6G and morphine respectively, confirming the compounds are 
acting via l1-opioid receptors in this tissue. 
In the guinea-pig MPLM, potency was determined for morphine and M6G. 
It was shown that M6G had twice the potency of morphine affording ICSO's 
of S8 and 130nM respectively. Naloxone Ke values for both compounds 
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were in the range corresponding to an interaction with 11 receptors (3.00 
and 3.4SnM). This agrees with Kosterlitz & Watt who quoted an ICSO of 
68.2nM for morphine and a naloxone Ke of 1.22nM (Kosterlitz & Watt, 1968), 
and Schulz (1979) who obtained an ICSO for morphine of 12S.9nM. During 
the writing of this thesis Schmidt et al (1994) report that M6G and 
morphine are equipotent in the guinea-pig ileum, acting via ~ receptors, 
thus supporting findings here. 
M3G was inactive as an agonist in the guinea-pig MPLM up to 10,OOOnM. 
Previous workers (Gong et ai, 1991; Smith et ai, 1990) report that M3G is an 
antagonist at 11 receptors. The potential antagonist nature of M3G was 
investigated in vitro, in the MPLM. No functional antagonism was seen 
against either DAMGO or morphine at doses of M3G up to 10,OOOnM. This is 
consistant with results obtained in binding assays obtained here and by 
other workers (Paul et ai, 1989 i), which show M3G to have no affinity for 
opioid receptors whether 11, oor K probably because it lacks the 3 - phenolic 
hydroxy group essential, for binding to opiate receptors (Casy & Parfitt, 
1986). Studies were also made of similar weaker compounds ego codeine in 
the MPLM. Codeine was relatively inactive in this tissue compared with 
morphine. The reason why codeine possesses some potency, whilst M3G 
does not, is probably due to steric effects ie. the glucuronide moiety is much 
larger than the methoxy group. The low potency of codeine in the guinea-
pig MPLM as compared with its antinociceptive effect in the whole animal, 
may be due to the metabolic formation of morphine in the whole animal 
(Casy & Parfitt, 1986). 
The higher affinity of M6G for the 0 receptor in binding assays was 
confirmed in the hamster vas deferens preparation, where M6G shows a 
slightly higher potency than morphine (ICSO's of 286 & 71SnM 
respectively). 1CSO values were predicted by interpolation using Barlow's 
programme (1991), as SO% inhibition was not reached. However both 
compounds only showed partial agonism, and reached a maximum 
inhibition of 40 and 44% for morphine and M6G respectively. Miller and 
Shaw (198S) report that morphine shows no agonist properties in this 
preparation and Sheehan et al (1986) reports that normorphine and 
fentanyl were both inactive as agonists at doses up to 10,OOOnM in the same 
strain of hamster. 
An ICSO is a measure of potency, so in order to study the affinity of a 
compound in isolated tissue preparations it is necessary to use a 
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preparation in which the compounds can be shown to be antagonists. Such 
a preparation is the rat vas deferens (RVD). The RVD contains a 11 receptor 
population which possesses a high intrinsic activity requirement for 
activation, ie. it has a low receptor reserve such that partial agonists 
(including morphine) demonstrate antagonist properties, for example 
Schulz (1979) quotes an IC50 of> 100,000nM for morphine. 
In the RVD full agonist potency could not be obtained with either M6G or 
morphine; both compounds reaching a maximum of 30% inhibition. 
However M6G had twice the potency of morphine at the IC20 level. The 
relative efficacies of morphine and M6G were found to be 18.0 and 7.8 times 
less than DAMGO. 
Since morphine and M6G acted as weak partial agonists the Ke values could 
be determined against DAMGO as an agonist. M6G (l94nM) had an affinity 
five times that of morphine (l007nM). Carroll et al (1988) quote a similar 
Ke for morphine of 1500±230nM and Smith and Ranee (1983) obtain a Ke 
value of 1226nM. 
The affinity of morphine was also determined in the MPLM, following 
reduction in the number of 11 receptors using J3-FNA. Results in the MPLM 
(after 100nM J3-FNA treatment) gave affinity values of 900nM, 1900nM and 
830nM for M6G, morphine and DAMGO respectively ie. M6G had twice the 
affinity of morphine. Using N-ethylmalemide (NEM) as an alkylating 
agent M6G again afforded twice the affinity for the 11 receptor compared to 
morphine (800 compared to 1600nM), in agreement with results obtained 
using J3-FNA. Although the results agree with others (Carroll et ai, 1988; 
Smith & Ranee, 1983), they do not however agree with those obtained by 
Kosterlitz. He reports an affinity of morphine (Ke) of 87.5±18.lnM in the 
MPLM. The reason for this discrepancy may relate to experimental 
differences. Kosterlitz did not use Furchgott analysis, but used a method 
developed by himself and other co-workers (See Chapter 3, page 49, 
Kosterlitz & Watt, 1968). 
After J3-FNA pre-treatment, a much greater flattening of the dose-response 
curve for M6G than morphine was seen. This may be that as few 11 
receptors were present, morphine exerts part of its action vja le receptors 
(Franklin & Traynor, 1992), whereas the M6G response was solely due to the 
remaining 11 reeeptors, as it lacks affinity for the 1( receptor. 
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5 4 3 Overview 
The results showed that morphine and M6G had comparable affinities by 
Furchgott analysis, in the MPLM. Binding assays in Tris-Na and 
HEPES/Krebs gave similar results for morphine and M6G. However results 
in the rat vas deferens preparation may indicate a slightly higher 11-
affinity for M6G (Table 5.21). The fact that morphine and M6G had similar 
affinities for the 11 receptor in both high and low affinity states, indicated 
that the glucuronic acid part of the molecule does not interfere with 
binding and consequently there is probably an area within the receptor, 
into which the sugar moiety can be accomodated. This means that the 6-
position of morphine is relatively free for chemical manipulation as 
demonstrated by the existence of many 6-substituted compounds ego ~FNA, 
some of which have been mentioned earlier (Vizi et ai, 1974; Gebhart & 
Sprall, 1976; Lidner & Raab, 1981; Takayaruji et ai, 1988). It is interesting 
that the sugar group increased the Il affinity, but reduced the K affinity. 
This may suggest that the sugar can be accomodated in the Il-site, but not 
the K-site, however lipophilic differences between Il and K-sites, may 
explain the findings, though again the HPLC studies did not show any 
marked overall differences in the overall lipophilicity of the compounds. 
From these studies it appeared that neither affinity or efficacy were 
responsible for M6G's increased activity over morphine. The especially 
high potency of M6G administered directly into the CNS, along with its 
ability to elicit analgesia when given peripherally are not explained by 
receptor differences. Thus pharmacokinetic studies ego distribution of M6G 
may be responsible. 
Table 5.21 Affinities of M6G and morphine measured in the rat vas deferens 
against the agonist OAMGO. and in the MPLM. following a reduction of u 
receptors by B-FNA and in Tris. Tris-Na and HEPES/Krebs and in the plexus 
Affinities (I1M) BRAIN MPLM 
KO Ke K· t K· t K· I K· I 
(MPLM) (RVO) Tris Tris-Na Krebs Tris 
M6G 0.9±0.1O 0.2±0.01 0.008 0.4 0.1 0.002 
Morphine 1.9±0.41 1.0±0.2 0.006 0.3 0.1 0.003 
OAMGO 0.83±0.1O 0.002 0.2 0.1 
Values are means ± sem of data from ~3 experiments 
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CHAPTER 6 
SYNTHETIC MORPHINE-6-SUBSTITUTED 
COMPOUNDS AS ANALOGUES OF MORPHINE-
6-GLUCURONIDE 
• INCLUDING A STUDY OF SOME 3·MORPHINE ETHERS 
6. I Introduction 
Many extensive reviews have covered structure activity relationships of 
the morphine skeleton (for example see Casy & Parfitt. 1986). Several 
points are relevant to the 6-position. Substitution at C-6 of the morphine 
skeleton is not essential for analgesic activity. For example desomorphine 
(Figure 6. I) is 10 times more potent than morphine as measured in the 
mouse. using the hot plate test. and is much more rapid in onset (Eddy et al. 
1957). 
Figure 6. I Desomorphine 
Similarly (-)levorphanol (Figure 6.2). which also lacks the 4.5-ether 
bridge. is 2 to 3 times more potent than morphine. Unlike morphine it is 
almost as effective by p.o. as by s.c. or i.m. administration (Bowman & Rand. 
1980 i). 
HO 
Figure 6.2 Levorphanol 
However whilst 6-substitution is not a requirement. analgesic activity can 
be manipulated by 6-substitutions as indicated by the analgesic activity of 
M6G. discussed in Chapter 5. Also there are other morphine-6-substituted 
compounds in addition to M6G. Yoshimura et al (1973) reported that 
morphine-6-sulphate (M6S) (Figure 6.3). a metabolite of morphine in mice. 
had analgesic activity in mice of the same order of magnitude as M6G. 
being much more potent than morphine and of longer duration. 
Morphine-3-sulphate was shown to be inactive (Yoshimura et al. 1973). 
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Figure 6.3 Morphine-6-sulphate 
Analgesia observed after M6S administration is not attributable to free 
morphine, which may have been liberated in vivo from M6S, because the 
potencies of morphine and M6S are so dissimilar in the two tests 
(Yoshimura et ai, 1976), as is the case with M6G (Shimomura et ai, 1971). 
The activities of some 6-substituted compounds have also been examined in 
vitro. Yoshimura (1977) studied the inhibitory effect of morphine, 
morphine-3-X, and morphine-6-X, X being glucuronides, ethereal 
sulphates and phosphates, on narcotine-induced contraction of the isolated 
guinea-pig ileum. The potency of the compounds decreased in the order:-
Morphine-6-sulphate > M6G > morphine = morphine-6-phosphate > M3G = 
morphi ne-3 -phosphate. 
Treatment of morphine-6-conjugates with lithium chloride or piperidine 
readily forms 6-chloro-6-deoxy-morphine (2) and 8-piperidino-6-deoxy-ll 
6-morphine (I), respectively, as shown in Figure 6.4 (Yoshimura, 1977). It 
is interesting to note that the reaction rates of the conjugates are roughly 
parallel with analgesic activity decreasing in the order :- sulphate> 
glucuronide = acetate> phosphate> morphine. Thus this nucleophilic 
substitution reaction gives an indication of the compounds analgesic 
potency. 
Some of the reported 6-substituted derivatives are of particular interest in 
relation to studies of M6G in that they contain a functional group linked by 
an oxygen to the alkaloid D-ring. Lidner and Raab (1981) studied the 
pharmacokinetics of morphine-6-nicotinate (Figure 6.5) following i.v. 
administration in rats. The strong analgesic activity of this compound 
corresponds with a high morphine-6-nicotinate level in brain. Indeed the 
transport of free morphine across the blood brain barrier decreases in the 
presence of morphine-6-nicotinate in the blood. 
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X=sulphate 
glucuronide 
acetate 
phosphate 
piperidine 
1 
2 
Figure 6.4 Scheme showing the reactivity of morphine-6-conjugates with 
lithium chloride or piperidine in boiling acetone or benzene. 
Figure 6.5 Morphine-6-nicotinate 
Morphine-6-hemisuccinate (Figure 6.6) is reportedly similar in potency to 
morphine and is 6 times less potent than morphine-6-sulphate in the hot 
plate test in mice when administered i.p. The peak analgesia and duration 
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of action being the same for morphine-6-hemisuccinate and morphine-6-
sulphate (Gebhart & Spratt. 1976). Codeine-6-succinate is also reported to 
retain its potency both in vitro (MPLM) and in vivo (mice). while having 
less antitussive potency in cats (Harris. 1987). 
HO 
.ICH3 
N 
Figure 6.6 Morphine-6-hemisuccinate 
In 1988 Takayaaruji et al found (- )-6~ acetylthiomorphine (Figure 6.7) to 
be IL-selective. with the same affinity as morphine for the IL-opioid binding 
site. but twice the potency in the guinea-pig MPLM preparation and S times 
the potency in vivo in the paw pressure test in rats. 
Figure 6.7 Acetylthiomorphine 
Compounds may also contain nitrogen in place of oxygen in the 6-position. 
6-Azidomorphine (Figure 6.8) is more potent than morphine. affording an 
ICSO in the MPLM of 2.0nM. compared to a value for morphine of S8.0nM. 
This improved activity can also be seen in vivo (Vizi et al. 1974). 
Azidomorphine and morphine afforded EDSO values in the rat as measured 
in the hot plate test of 0.036 and 4.0mg/kg respectively (Vizi et al. 1974). 
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Figure 6.8 6-Azidomorphine 
Many other 6-substituted derivatives exist. J3-funaltrexamine (J3-FNA) 
(Portoghese et al. 1980; Ward et al. 1982) and J3-chlornaItrexamine (J3-CNA) 
(Portoghese et al. 1987) are two such compounds containing large 
functional groups that act as irreversible alkylating agents. The size of 
these substituents and others. in particular the glucuronides. suggests 
considerable space exists in the receptor for exploitation by synthetic 
derivatives. 
The aim of the experiments described in this chapter was to evaluate a 
series of synthesised compounds designed as mimics of M6G. Such 
compounds would hopefully have greater potency and give more 
predictable kinetics over morphine and should be long lasting and 
preferably orally active for medical usage. The compounds were 
synthesised by Anna Di Pretoria at Loughborough University in a 
collaborative project. Previous studies show some 3-substituted ether 
compounds to possess antinociceptive potency (Mohacsi et al. 1982). so an 
investigation of the 3-position was carried out using a set of compounds 
supplied by Dr. Lewis (Bristol University). coded as BU18-BU25 inclusively. 
6.2 6-substituted compounds under study 
The derivatives (Table 6.2) were studied by ligand-binding assay and 
isolated tissue bioassay to investigate their opioid receptor affinities and 
potencies respectively. 
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RI 
(I) H 
(2) Me 
(3) Me 
(4) Me 
(5) H 
(I3) H 
(I4) H 
(IS) H 
(I6) H 
(17) H 
(18) H 
(19) H 
(20) H 
(21) Me 
(22) Me 
(I2) o3-TIPS 
R2 
H 
H 
phthalate 
succinate 
p-nitrobenzoate 
p-f1uorobenzoate 
p-c hI ora ben zoate 
p-bromobenzoate 
p-hydroxybenzoate 
O-protected glucuronide* 
phthalate (Figure 6.9) 
benzoate (Figure 6.10) 
succinate (Figure 6.11) 
l 
+Si-O 
I I 
R2 
(6) H 
(7) phthalate 
(8) benzoate 
(9) p-f1uoro benzoate 
(10) p-bromobenzoate 
(11 ) p-n i tro benzoa te 
O-protected glucuronide* (Figure 6.13) 
O-glucuronide 
H (Figure 6.12) 
* sugar hydroxyl groups protected as acetates and the acidic function as a 
methyl ester (Figure 6.13), oTIPS is triisopropylsilyl. 
HO 
Q-' C-O~\' 11 - 0 
C-OH 
11 
o 
Figure 6.9 Morphine-6-phthalate 
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Figure 6.10 Morphine-6-benzoate 
Figure 6.11 Morphine-6-succinate 
't 7-Si- O ~ 
Figure 6.12 3-TIPS-morphine (12) 
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HO 
F.~~ 
l1:{ 
OAc 
Figure 6.13 M6G (protected) (17) 
6.3 Ligand binding assays 
The binding of the various 6-substituted compounds was studied at pH 7.4 in 
Tris buffer (Table 6.1). M6G (Ki 8nM) showed a similar high affinity 
binding to the 11 receptor as morphine (Ki 6nM). The 6-substituted 
morphines. the nitrobenzoate (5) and halogenated. hydroxybenzoate. 
protected glucuronide. phthalate. benzoate and succinate(13)-(20) also 
showed high affinities for the 11 reccptor. having Ki's in the range 2nM for 
the 6-hydroxybenzoate derivative (16) to 30nM for the 6-nitrobenzoate 
derivative (5). 
As shown in chapter 5. M6G had a 3 times higher affinity for the li receptor 
than morphine. At the li-site other 6-substituted morphine derivatives. 
namely the hydroxybenzoate. protected glucuronide. phthalate. benzoate 
and succinate (16)-(20) had higher affinity than morphine with Ki's in the 
range 14nM for morphine-6-phthalate to 33nM for the M6G-protected 
sugar (17) (chapter 5). Indeed morphine-6-phthalate (18) had a higher li 
than Il-affinity. Other 6-substituted compounds (5), (18) and halogenated 
compounds (13)-(15) afforded affinities in the range similar to morphine 
and M6G ie. 69-205nM. 
The 6-substituted morphine derivatives had lower affinities for the lC-
receptor than the Il-receptor. This is similar to M6G which showed a 20-fold 
decrease in affinity over morphine. Indeed all of the morphine 
compounds (6) and (11)-(20) had lC-affinities less than morphine, ranging 
from 135-2774nM. The nitrobenzoate (5) had a very low affinity of 
>IO,OOOnM. 
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Codeine (2) had weak affinity at both 11 and a sites. Codeine phthalate (3) 
and codeine succinate (4) had similarly weak affinities for 11, but affinity 
for a was higher than codeine, especially for the codeine phthalate (3), 
which had a 30-fold higher affinity for the a receptor, having an affinity 
in between morphine and M6G. 
The immediate synthetic precursors to all of the 6-substituted morphine 
compounds were their 3-silyl ethers. Several of these were evaluated in 
the binding assays. Surprisingly in view of the site of substitution all of 
the compounds had some degree of affinity for the 11 receptor. Indeed 3-0-
silyl morphine, with a Ki of 2.5nM, had higher affinity even than 
morphine. The phthalate (7) also had high affinity for a receptors with a 
Ki of 4.10nM, whilst 3-0-silyl morphine (6), (175nM) and benzoate (8), 
(485nM) also bound reasonably well at the a-site. 3-0-silyl morphine (6), 
(135nM) was the only silyl compound with affinity for the 1C receptor 
(Table 6.1). Even 3-TIPS morphine (12), with a very large 3·substituent, 
showed affinity for opioid receptors, having highest affinity for the 11 
(I07nM), 1C (356nM) then Ii (3048nM) receptor. 
The selectivities of the various 6-substituted compounds for the opioid 
receptor types, as derived from binding experiments, are shown in Table 
6.2. The most highly ilia selective compounds were 3-0-silyl morphine (6), 
3-0- TIPS morphine (12), morphine-6-hydroxybenzoate (16), the protected 
codeine glucuronide (21) and the codeine glucuronide (22). All being 
comparable with morphine, having a preference for 11 over a of > lO-fold. 
Compounds selective for 11 over 1C include the morphine-6-substituted 
compounds p-ni trobenzoate (5) and bromo benzoate, hydroxybenzoate, 
protected glucuronide, phthalate, benzoate and succinate, protected codeine 
glucuronide and codeine glucuronide (15)-(22) and 3-silylmorphine (6), 3-
silylmorphine-6-phthalate (7) and 3-silylmorphine-6-benzoate (8). All 
having a preferred affinity of 11 over 1C of at least 17 times, being 
comparable to M6G. Compounds with a similar ratio to that of morphine 
include 3-TIPS morphine (12) and morphine-6-chlorobenzoate (14). 
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Compounds selective for a over I( include morphine-6-nitrobenzoate (5). 3-
silylmorphine-6-phthalate (7). 3-silylmorphine-6-benzoate (8). and 
morphine-6-protected glucuronide. phthalate. benzoate and succinate (17)-
(20). having 1(/ a ratios of <0.05. being comparable to M6G. In contrast the 
only compounds which have a higher affinity for the I( receptor than the a 
receptor. were 3-silylmorphine-6-nitrobenzoate (11). and 3-TlPS morphine 
(12). 
Compounds 3 -si Iyl morphi ne-6 -fl uorobenzoate (9). 3 -si I ylmorph i ne-6-
bromobenzoate (10) and codeine glucuronide (22) were largely inactive 
and thus non-selective between a and I( receptors. Indeed some compounds 
showed no affinity for I( receptor binding sites up to 10.000nM. 
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!abl!: (i,1 At:(inili!:S(KiiI!Ml Q( (i-Sl!bSlill!l!:lI WQ[llbiD!: Ihab:aliY!:s al Lt, Il 
!lnll K Ollioid binding sites in mQuse br!lin homogen!!te§ 
Compound Ki(nM) 
11 II 
M-6-G 7.90±1.48 75.1±15.6 "850±1l8 
(1) morphine 6.22±0.86 218±41.2 "84.7±4.01 
(2) codeine 2700±302 >\0,000 nt 
(3) codeine derivative 4500±513 I 82.0±21.3 nt 
(4) codeine derivative 2010±298 3,001±23I nt 
(5) 30.1±1.4O 68.5±4.61 >\0,000 
(6) silyl derivativex 2.50±0.41 175±5.60 135±14.1 
(7) silyl derivativex 17.5±2.80 4.\O±0.30 >10,000 
(8) silyl derivativex 310±22.1 485±24.5 >10,000 
(9) silyl derivativex 1,477±251 >\0,000 >10,000 
(10) silyl derivativex 5,081±428 >10,000 >10,000 
(11) silyl derivativex 1282±87.1 >10,000 737±52.6 
(12) 107±15.8 3,048±247 356±20.2 
(13) 16.6±3.2 83.3±6.8 193.2±14.1 
(14) 17.7±2.8 84.9±8.4 149.9±12.2 
(15) 28.4±5.2 205.O±\O.2 832.9±24.1 
(16) 1.73±0.26 22.2±3.41 157±12.6 
(17) 11.2±2.6 33.0±3.24 820±26.3 
( 18) 27.8±3.8 14.2±2.9 2,774±205 
(19) 9.25±3.65 20.7±2.65 161.1±12.6 
(20) 9.83±2.68 32.2±3.56 1187±156 
(21 ) 125.9±10.3 4,100±36.4 >\0,000 
(22) 430.1±23.6 7,964±126 8,392±206 
11 Sites were label1ed with [3H] DAMGO (1.02±0.19nM), II sites by [3H]DPDPE 
(1.60±0.29nM) and K sites by [3H]CI977 (0.15±0.03nM, except "where tritiated 
U6953 (1.07±0.13nM) was used. Ki values were determined from KD values 
of the ligands at 11 (DAMGO 1.37nM), II (DPDPE 5.75nM) and K (CI9770.25nM) 
(Chapter 5). Experiments were performed at 25°C for 40 mins in Tris-HCI 
buffer pH 7.4. In al1 cases Hill Coefficients were not significantly 
different from unity. Values are means ± sem of > 3 experiments unless 
stated, nt denotes not tested and x 3-0-silyl substituted. 
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Table 6.2 Selectivities of 6-substituted compounds for IL /i. or K sites. taken 
from Table 6.1 
Ko "'K ./i 
1 '" 1 
K· "'K· K 
1 '" 1 
K·/i/K'K 1 1 
M6G 0.11 0.01 0.09 
(1) morphine 0.03 0.15 5.34 
(2) <0.27 
(3) 24.73 
(4) 0.67 
(5) 0.44 <0.01 <0.01 
(6) 0.01 0.02 1.30 
(7) 4.27 <0.01 <0.01 
(8) 0.64 <0.03 <0.05 
(9) 0.15 <0.15 
(10) <0.51 <0.51 
(11 ) 0.13 1.74 13.57 
(12) 0.04 0.30 8.56 
(13) 0.20 0.09 0.43 
(14) 0.21 0.12 0.57 
(15) 0.14 0.03 0.25 
(16) 0.08 0.01 0.14 
(17) 0.33 0.01 0.04 
(18) 1.96 0.01 <0.01 
( 19) 0.45 0.06 0.13 
(20) 0.31 <0.01 0.03 
(21 ) 0.03 <0.01 <0.41 
(22) 0.05 0.05 0.95 
6.4 Isolated tissue studies 
Binding assays only give a measure of the affinity of a drug for a receptor. 
They give no indication of possible agonist or antagonist nature. ie efficacy 
at various receptor sites. In order to study this. compounds were evaluated 
in two in vitro isolated tissue preparations. namely the guinea-pig 
myenteric plexus longitudinal muscle (MPLM) and the mouse vas deferens 
(MVD). The results are shown in Table 6.3. 
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Table 6.3 Potency of 6-substituted morphine derivatives (unless indicated) 
on the guinea-pig ileum (MPLM) and moyse vas deferens (MVD) 
preparations 
Compound 
M-6-G 
(1) morphine 
(2) codeine 
(3) codeine derivative 
(4) codeine derivative 
(5) 
(6) silyl derivative x 
(7) silyl derivative x 
(8) silyl derivative x 
(9) silyl derivative x 
(10)silyl derivative x 
(13) 
(14) 
(15) 
(16) 
(17) 
(18) 
(19) 
(20) 
IC50 (nM) 
MPLM 
58.0±4.30 
130±7.8 
1600±403 
3200±123 
1000±205 
MVD 
104±17.1 
173±62.8 
>1000 
nt 
nt 
132.4±11.85 1166±467 
302.0±21.2 279±45.0 
429±4.31 41.0±8.60 
>10,000 2,633±502 
>10,000 
>10,000 
1010±102 
1506±161 
1800±183 
9004±106 
40.6±4.32 
350±25.3 
IO,OOO±265 
158.5±2.65 
>10,000 
5,625±618 
1325±262 
1162±151 
1281±186 
230±18.6 
140±11.3 
24.3±3.54 
280±21.6 
171±12.8 
MPLM/MVD 
0.56 
0.75 
>1.60 
O. I I 
1.08 
10.46 
>3.80 
>1.78 
0.76 
1.30 
1.41 
39.1 
0.29 
14.40 
35.7 
0.93 
Values are means ± sem of <! 3 experiments, unless stated otherwise, nt 
denotes not tested. x 3-0-silyl substituted. 
In the MPLM, morphine-6-nitrobenzoate (5), M6G (protected) (17), 
morphine-6-phthalate (18) and morphine-6-succinate (20) had IC50 values 
in the range 132-350nM, similar to morphine, while the morphine-6-
halogenated compounds (13 )-(15) and hydroxybenzoate (16) and morphine-
6-benzoate (19) had IC50 valuess in the range 1010-10,OOOnM. AI! these 
compounds acted as agonists. In the MVD the morphine-6-substituted 
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hydroxybenzoate, protected sugar, phthalate, benzoate and succinate (16)-
(20) had ICSO values in the range 24-2S0nM, potencies similar to morphine. 
The morphine-6-halogenated compounds (13)-(lS) had IC SO values in the 
range 1162-132SnM. Compounds of particular interest with good potency 
include morphine-6-nitrobenzoate (S) (Figure 6.14), which showed a 
higher potency in the MPLM (I32nM) as opposed to the MVD (1166nM), 
where (S) was a partial agonist. In contrast morphine·6·phthalate (IS) 
was much more active in the MVD (24nM) than in the MPLM 
(3S0nM)(Figure 6.IS), while morphine-6-succinate (20) was non-selective 
between the MPLM (lS9nM) and the MVD (l7InM) (Figure 6.16). Other 
compounds which had higher potency in the MVD as opposed to the MPLM 
incl uded morphine-6-hydroxybenzoate (16) (Figure 6.17) and morphine-6-
benzoate (19) (Figure 6.IS), and acted as full agonists in the guinea-pig 
MPLM. The compounds appeared to be only partial agonists in the MPLM at 
the levels used, and was due to the shallow slopes obtained. 
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Figure 6.14 Inhibition of contractions of the field stimulated MPLM (closed 
circles) and MVD (open circles) by morphine-6-nitrobenzoate (S) 
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Figure 6.15 Inhibition of contractions of the field stimulated MPLM (closed 
circles) and MVD (open circles) by morphine-6-phthalate (J 8) 
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Figure 6.16 Inhibition of contractions of the field stimulated MPLM (closed 
circles) and MVD (open circles) by morphine-6-succinate (20). showing a 
lack of selectivity between the 2 preparations. 
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Figure 6.17 Inhibition of contractions of the field stimulated MPLM (closed 
circles) and MVD (open circles) by morphine-6-hydroxybenzoate (16) 
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Figure 6.18 Inhibition of contractions of the field stimulated MPLM (closed 
circles) and MVD (open circles) by morphine-6-benzoate (19). showing 
weaker activity in the MPLM. 
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The 6-substituted derivatives in which the phenyl ring was substituted 
with a p-halogen [morphine-6-fluoro (13) (Figure 6.19). chloro (14) 
(Figure 6.20) and bromo benzoate (15) (Figure 6.21)] showed weak agonist 
action in both the MPLM and the MVD, with IC50 values of > 1000nM. in spite 
of showing similar binding profiles to M6G. This implied that the 
compounds had high affinity, but low efficacy. 
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Figure 6.19 Inhibition of contractions of the field stimulated MPLM (closed 
circles) and MVD (open circles) by morphine-6-fluorobenzoate (13). 
showing a lack of selectivity between the two preparations. 
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Figure 6.20 Inhibition of contractions of the field stimulated MPLM (closed 
circles) and MVD (open circles) by morphine-6-chlorobenzoate (14) 
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Figure 6.21 Inhibition of contractions of the field stimulated MPLM (closed 
circles) and MVD (open circles) by morphine-6-bromobenzoate (15) 
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Of the 3-0-silylcompounds. only silyl morphine (6) and silyl phthalate (7) 
afforded a reasonable potency. Silyl morphine (6) afforded IC50 's of 302 
and 279nM in the MPLM and MVD respectively. In contrast 3-silyl 
phthalate (6) had a much greater effect in the MVD than the MPLM. (ICSO 
values of 41 and 429nM respectively). The 3-silyl-6-benzoate (8). 6-
f1uorobenzoate (9) and 6-bromobenzoate (10) had no effect in the MPLM 
and the 6-benzoate (8) and 6-bromobenzoate (10) only had a partial agonist 
effect in the MVD. 
In order to determine with which receptors the various 6-substituted 
morphines were interacting. in the two tissues. the antagonist affinity 
constants (Ke) for two antagonists. the relatively non-selective naloxone 
and the l1-selective cyprodime were determined (Table 6.4). 
Table 64 Antagonist equilibrium affinity constants (Ke • nM) for naloxone 
and cyprodime against 6-substituted morphine derivatives 
Compound 
M-6-G 
(I) morphine 
(5) 
(6) 
(7) 
(16) 
( 19) 
Naloxone 
MPLM 
3.00±0.80 
3.45±0.59 
3.50±0.31 , 
5.91±0.52, 
4.12±1.40 
3.21±0.35 
3.1O±0.62 
Ke (nM) 
Cyprodime 
MVD MPLM MVD 
2.60±0.90 nt nt 
3.60±0.80 nt nt 
14.9±1.521 60.4±5.80 >300 
S.IO±1.l11 42.1±1O.4 30.4±6.42 
20.2±2.96 42.4±9.63 >300 
17.8±1.90 nt nt 
18.4±3.12 nt nt 
Values are means ± sem of ~ 3 experiments. unless stated otherwise. 
Naloxone Ke's were determined using Schild plots. unless marked by a 1. 
which represent a single concentration (30nM) of naloxone. Cyprodime 
Ke's were obtained using a single concentration (300nM) of cyprodime. nt 
denotes not tested. 
The results suggested that M6G. morphine (I) and 3-0-silylmorphine (6) 
were acting via 11 receptors in both the MPLM and MVD. all affording 
naloxone Ke values of approximately 3nM. whereas morphine-6 
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nitrobenzoate (5) and 3-0-silyl-morphine-6-phthalate (7) acted via 11 
receptors in MPLM and li receptors in the MVD. The values for 3-0-silyl 
morphine (6) suggested the compounds acted mainly by 11 receptors. but the 
Ke values indicated a mixed receptor population. However cyprodime Ke 
values confirmed 11 receptor involvement. 
Some of the morphine-6-substituted compounds showed affinity for opioid 
receptors in binding assays. but possessed only weak efficacy in isolated 
tissue preparations. These compounds may act as antagonists in some 
situations. Morphine-6-halogenated and hydroxybenzoate compounds (13). 
(14). (IS) & (16) were tested for their antagonist nature at concentrations 
varying between 30-1000nM against DAMGO. DPDPE and U69593 as agonists 
for ~ li. and K receptors respectively in the MVD and MPLM. The affinity 
values (Ke) obtained are given in Table 6.S. It should be noted that these 
compounds did exhibit weak agonist properties and so antagonist affinity 
constants were determined using the method devised by Kosterlitz & Watt 
(1968) for partial agonists. as described in Chapter 3. 
Table 6 S Antagonist equilibrium affinity constants (K e nM) of morphine-
6-substituted compounds in the MVD and MPLM 
Ke (nM) 
MVD MPLM 
li K 11 
F Benzoate (13) #21.S±3.0 , 107±9.6 nt 
Cl Benzoate (14) o288±2S.3 #20.6±2.1 nt 
Br Benzoate (I S) oI93±23.3 ,3S.8±S.6 nt 
OH Benzoate (16) '86.7±6.S ,31.0±S.0 #11.7±2.1 #5.S±O.3 
N~ Benzoate (S) nt nt nt #0.7±O.1 
Compounds tested at 30nM(#). 300nM(t). or 1.000nM(o). 
- indicates no antagonist action at this receptor type. ie no shift in the 
dose-response curve observed at a concentration of 1.000nM. nt denotes 
not tested. 
All of the compounds tested acted as antagonists. but to varying degrees. 
Compound (S) (6-p-nitrobenzoate) and (16) (6-p-hydroxybenzoate) showed 
a high degree of 11 antagonism in the MPLM. It is interesting to note that 
(5) afforded a Ke of 0.7nM in the MPLM. but a Ki of 30nM in mouse brain 
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homogenate (Table 6.1). The reason for this is at present unexplained. In 
the MVD however compounds (13)-(16) acted as both ~ and 0 antagonists, 
morphine-6-chlorobenzoate (14) had the highest affinity for the 0 
receptor. The hydroxybenzoate analogue (16) was the only compound 
tested to demonstrate antagonism at the K-receptor site. 
6.5 Stability studies 
The observed activity of some of the 3-0-silyl compounds (6 and 7) was 
unexpected, as a 3-0H group is believed important for activity (Chen et ai, 
1991). Studies were performed in mouse brain homogenate to determine 
whether activity was due to loss of the 3-0-silyl group. Compounds were 
evaluated by TLC before and after incubation with homogenate for 30 mins 
at 37°C. Rp values of the compounds are shown in Table 6.6. 
Table 6 6 TLC analysjs of morphine and related synthetic compounds and 
stabjljty following treatment for 30 mins at 3ZOC in Trjs-HCI buffer or 
mQUS~ IH@jn hQIllQg!:n@l!: 
Control Treatment 
Compound Rp value Buffer alone Homogenate 
(Rp in brackets) (R F in brackets) 
Morphine (1) 0.30 Stable (0.30) Stable (0.30) 
30Si morphine ( 6) 0.70 Unstable (0.30) Unstable (0.30) 
M6G(prot.sug) (17) 0.70 Stable (0.70) Stable (0.70) 
M-6-N02benzoate (5) 0.63 Stable (0.63) Stable (0.63) 
30SiM-6-N02 
benzoate (11) 0.86 Stable (0.86) Stable (0.86) 
M-6-Fbenzoate (13) 0.50 Stable (0.50) Stable (0.50) 
30SiM-6Fbenzoate (9) 0.80 Stable (0.80) Stable (0.80) 
M-6-Brbenzoate (15) 0.53 Stable (0.53) Stable (0.53) 
30SiM-6Brbenzoate (10) 0.81 Stable (0.81) Stable (0.81) 
A solvent system of composition 80:20 % dichloromethane:water with silica 
as the stationary phase was used. 
All of the compounds tested were stable to the buffer, the extraction process 
and mouse brain homogenate, except for 3-0-silyl morphine, which was 
broken down to the parent compound. This occured even in the absence of 
homogenate. It would thus appear that the observed activity of (6) was due 
to the loss of the 3-0-silyl group to afford morphine. However this did not 
seem to be the case for other 3-0-silyl compounds. 
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6 6 Lipoohilicities of morphine and related compounds 
6 6 I Rates of onset and offset of morphine and derivatives as measured in 
the MPLM 
To determine whether the change in Iipophilicity afforded by 
glucuronidation is reflected in kinetics, the onset and offset times of drugs 
in reducing the electically induced twitch were assessed. Half-times of 
onset and offset of action (to.S) were measured in the MPLM for 3 different 
doses of the drug. The drug doses were chosen to give between 30 and 70 % 
inhibition of the twitch. Results for morphine and M6G are given in Table 
6.7 and show M6G to have the same onset and only slightly shorter offset of 
action compared with morphine. 
Table 6,7 Rates of onset and offset of action of morphine and M6G in MPLM 
of the guinea-pig ileum 
Onset to.S (s) 
M6G 2S.7±4.4 
Morphine 26.8±3. I 
Offset 10.5 (s) 
67. t±IO.2 
90.0±12.4 
6 6 2 Lipophilicities as determined using an HPLC system 
The lipophilicities of morphine and three other selected, related 
compounds were analysed using an octanol:water solvent system (see 
Chapter 2, page 39). The Iipophilicities were compared as log P values. Log 
P is defined as the logarithm of the ratio of the absorbance in octanol to the 
absorbance in phosphate buffer pH 7.4 (Leo et ai, 1971), the higher the 
number the more lipophilic the drug. The determined lipophilicities of the 
compounds are shown in Table 6.8. The order of lipophilicity is thus 
methadone> heroin> codeine> morphine. The retention times of these 
compounds were determined by HPLC (Table 6.9) and a calibration curve 
constructed of log P against log k' where k' is the capacity factor and is 
defined as the difference in retention times between the test compound and 
morphine-6-f1uorobenzoate, divided by the retention time of morphine-6-
f1uorobenzoate (13) (Figure 6.22). This was used as it had the shortest 
retention time. 
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Table 6 8 Lipophilicities (log Poct ) of morphine and related compounds 
log P 
Morphine 0.70±0.04 
Methadone 1.85±0.06 
Codeine 0.92±0.04 
Heroin 0.95±0.02 
- Solvent used is ethyloleate 
, Solvent used is heptane 
Lit. values 
0.76 (Hansch & Anderson, 1967) 
1.65t (Kutter et al, 1970) 
1.01(Bashilova & Figurouski, 1959) 
1.07- (Valette & Etchererry, 1958) 
To determine the lipophilicities of other synthetic compounds without 
direct measurement, the retention times of the test compounds were 
determined using HPLC, and the log P value interpolated from the 
calibration curve of log P against log k' (Terada, 1986) (Table 6.9). 
1.0 H 
0.8 
0.6 
~ 
-0.4 
0.2 
0.0 -t--......---,---.---r-...... ----.----.----,,-----, .... 
-1.5 ·1.0 -0.5 0.0 0.5 
log k 
Figure 6.22 Calibration curve of log P against log k' for standard compounds 
morphine (M), heroin (H) and codeine (C). (Methadone was not added due 
to its very long retention time). 
140 
Table 6.9 Lipophjlicjties (Jog P) of synthesised morphine-6-substituted 
comoounds derived from log k' values 
Retention time (mins) log k' log P 
M6succ(20) 3.6±0.1 -1.23 0.22 
M6CIB(14) 3.6±0.1 -1.23 0.22 
M6BrB(15) 3.8±0.1 -0.93 0.33 
M6ph(18) 3.8±0.1 -0.93 0.33 
M3G 4.0±0.2 -0.75 0040 
M6G (p)(17) 4.0±0.2 -0.75 0040 
C6G (p)(21) 4.2±0.1 -0.63 0045 
M6G 5.1±0.1 -0.30 0.57 
M6FB(13) 3.4±0.1 0 0.68 
Morphine( I) 7.0±0.2 0,02 0.70 
M6B(19) 7A±0.1 0,07 0.72 
M60HB(16) 8A±0.2 0.17 0.75 
C6G(22) 8.8±0.1 0.20 0.77 
CPE(3) 9.0±0.2 0.22 0.78 
Codeine(2) 16.8±0.2 0.60 0.92 
M6NB(5) 16.6±0.2 0.59 0.92 
Heroin(H) 22.0±0.3 0.74 0.95 
CSE(4) 22.6±0.2 0.75 0.97 
Methadone *2703 2.90 1.85 
*The retention time of methadone was determined from the log k' value, 
which was interpolated off the calibration curve from the log P value. 
Morphine-6-f1uorobenzoate was used as the reference compound, as it had 
the shortest retention time. 
The order of Iipophilicities of morphine-6-substituted compounds in 
increasing order is as follows:-
Morphine-6-chlorobenzoate (14) = morphine-6-succinate (20), morphine-
6-phthalate (18)= morphine-6-bromobenzoate (15), M3G= M6G(protected) 
(17), C6G(protected)(21), M6G, morphine-6-f1uorobenzoate (13), morphine 
(I), morphine-6-benzoate (19), morphine-6-hydroxybenzoate(16), C6G(22), 
codeine phthalic ester(3), morphine-6-nitrobenzoate (5) = codeine (2), 
heroin, codeine succinic ester (4), methadone. 
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Methadone was the most lipophilic compound tested here. The only 
morphine-6-substituted compound tested which was more lipophilic than 
morphine was morphine-6-nitrobenzoate. Morphine-6-benzoate (19). 
morphine-6-hydroxybenzoate(16) and morphine-6-f1uorobenzoate (13) had 
similar Iipophilicities. whilst all of the others were less lipophilic than 
morphine. Compounds with closest lipophilicities to M6G (0.57) were 
morphine-6-benzoate (0.72) and morphine-6-hydroxybenzoate (0.75). 
Drugs less lipophilic than M6G included morphine-6-chlorobenzoate 
(0.22). morphine-6-succinate (0.22). morphine-6-bromobenzoate (0.33). and 
morphine-6-phthalate (0.33). 
This altered lipophilic nature can be seen in isolated tissue preparations. It 
was noticable that the onset and offset of action of morphine-6 
nitrobenzoate was much longer than that of morphine in isolated tissue 
preparations (Table 6.10). 
Table 6.10 Rates of onset and offset of action of morphine and momhine-6-
nitrobenzoate (5) in MPLM of the guinea-pig ileum 
(5) 
morphine 
Onset to.5 (s) 
270±18.2 
26.8±3.1 
Offset to.5 (s) 
> 1200 
90.0±12.4 
6.7 Antinociceptive activity of momhine-6-substituted compounds in yiyo 
From the in vitro studies compounds were chosen for further investigation. 
The criteria for selecting compounds was that the compounds should 
possess affinity in binding assays and potency in isolated tissue 
preparations. Thus the compounds chosen were morphine-6-glucuronide 
'protected' (17). morphine-6-p-nitrobenzoate (5). morphine-6-phthalate 
(18) and morphine-6-succinate (20). The in vivo potency and duration of 
action of these was evaluated. The compounds were all free base and 
insoluble in aqueous solvents. and so for injection a suspension was made 
up in saline containing 0.25% carboxy methyl cellulose. 
The model used was the mouse tail-flick test. following s.c. administration of 
the drug. Time course and dose-response curves are shown for morphine-
6-nitrobenzoate and morphine-6-phthalate in Figures 6.23-6.26. 
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The nitrobenzoate (5) (Figure 6.23) showed a different time course to 
morphine. reaching peak analgesia slower. ie after 90 mins compared to 30 
mins for morphine. As soon as the peak analgesia was reached. the effect 
decreased gradually with time. returning to control values after 6 h. This 
compared with morphine. which maintained maximal allowed analgesia (ie. 
10s cut off) for 2 h and suggested a lesser activity for the nitrobenzoate. 
The reduced activity of morphine-6-nitrobenzoate (5) was confirmed by 
constructing a dose-response curve at 60 mins (Figure 6.24). 
The phthalate also showed a slower time course than that of morphine and 
reached peak analgesia after 120 mins compared to 30 mins for morphine 
(Figure 6.25). After 120 mins the antinociceptive effect decreased 
gradually with time. and showed no antinociception after 6 h. The dose-
effect curve showed the phthalate to be weaker than morphine. and did not 
attain maximal allowable time flick latency. even at 30mg/kg (Figure 6.26). 
although maximal tail flick latency was achieved in Figure 6.27. 
Since morphine-6-phthalate acted via li receptors in vitro (MVD/MPLM 
ratio of 14.4. Table 6.3). it was tested in vivo in animals pretreated with 
naltrindole (Img/kg). a selective li antagonist. The in vivo analgesia 
induced by morphine-6-phthalate was blocked by naltrindole. whereas 
morphine induced analgesia was unchanged (Figure 6.27). 
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Figure 6_23 Time course for the antinociceptive action of morphine-6-
nitrobenzoate (closed circles)(30mg/kg) and saline controls in 0.25% 
carboxy methyl cellulose (CMC) (open circles) assessed by the tail-flick test. 
* p < 0.05 [Wilcoxon signed rank test) indicating that the response in the 
morphine-6-nitrobenzoate treated animals is significantly different from 
the saline in 0.25% carboxy methyl cellulose (CMC) treatment. 
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Figure 6.24 Dose-response curve for morphine-6-nitrobenzoate (closed 
circles) and saline in 0.25% carboxy methyl cellulose (CMC) controls (open 
circles) at 60 mins assessed by the tail-flick test. * p < 0.05 [Wilcoxon 
signed rank test) indicating that the response in the morphine-6-
nitrobenzoate treated animals is significantly different from the saline in 
0.25% carboxy methyl cellulose (CMC) treatment. 
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Figure 6.25 Time course for the anti nociceptive action of morphine-6-
phthalate (closed circles)(lOmg/kg) and saline controls in 0.25% CMC(open 
circles) assessed by the tail-flick test." p < 0.05 [Wilcoxon signed rank test] 
indicating that the response in the morphine-6-phthalate treated animals 
is significantly different from the saline in 0.25% CMC treatment. 
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Figure 6.26 Dose-response curve for morphine-6-phthalate (closed circles) 
and saline controls for 60 mins assessed by the tail-flick test." p < 0.05 
[Wilcoxon signed rank test] indicating that the response in the morphine-
6-phthalate treated animals is significantly different from the saline in 
0.25% CMC treatment. 
145 
12 
• pretest 
# # I!lliI saline 
10 I!lliI N (lmglkg) + saline 
~ phthalate (l<mglkg) 
8 0 N + phthalate ~ 121 '" morphine (Smglkg) ~
,., E:l N + morphine 
u 6 
'"  :0 
..J 4 
2 
0 
Categories 
Figure 6.27 Effect of naItrindole (N) (lmg/kg s.c) on morphine-6-phthalate 
(phthalate) (lOmg/kg s.c.) and morphine (Smg/kg s.c.) analgesia as 
determined by the mouse tail-flick test. NaItrindole was injected IS mins 
prior to the agonist and the responses were tested after 90 mins for 
morphine and 120 mins for the phthalate. * p > O.OS [Wilcoxon signed rank 
test] indicating that the treatment is not significantly different from the 
pretest saline treatment and # p > O.OS [Wilcoxon signed rank test] 
indicating not significantly different from the morphine treatment. n=6 
mice in each category. 
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6.8 Discussion 
Initially 6-substituted codeine derivatives were investigated as target 
compounds due to their easier synthesis. However such derivatives (2-4) 
had low affinity for opioid receptors, and were comparatively weak 
agonists in the MPLM. This agrees with previous studies that codeine 
compounds are inactive due to the lack of a 3-phenolic hydroxy group, 
which is essential for binding to the opioid receptor (Chen et ai, 1991). 
However two codeine-6-substituted compounds, namely the phthalate (3) 
and the succinate (4) showed a similar affinity for the !1 receptor as codeine 
(2), indeed codeine phthalate (3) showed improved li receptor affinity and 
efficacy. Consequently studies concentrated on 6-substituted morphines. 
The synthesised compounds were essentially 6-substituted aromatic esters 
of morphine designed as potential mimics of M6G. The parent compound 
morphine-6-benzoate (\ 9) had a similar affinity to morphine and M6G for 
the !1 receptor (9nM as compared to 6nM and 8nM respectively). However 
(19) had a 3-fold higher affinity over M6G for the li receptor (21nM as 
compared to 7SnM), and a 5-fold higher affinity for the K receptor than 
M6G (\62nM as compared to 850nM). Isolated tissue studies performed on 
(\9) showed it to have approximately half the potency to that of M6G in the 
MVD (ICSO of 280nM), but to be essentially inactive in the MPLM (ICSO of 
10,OOOnM), where M6G was a potent agonist (ICso 58nM). This would 
suggest that compound (\9) was acting as a li agonist in the MVD, confirmed 
by a naloxone Ke of 18.4nM, but that it may also act as a !1 antagonist since it 
showed affinity for the !1 receptor, with extremely low potency in the 
MPLM. 
Introduction of a para-OH group onto the benzene ring gave a compound, 
morphine-6-hydroxy benzoate (\ 6), which showed a very similar receptor 
binding profile to the parent benzoate, at 11 and K sites, but with improved !1 
affinity (Ki 2nM). In isolated tissue preparations, it afforded similar 
potency and appeared like the parent morphine-6-benzoate, to be acting 
via li receptors in the MVD, but was essentially inactive in the MPLM. 
Morphine-6-hydroxy benzoate (16) evaluated 'in vivo did show 
antinociceptive activity as measured in the mouse tail flick test, giving a 
tail flick latency of 7.2±1.3s at a dose of 10mg/kg, compared with the saline 
control of 3.0s. A similar dose of M6G would afford long lasting 'cut-off' 
analgesia. The in vitro data would appear to suggest that this analgesic 
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activity may be via an action on I) receptors in this test. 
Introduction of a para-nitro group afforded morphine-6-p-nitrobenzoate 
(5). This showed somewhat reduced l1-affinity compared to M6G, resulting 
in a compound which was relatively nonselective between 11 or I) receptors. 
There was no measurable affinity for the K-opioid receptor. The 6-p-
nitrobenzoate derivative (5) had agonist activity in the MPLM comparable 
to M6G, though potency in the MVD was much reduced. The equilibrium 
dissociation constants (Ke) for naloxone and cyprodime confirmed that 
morphine-6-p-nitrobenzoate acted via l1-receptors in the MPLM and via 0-
receptors in the MVD. Morphine-6-nitrobenzoate (5) was a highly 
lipophilic drug compared to morphine, and thus showed slow kinetics in 
the MPLM. This was reflected in the onset and offset times for the drug, 
which were much longer than that of morphine, whereas M6G had the 
same onset and only slightly shorter offset of action compared with 
morphine. M6G and morphine were not that dissimilar in terms of their 
Iipophilicities, confirmed by similar retention times determined by HPLC, 
giving values of 12 and 14 mins respectively (see Chapter 4). These 
findings are consistent with the findings of Kosterlitz et al (1975) that more 
hydrophilic compounds have faster kinetics. In vivo experiments however 
show the opposite. Herz & Teschemacher (1971) found that in vivo the rate 
of onset and offset is directly proportional to a drugs lipid solubility. The 
values obtained here for the onset and offset of morphine and M6G are 
similar. Morphine-6-nitrobenzoate (5) showed in vivo analgesic activity 
in the mouse tail flick test, but reached a maximal tail-flick latency of only 
5.3s and peak analgesia was reached after 90 mins (Table 6.11). The onset 
to.5 was 40 mins in vivo, longer than M6G (30 mins). The offset to.5 
(measured as the time taken for analgesia to be no longer evident divided 
by two) for (5) was 90 mins in vivo, whereas for M6G it was 1050 mins. 
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Table 6.11 Comparative antinociceptive properties of morphine. M6G. M6G 
(protected) and the 6-phthalate (] 8) and 6-njtrobenzoate (S). Onset and 
duration are taken for peak analgesia 
max analgesia (lOs) 
EDSO(mg/kg) onset offset duration 
(mg/kg) (m ins) (mins) (mins) 
Morphine 
M6G 
M6G (protected) 
2.2±0.3 
1.9±0.3 
1.5±0.4 
M-6-nitrobenzoate 16.2±2.6 
M-6-phthalate 2.6±0.4 
30 
30 
60 
90 
120 
.. maintains >6s tail-flick latecy for 2.S h 
X maintains >6s tail-flick latency for I.S h 
270 
10SO 
IOS0 
ISO 
120 
90 
330 
300 
.. 
x 
active 
(h) 
4 
11 
11 
3 
3 
Introduction of an ortho-carboxyl group as in the phthalate afforded a 
closer chemical mimic of M6G and also a closer pharmacological mimic. 
Thus morphine-6-phthalate (18) had a good affinity for 11 and Ii receptors in 
ligand binding assays, with a S-fold higher affinity for Ii receptors than 
M6G and a 3-times lower affinity for 11 receptors. Its affinity for K 
receptors (2774nM) was 3 times lower than M6G. In vitro bioassay 
experiments, showed (18) was more potent than the parent benzoate and 
had an improved activity at the Ii receptor. Also it was 14-fold more potent 
in the MVD than the MPLM (Table 6.2, Figure 6.15) and 4-fold more potent 
than M6G in the MVD. It was the most potent compound tested in the MVD 
and together with (16) and (19) had greater activity in the MVD compared 
to the MPLM. However unlike (16) and (19), (18) was a full agonist in the 
MPLM. 
Analysis of morphine-6-phthalate (18) in vivo, afforded a a lower ceiling 
than morphine, with a maximum tail flick latency of 8.2s at IOmg/kg. The 
time to reach peak analgesia was 120 mins. The effect of naltrindole 
(lmg/kg), the Ii selective antagonist (Rogers et al, 1990) on morphine-6-
phthalate (lOmg/kg) and morphine (Smg/kg) analgesia was investigated. 
In this experiment peak analgesia was reached and naltrindole antagonised 
morphine-6-phthalate (18), but not morphine, demonstrating that 
analgesia produced by morphine-6-phthalate was li-mediated (Figure 6.27). 
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This confirmed in vitro findings and implies that morphine-6-phthalate 
produces its analgesia via 0 receptors. whereas morphine. as is well known. 
exerts its actions not via O. but by 1.1 receptors (Paul et al • 1989 i; Frances et 
al. 1992). 
The in vivo O-activity of the morphine-6-phthalate could be an important 
finding since the majority of o-selective ligands reported to date are 
peptides (Corbett et al. 1984). for example the O-agonist DPDPE and the 0-
antagonist N.N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH (ICI 174864). Portoghese 
et al (I990) reports on non-peptide naltrindole analogues with 0 agonist 
and antagonist properties. but the only non-peptidic o-opioid agonist 
reported to date is BW373U86 (Figure 6.28) (Childers et al. 1993). It shows a 
high degree of selectivity for the 0 receptor in both in vitro and ex-vivo 
binding assays. affording Ki's of 85. 1.8 and 34nM for 1.1. O. and K receptors 
respectively and an IC50 of 0.2nM in the mouse vas deferens (Chen et al. 
1993). BW373U86 was reported not to be antinociceptive in the mouse tail-
flick test (Corner et al. 1993) and not to induce any physical dependance 
(Lee et al. 1993), but it has been shown to produce brief. non-lethal 
convulsions in mice when administered systemically (Corner et al. 1993). 
o 
11 
Et2N-C 
Figure 6.28 BW373U86 
The actIvIty of the morphine-6-substituted benzoates indicated that the 
benzene ring can be accomodated in opioid 1.1 and 0 receptors. Of the 
compounds tested. all had electron-withdrawing groups at the para position 
(and the phthalate having electron withdrawing groups ortho). The 
hydroxy and nitro groups possessing lone pairs of electrons. increasing 
the negative charge delocalisation. It is surprising though that the 
halogenated benzoates (13)-(15) were inactive as they also had electron 
withdrawing groups. It is possible that the halogenated compounds may act 
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as antagonists. because they possess affinity. but not efficacy. 
The only non-aromatic ester in the current study was the 6-succinate. This 
can take up a similar shape to that of the phthalate. Morphine-6-succinate 
(20) had a similar affinity to morphine and M6G for the 11 receptor (IOnM 
as compared to 6nM and SnM respectively) and a 2-fold higher affinity 
over M6G for the I) receptor (32nM as compared to 75nM). but no affinity 
for the 1( receptor (>10.000nM). Isolated tissue work performed on (20) 
showed it to have a very similar potency to morphine and M6G (IC50 values 
of 159nM and 171nM in the MPLM and MVD respectively). Unfortunately 
the synthesis of the 6-maleic derivative was unsuccessful and so could not 
be tested. The maleic derivative is important because it has a double bond. 
which means the position of the carboxyl group is more fixed and this 
could provide invaluable information about stereochemistry. This provides 
scope for. additional work in the future. 
It is very notable that all of the 6-substituted compounds tested had a low 
affinity for the 1(-receptor (ranging from 150nM to >10.000nM). This is 
similar to M6G. which also has a very low affinity for the 1( receptor. This 
does suggest that constraints in the 1(-receptor for the 6-position are 
greater at the 1(-site. In support of this is the fact that ~-FNA is an 
irreversible 11 (and perhaps I) antagonist. but a reversible agonist at the 1( 
receptor site whch does suggest differences at this position. However this 
low 1( affinity of the 6-substituted compounds could be a therapeutic 
advantage in novel drug design because of the reducion in 1( mediate 
adverse effects ego sedation and psychotomimetic effects (Wollemann et al. 
1992). 
Although the codeine derivatives and M3G are inactive. 3-silyl derivatives 
were synthesised as intermediates (protecting groups) in the synthesis of 
the 6-substituted analogues. It was decided to examine these for their 
ability to interact with opioid receptors. 
It was found that 3-silylmorphine (6) had a similar profile in binding 
assays to the parent compound morphine (Table 6.1). This was unexpected 
in view of the supposed necessity of a 3-phenolic hydroxy group for 
binding to opiate receptors. 3-Silyl morphine (6) did however have 
reduced potency in the bioassays (MPLM and MVD). which may indicate a 
lower efficacy. In addition this potentially suggests two properties of the 
opioid receptor : (i) that it must be able to accomodate the bulky silyl 
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group; and (ii) that hydrogen bonding due to the OH is not necessary for 
binding affinity. The much larger 3-substituted compound. 3-
triisopropylsilyl morphine (12) also had affinity for opioid receptors being 
most active for the 11 receptor (K i=107nM). However the affinity was 
reduced (by 10 times compared with morphine) at each receptor type 
(Table 6.2). suggesting steric constraints do exist at this position. This 
agreed with much previous work which demonstrates that bulky groups 
are not tolerated and dramatically reduce affinity. Mohacsi et al (1982) 
reports that 3 tSu morphine has a much reduced affinity (1000 times less) 
and potency (50 times less as measured in the writhing test) than 
morphine. However studies showed that 3-silyl morphine was metabolised 
to morphine. and this was responsible for its effects. 
Nevertheless the 3-silyl 6-substituted compounds did have some opioid 
properties and were not metabolised. especially the phthalate (7). 
Presumably the binding of 6-phthalate enhances the binding of 3-silyl-6-
phthalate derivative. so overcoming the absence of a 3-0H. 
Introduction of phthalic acid into the 6-position of 3-silyl morphine gave 
improved 0 affinity compared with M6G and morphine. Since the affinity 
of 3-silyl morphine-6-phthalate (7) for the l1-receptor was less than M6G 
. and it had no affinity for the IC-receptor the selectivity of this compound 
was different from M6G with a preference. albeit small. for the 5-receptor. 
The improved affinity for the 0 receptor was confirmed in isolated tissues. 
since it was 10-fold more potent in the MVD compared to the MPLM. 
Naloxone and cyprodime Ke values confirmed that 3-silylmorphine-6-
phthalate (7) acted via l1-receptors in the MPLM and 5-receptors in the 
MVD. Thus it acted like its parent compound. morphine-6-phthalate (18). 
Alteration of the ester grouping in the 6-position had a marked effect on 
the activity of the 3-silylmorphines (Tables 6.1 and 6.2). Thus 3-
silylmorphine-6-benzoate (8) had a much reduced affinity for 11- and 0-
receptors. and was inactive at the IC-receptor. It showed no agonist activity 
in the MPLM and was only weakly active in the MVD. 3-Silylmorphine-6-
p-fluorobenzoate (9). 6-p-bromobenzoate (IO) and 6-p-nitrobenzoate (11) 
also had a much reduced affinity for the l1-receptor and essentially no 
measurable affinity for 5- and IC- receptors. The 3-silyl 6-p-
fluorobenzoate (9) was inactive as an agonist in both the MPLM and MVD. 
whereas the 3-silylmorphine 6-p-bromobenzoate (10) did have a very 
slight effect in the MVD. 
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6.9 Inyestigation of 3-positjon substjtuents 
It is reported that morphine-3-substituted compounds like codeine and M3G 
are devoid of analgesic activity because of the absence of the 3-0H group 
which is reputed to be essential for binding to opioid receptoTs (Casy & 
Parfitt, 1986). The 3-substituted OH-protected morphine analogue 3-tBu 
morphine had a much reduced affinity (1000 times less) and potency (50 
times less as measured in the writhing test) than morphine (Mohacsi et ai, 
1982), as did 3-T1PS morphine in this study. 
Interestingly as reported above, 3-silyl morphine showed a similar 
receptor profile to that of morphine, but was less potent, though this 
appears to be due to metabolism to free morphine. 3-Tri isopropylsilyl 
morphine also had affinity for opioid receptors, showing the highest 
affinity for the !1 receptor (K i=107nM). However other compounds remain 
active even if apparently not metabolised. Similarly a lack of any 
substituent at the 3-position (eg. 3-deoxymorphine) results in a reduced 
affinity by 13 times and 8-fold reduced in vivo potency as measured in the 
hot plate test, compared with morphine, showing that the 3-0H is not 
absolutely essential for analgesic activity (Red en et ai, 1979). These 
observations prompted an investigation of the 3-position more fully. A 
group of compounds supplied by Or. Lewis (Bristol University), BUI8-BU25 
inclusively, were used for these studies and were of the general structure 
shown below, R3 is the variable moiety. 
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BU 
BUl8 (C-CAM) 
BUI9 
BU20 
BU21 
BU22 
BU23 
BU24 
BU25 
,R1 
N 
NHCOCH=CH-R2 
RI R2 
CPM C{;H4C1 
CPM C{;H4C1 
CPM C{;H4C1 
CPM C{;H4C1 
CPM C{;H4C1 
CPM C{;H4C1 
CPM C{;H4C1 
CPM C{;H4Cl 
R3 
H 
CH2-CH=CH2 
CHTC=N 
CPM 
CH2CH2CH3 
CH2C=CH 
CH2~CH3 
CH(CH3)2 
CPM denotes cyclopropylmethyl. Binding of these compounds to opioid 
receptors was evaluated in rat brain homogenates. Dissociation constants 
(Ki ) are shown in Table 6_12. and the selectivities for 1l.1i and 1C receptors in 
Table 6.13. 
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Table 6 12 Affinities Ki (nM) of 3-substituted BlI coml)Ounds for u, 0 and K 
opioid binding sites 
Compound Kj(nM) 
11 0 K 
But8 9,O±2,1 12,5±2,2 5.4±1.! 
But9 8,9±1.6 65.4±3, I 17,9±2,2 
BU20 12.4±1.9 89,5±2,6 18,O±2,1 
BU21 7,6±1.2 56,5±2,1 !31.2±4,2 
BU22 24,6±2.4 82,6±2,5 9,5±1.0 
BU23 1,6±O,3 21.3±1.0 19,1±O,9 
BU24 7 ,6± 1.3 24,8±1.3 95.4±4,6 
BU25 39,8±4,2 96.4±2,2 14,9±1.8 
IlSites were labelled with [3 H]DAMGO (O,97±O,1 InM), 0 sites by [3 H]DPDPE 
(1.83±O,23nM) and K sites by [3H]U69593 (1.I3±O,22nM), In all cases Hill 
coefficients were not significantly different from unity, Values are means 
± sem of >3 experiments, 
Tab[e 6,13 Selectjyities of BU compounds fQr u, 0, or K sites, taken from Table 
.6..ll 
K, "'K ,0 
1 '" 1 
K, "'K, K 
1 '" 1 
K,o/K'K 1 1 
But8 0,72 1.67 2,3 I 
BUI9 0,14 0,50 3,65 
BU20 0,14 0,69 4,97 
BU21 0,13 0,06 0.43 
BU22 0,30 2,59 8,69 
BU23 0,08 0,08 I.! 2 
BU24 0.31 0,08 0,26 
BU25 0.41 2,67 6.47 
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All of the compounds showed high affinity for opioid receptors. despite 
being 3-substituted. None of the compounds tested above were exclusively 
selective for a particular opioid receptor site. though most showed a 
slightly higher affinity for one receptor type. Thus BUI9 (R3=propene). 
BU20 (R3=cyanoethane). BU22 (R3=propane) and BU25 (R3=isopropyl) 
showed a relatively lower affinity for the 5receptor as compared with the I.l 
or lC receptors. B U21 (R3=CPM) showed a much lower affini ty atlC receptors 
than I.l or 5 receptors. BU21 and BU23 (R 3=propyne) had some preference 
for the I.l receptor. 
As can be seen from the binding data. the introduction of an alkyl group 
substituent at R3' replacing OH in BUI8 caused a loss in affinity for the 5 
receptor and no significant change in affinity for the lC receptor [except 
for BU21 (R3=CPM) and BU24 (R3=ester)]. Some changes were seen at the I.l 
receptor. Thus BU23 (R3=propyne) had a higher affinity than BU18 (R3=H). 
which was equivalent with BUI9 (R 3=allyl). BU20 (R3=cyano). BU21 
(R3=CPM) and the BU24 (R3=ester). which has higher affinity than BU22 
(R3=propyl). which in turn had a higher affinity for BU25 (R3=isopropyl). 
ie in order of decreasing affinities for the I.l receptor: 
23> 18=19=20=21 =24>22>25. Thus alkyl substituted compounds are less active 
than their parent compound and introduction of multiple bonds or 
heteroatoms causes no change or improved I.l affinity. Overall this set of 
compounds were either branched or unsaturated. The substituent at the 3-
position could be interacting in some way with the receptor to overcome 
loss of the 3-0H. 
The agonist potencies of these compounds were assessed in the guinea-pig 
MPLM (Figure 6.29). None of the compounds reached 50 % inhibition even 
at 1000nM and BUI8. BU22 and BU24 showed no agonism at all. The 
compounds did not washout after continual washing for 4 h. suggesting 
they bind very tightly to opioid receptors. The remaining compounds 
(BUI9.20.21.23 and 25) acted as agonists at lower doses. but at higher doses 
as antagonists. showing bell-shaped dose-response cllcrves. This is similar 
to the situation with buprenorphine. which is a partial agonist. acting at 
low doses as a agonist at one site. and at higher doses. interacting with the 
second site of lower affinity. counteracting the effects of the high-affinity 
site. This is known as non-competitive autoinhibition (Rance et al. 1980). 
It is not clear though whether this action is due to non-specific. possibly 
cholinergic effects or to a more intricate opioid mechanism. such as 
allosteric interactions among opioid receptor subtypes (Rothman & 
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Westfall. 1981). Another hypothesis assumes the existance of only one type 
of receptor site and bell-shaped dose-response curves may be 
generatedeither by multiple subsites of drug attachment within the 
receptor (De Leon et al. 1979) or by cooperative binding interactions (Dum 
& Herz. 1981). 
These BU compounds are not the only 3-ether series to possess opioid 
activity. since 14-p-nitrocinnamoyl derivatives also have activity. A series 
of 3-substituted 14-p-nitrocinnamoyl amino morphinones (R2=<t;H4pN02 in 
BU type structure on page 154) showed affinities for 11. /) and 1C opioid 
receptors and some 14-p-nitrocinnamoyl amino 7.8-dihydromorphinones 
acted as 11 antagonists after i.c.v. administration (Sebastian et al. 1993). This 
contradicts findings that the 3-0-cyclopropylmethyl ethers of 
buprenorphine. naItrexone and diprenorphine all have low affinities. 
compared to the 3-0H parents (Lewis. 1994). It could be that the BU 
compounds are metabolised to 3-0H. but this is unlikely as one might expect 
the 3-0-cyclopropylmethyl ethers of buprenorphine. naltrexone and 
diprenorphine to also show activity if this were the case. 
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Figure 6.29 Potency of BU compounds 19 (closed circles). 20 (open circles). 
21 (open triangles). 23 (+) & 25 (x) in the MPLM 
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6 10 Overview 
M6G has a much longer duration of action than morphine. This. allied to a 
lack of first-pass metabolism potentially means a better control of 
analgesia. An interesting finding was the very low affinity for 1< 
compared to 11 and 0 receptors. This was seen in both ligand binding and 
bioassay preparations. However the measured properties were mediated 
via 11 receptors. suggesting a similar pharmacological profile to that of 
morphine. possibly with reduced potential for side-effects mediated via 1< 
receptor activation. Thus. in order to take advantage of these properties 
the emphasis must be towards morphine-6-substituted compounds in the 
hope of finding compounds with similar analgesic potency and duration to 
M6G. but with simpler synthesis and increased stability to air and light. and 
therefore more cost effective production. 
The newly synthesised compounds morphine-6-phthalate (18) and 
morphine-6-nitrobenzoate (5) studied in this thesis did exhibit good 
analgesic activity. but had a lower antinociceptive ceiling than morphine 
or M6G. and a shorter length of action. Their stability to metabolism has 
not been studied. Also identified in this work was morphine-6-
hydroxybenzoate (16). Morphine-6-hydroxybenzoate (16) had a similar 
binding profile to M6G. but a much reduced efficacy. in vitro as measured 
in isolated tissue preparations. and in vivo. Morphine-6-nitrobenzoate (5) 
was relatively non-selective for ll. or 0 receptors. It was active in isolated 
tissue preparations. being more potent in the MPLM. but acted as a partial 
agonist in vivo. Morphine-6-phthalate (18) showed a higher affinity for 
0> 11 »>1< receptors. although 0/11 selectivity was not great. This was 
confirmed in the in vitro isolated tissue preparation the MVD. where an 
IC50 of 24nM was obtained and was antagonised by naltrindole. a selective 0 
antagonist. Morphine-6-phthalate (I8) acted as a good agonist in vivo. 
where its activity was seen to occur via 0 receptor activation. This may 
prove to be a suitable lead compound in the development of a non-peptide 0 
active agonist exhibiting analgesic activity. and hopefully with an 
improved side-effect profile over Il-agonists. 
Differentiation between 11 and 1< receptors and 0 and 1< receptors is an 
important consideration. Morphine-6-phthalate and morphine-6-
nitrobenzoate had ll.f 0 and ll.f 1< ratios of <0.01. This selectivity for ll.f 0 and 
ll.f 1< was greater than that of M6G. and may allow the development of 
compounds without the unwanted 1< side effects. such as sedation and 
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psychotomimetic effects. 
This project has thus enabled a beller understanding of antinociception 
induced by M6G and related synthetic derivatives. The reported improved 
in vivo activity of M6G over morphine is not due to improved receptor 
affinity or efficacy of the compound, at least as examined in the systems 
used here, in ligand binding and isolated tissue preparations. It is likely 
that pharmacokinetic differences between M6G and morphine will reveal 
why M6G is much more potent and long lasting. The next step in a 
continuation of this study would therefore be to investigate 
pharmacokinetic parameters, for example, the assays of eNS levels reported 
in this thesis only concern 'morphine-like' material. It is important to 
identify this. Indeed when administered centrally M6G is very potent. A 
possible explanation would be that extremely high local concentrations of 
M6G are in the eNS, which diffuse away very slowly. 
The involvement of second messenger systems could also pI ay a major role 
in the effectiveness of M6G and this could also be investigated, by studying 
efficacy in eNS preparations, for example by measuring changes in cyclic 
AMP levels in brain slices, to probe possible differences between the 
effectiveness of M6G at opioid systems in the periphery compared to 
centrally exist. 
3-Substituted opioids, ego codeine are generally weakly active agonists and 
confirmed to have low affinity for ~,/i and K receptors. However a series of 
3-substituted derivatives investigated, containing saturated and 
unsaturated substituents, did show affinity for opioid ~,/i and le receptors. 
Unfortunately though only very weak agonist activity and bell-shaped 
dose-response curves were shown in vitro. Nevertheless the results 
demonstrate that the 3-phenolic hydroxyl group is not absolutely essential 
for high affinity receptor binding and opens up possibilities for beneficial 
structure activity relationships of opioid receptors within this group. 
SynthetiC derivatives at positions 6 and also at 3 do appear to be able to 
control both affinity selectivity and efficacy. There is still scope for a 
tremendous number of of compounds to be evaluated and studied. In 
particular, it would be interesting to extend the structure-activity 
relationship study to try to develop the li-activity of morphine-6-phthalate, 
since this group of compounds are relatively new, and the pharmacology of 
non-peptide /i·compounds is only in its infancy. 
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What is now proved 
was once only imagined 
WILLlAM BLAKE 
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